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“If sleep does not serve an absolutely vital function, then it is the biggest mistake the evolutionary 
process has ever made.” 
Allan Rechtschaffen  
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2. Abstract 
Currently, there is an increased interest in γ-hydroxybutyric acid (GHB) and its effects on 
sleep. This compound, sometimes referred to as ‘rape drug’, was recently approved as a 
treatment for the sleep disorder narcolepsy. Although several studies suggest that GHB 
induces slow-wave sleep duration and improves sleep quality by increasing EEG slow-wave 
activity, others question its ability to induce physiological sleep. GHB’s mechanism of action 
is still unclear, although in vivo and in vitro it seems to act at high doses as a low-affinity 
agonist of GABAB receptors. Furthermore, the role GABAB receptors play in sleep and the 
electroencephalogram (EEG) is largely unknown. 
 
The aim of this project was therefore to investigate the effects of GHB on sleep and EEG, the 
involvement of GABAB receptors in mediating these effects, as well as the intrinsic role of 
each GABAB receptor subunit in the regulation of sleep. Thus, we administered GHB and 
baclofen (BAC, a high-affinity agonist at GABAB receptor) to mice lacking the different GABAB 
receptor subunits  and to healthy human volunteers. 
 
Our results, both in mice and humans, showed that GHB produced slow waves exclusively 
through the stimulation of GABAB receptors, but did not induce physiological sleep 
necessary to reduce sleep need and to increase cognitive performance. Unlike GHB, BAC 
affected the homeostatic regulation of sleep (sleep need) and induced a delayed 
hypersomnia. Finally, GABAB receptor and its subunits seem to play an important role in 
sleep and in particular its circadian distribution. 
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3. Résumé 
L’acide γ-hydroxybutyrique (GHB) suscite actuellement un grand intérêt quant à son effet sur 
le sommeil. Cette substance, également appelée ‘la drogue du violeur’, a été récemment 
acceptée en tant que traitement de la narcolepsie, une maladie du sommeil. Bien que 
plusieurs études suggèrent que le GHB augmenterait la quantité et la qualité du sommeil 
lent (caractérisé par une grande densité d’ondes lentes sur l’électroencéphalogramme 
(EEG)), d’autres mettent en doute sa capacité à induire du sommeil physiologique. Son 
mécanisme d’action est encore indéterminé bien que, in vivo et in vitro, il semblerait agir à 
haute dose comme agoniste à faible affinité des récepteurs GABAB. De plus, le rôle joué par 
les récepteurs GABAB sur le sommeil et l’EEG est très peu connu. 
 
Le but de ce travail a été d’étudier les effets du GHB sur le sommeil et l’EEG, l’implication des 
récepteurs GABAB dans ces effets, ainsi que le rôle intrinsèque de chaque sous-unité des 
récepteurs GABAB sur le sommeil. Nous avons administré du GHB, du baclofen (BAC ; un 
agoniste à haute affinité des récepteurs GABAB), et un placebo à des souris n’exprimant pas 
l’une ou l’autre des sous-unités des récepteur GABAB ainsi qu’à des volontaires sains. 
 
Nos résultats chez l’homme et chez la souris ont montré que GHB produisait des ondes 
lentes exclusivement par l’intermédiaire des récepteurs GABAB, mais n’induisait pas de 
sommeil physiologique nécessaire à la réduction du besoin de sommeil et à l’augmentation 
de la performance cognitive. Au contraire de GHB, BAC a affecté la régulation homéostatique 
du sommeil (besoin de sommeil) et induit une hypersomnie retardée. Finalement,  les 
récepteurs GABAB et ses sous-unités semblent jouer un rôle très important dans le sommeil 
et en particulier sur sa distribution circadienne. 
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4. Résumé pour un large public 
L’acide γ-hydroxybutyrique (GHB) semble jouer un rôle très important dans le sommeil. Cette 
substance, également appelée ‘drogue du violeur’, a été récemment acceptée en tant que 
traitement de la narcolepsie, une maladie du sommeil. Bien que le mécanisme d’action de 
GHB ne soit pas encore élucidé, il semble activer les récepteurs GABAB qui exercent une 
action inhibitrice dans le cerveau des mammifères. De plus, l’implication des récepteurs 
GABAB dans le sommeil est encore méconnue. C’est pourquoi nous avons étudié les effets 
sur le sommeil du GHB, des récepteurs GABAB et leur interaction chez la souris et chez 
l’homme.  
 
Les récepteurs GABAB jouent un rôle important dans le sommeil et notamment sur sa 
composante circadienne.  En effet, la perte de ces récepteurs chez la souris conduit à une 
distribution très différente du sommeil et de l’éveil sur 24h. Nous avons également montré 
que le GHB agissait uniquement à travers les récepteurs GABAB pour modifier l’activité 
électrique générée par le cerveau et le comportement de la souris. Finalement, bien que le 
GHB augmente les ondes lentes du cerveau (caractéristique du sommeil profond), il ne 
semble pas induire du sommeil physiologique, comme suggéré par d’autres études 
scientifiques, ni chez la souris, ni chez l’homme. 
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5. Introduction 
Why do we sleep? This seemingly simple question turns out to be much more complex in 
reality. Sleep has fascinated poets, writers as well as scientists since the dawn of time. 
However, still today, sleep remains an intriguing mystery. In his book “Why do we sleep?” 
James Horne claimed: “despite 50 years of research, many think that the only thing we can 
say about sleep is that it prevails over drowsiness”1.  
Sleep is a natural, periodically recurring state of rest, during which there is a decrease of 
responsiveness to external stimuli and a minimal processing of sensory information. All 
mammals and birds as well as certain invertebrates spent a substantial portion of their life in 
this behavioral state. Given the conservation of this behavior throughout evolution and the 
fact that lack of sleep or disturbed sleep lead to strong negative consequences on health and 
performance, and even death2,3, sleep appears to fulfill a vital function comparable to 
feeding and reproduction. Surprisingly, the neurobiology and the molecular basis of sleep 
have attracted little attention until recently. Modern sleep research is usually dated back to 
the early 1950s when rapid-eye movements (REMs) and muscle atonia during sleep have 
been discovered leading to the characterization of a new vigilance state; i.e. REM sleep 4. 
Since then, substantial progress has been achieved in our understanding of the 
neurobiology of expression and regulation of sleep. Lesion and pharmacological studies 
show that sleep and wakefulness are controlled by multiple neuronal systems using different 
chemical neurotransmitters such as glutamate, acetylcholine, noradrenaline, dopamine, 
serotonin, histamine, adenosine, orexin, and γ-aminobutyric acid (GABA)5. However, the 
precise mechanisms by which each neuronal system regulates sleep and wakefulness remain 
to be discovered6. The investigation of these mechanisms is crucial not only to better 
understand the function of sleep but also to improve the treatment of sleep disorders. 
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Indeed, pathophysiology of insomnia, narcolepsy, idiopathic hypersomnia and many other 
sleep disorders are still unclear and their treatments far for optimum.  
A first aim of the present work is to improve our understanding of the mechanism by which 
the GABAergic system regulates sleep. This system is the predominant inhibitory system in 
mammalian brain and is known to play a key role in sleep. Two distinct types of GABAergic 
receptors, GABAA and GABAB receptors, modulate respectively the fast and slow inhibition of 
the neuronal GABAergic target systems. The implication of GABAA receptors and their 
ligands in sleep regulation are well studied and the majority of sleep-promoting drugs are 
GABAA receptors modulators. However, very little is known about the effects of GABAB 
receptors and their ligands on sleep and electoencephalographic (EEG) activity. Thus, the 
first aim of my PhD project was to investigate the effects of GABAB receptor subunits and 
their role in sleep regulation and EEG activity. Furthermore, as a pharmacist, I have a major 
interest in pharmacology and I was particularly drawn to understand sleep and EEG effects as 
well as the mechanism of action of a recent drug used to treat narcolepsy; i.e. γ-
hydroxybutrate (GHB). Among the potential mechanisms of action of GHB, there is its ability 
to stimulate GABAB receptors. Therefore, I also investigated the role of GABAB receptors in 
the response to GHB by using animal and human models, and by comparing GHB with a 
high-affinity agonist of GABAB receptors, baclofen (BAC). This work may contribute to the 
improvement of narcolepsy treatment, to a better understanding of the pathophysiology of 
narcolepsy, and bring some new insights into the mechanisms by which the GABAergic 
system regulates sleep. 
Before the experimental work is introduced, the neurobiology and regulation of vigilance 
states, sleep pharmacology with special focus on GHB, and scientific knowledge about 
GABAB receptors will be summarized. 
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5.1. Vigilance states: 
5.1.1. Organization 
Three major vigilance states are easily distinguishable in all normothermic mammals and 
birds: Wakefulness, Non-Rapid Eye Movement Sleep (NREMS), Rapid-Eye Movement Sleep 
(REMS). According to a simple behavioral definition, sleep is a reversible behavioral state of 
perceptual disengagement from and unresponsiveness to the environment7. More precisely, 
sleep has to fulfill the following criteria: (1) specific sleeping site, (2) typical body posture, (3) 
physical quiescence, (4) elevated arousal threshold, (5) rapid state reversibility, and (6) 
regulatory capacity, i.e., compensation after loss8. Within sleep two separate states are 
distinguished on the basis of different physiological parameters: NREMS and REMS, which 
are also called slow-wave sleep (SWS) and paradoxical sleep, respectively (more commonly 
used in animal research). These two states exist in virtually all mammals and birds and are 
distinct one from another as each is from wakefulness9. Note that SWS can also refer to deep 
sleep stages in humans (see Figure 5.1) and it is under this definition that it will be used 
below.  
In any typical sleep episode the two sleep states, NREMS and REMS, alternate. This NREMS-
REMS cycle has a period of 12 minutes in rats10, and 90-100 minutes in humans4. Because this 
period is shorter than 24 hours and occurs 4-5 times a night in humans, it is also referred to 
as an ultradian sleep-dependent rhythm. The two substrates are distinguished by different 
patterns in the EEG, electromyogram (EMG) and electrooculogram (EOG). Other 
physiological parameters change during sleep, such as arterial blood pressure, body 
temperature, cardiac and respiratory rhythms, and the production of different hormones 
(melatonin, growth hormone, etc.). However, the more complete description is derived from 
the EEG and the EMG.  
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EEG is a complex signal resulting from postsynaptic potentials of cortical pyramidal cells 
which can be recorded by electrodes placed on the scalp11. This signal summarizing cortical 
activity in the brain is visualized in terms of line tracings called brain waves. These brainwave 
tracings vary in amplitude (height) and frequency (cycles per second, Hz). Frequently, EEG is 
divided into several frequency bands, named after letters in the Greek alphabet: delta (1-4 
Hz), theta (5-7 Hz), alpha (8-11 Hz), sigma (12-15 Hz), and beta (16-30 Hz)12. As the EEG, the 
EMG and EOG are also recorded by electrodes, but they summarize the electrical activity of 
muscles (muscle tone) and eye movements, respectively.  
 
NREMS  in  humans  is  traditionally  subdivided  into  stages  I  to  IV13, corresponding roughly to 
increasing depth of sleep. NREMS occupies about 70 – 80% of sleep of human adults14, 
whereas REMS represents the remaining 20 – 30% (Figure 5.1). 
 
The conventional method of sleep scoring, which is used to differentiate sleep stages in 
humans and in animals is inadequate for quantitative EEG analysis because the definition of 
sleep stages is based on rather general and arbitrary criteria. Thus, the quantitative analysis 
of the EEG is usually performed by computer-aided methods of signal analysis, such as 
spectral analysis. Spectral analysis is a mathematical approach allowing the decomposition 
of the EEG signals into its frequency components. The fast Fourier transformation (FFT) is a 
widely applied method for obtaining the EEG power spectrum, which displays the 
distribution of power over the frequency components of the signal11. 
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Figure 5.1: Sleep parameters and measures. 
Panel (A) shows characteristic brainwave tracings (blue) of wakefulness, NREMS and REMS. In humans, NREMS is 
divided into four stages, corresponding to increasing depth of sleep as indicated by progressive dominance of 
the slow-wave activity (delta activity). NREMS and REMS alternate in each of the four or five cycles that occur in a 
typical adult human sleep. Early in the night, NREMS is deeper and occupies a disproportionately large amount of 
time, while the REMS episode is short or aborted. Later in the night, NREMS is shallow, and more of each cycle is 
devoted to REMS (red bars). Panel (B) illustrates these changes over the course of a night’s sleep and panel (A) 
depicts, in detail, features of an early-night sleep cycle. Total sleep time, number of awakenings, and the time to 
reach a stage are some of the variables that can be measured after EEG/EMG/EOG analysis (polysomnography).  
REMS is characterized by the followings: high-frequency, low-amplitude (wake-like or ‘desynchronized’) activity in 
the EEG; singlets and clusters of REMs in the EOG; and very low muscle tone (atonia) in the EMG4. NREMS Stage I is 
a light and drowsy sleep, dominated by low-amplitude and theta frequency EEG activity (4-8 Hz) and displaying 
slow eye oscillations. People drift into unconsciousness from NREMS Stage II, which shows EEG characteristics 
such as sleep spindle and K-complex waveforms, as well as slow oscillations. Stages III and IV, also termed SWS, 
represent the deepest stages of NREMS, with high-amplitude and low-frequency (‘synchronized’ or delta (0.5-4.5 
Hz)) EEG activity. This EEG delta activity occupies less than 50% of the time in stage III and more than 50% in stage 
IV. In rodents, sleep stages are usually divided in REMS and NREMS. Sometimes, NREMS is divided into SWS-1 and 
SWS-2, mimicking stage I-II and III-IV, respectively. (Figure modified from ref. 15) 
 
 
5.1.2. Sleep/wake neuronal pathways and neurochemistry 
This part is dedicated to the description of the brain circuitry that regulates sleep and 
produces wakefulness, including cell groups in the brainstem, hypothalamus and basal 
forebrain (BF) that are crucial for arousing the cerebral cortex and thalamus. These neurons 
are inhibited during sleep by a system of GABA-containing neurons, amongst which the 
ventrolateral preoptic nucleus (VLPO) seems to have a key role. Mutual inhibition between 
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the arousal- and sleep-producing circuitry results in switching properties that define discrete 
wake and sleep states, with sharp transitions between them. This switch is supposed to be 
stabilized by hypocretin (orexin, Orx) neurons in the lateral hypothalamus5 (Figure 5.2). 
 
Figure 5.2 : Schematic sagittal view of 
the rodent brain showing the major 
structures and neurotransmitters 
involved in the regulation of the 
vigilance states. 
(a) Wakefulness is maintained by 
cholinergic (Ach: acetylcholine; in 
blue) ascending inputs from the 
brainstem (PFP: pontine reticular 
formation, LDT: laterodorsal 
tegmentum, and PPT: 
pendonculopontine tegmentum) to 
the thalamus, which in turn activates 
the cortex, and from the basal 
forebrain (BF). Additionally, 
monoaminergic [in red; i.e., 
serotonergic (5-HT) DRN: dorsal 
raphe nucleus), noradrenergic (NA) 
(LC: locus coeruleus), dopaminergic 
(DA) (vPAG: ventral periaqueductal 
gray matter), histaminergic (His) 
(TMN: tuberomammillary nucleus)], 
and orexinergic/hypocretinergic 
(Hcrt; in green) inputs, contribute to 
the waking cortical activation. (b) 
NREM sleep may be initiated and 
maintained by inhibitory inputs 
(GABA and Galanin (Gal); in orange) 
from the ventrolateral preoptic 
nucleus (VLPO) to all wakefulness-
promoting brain sites. (c) REMS 
cortical activation is under the control of cholinergic and non-cholinergic structures arising from the brainstem, 
while REMS atonia is under the control of the glutamatergic (Glu) and glycinergic (Gly) projections to the spinal 
cord (in purple). (Figure from ref. 6). 
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5.1.2.1.  Ascending reticular activating system 
In the 1910s, Baron Constantin von Economo, a Viennese neurologist, began to see patients 
with a new type of encephalitis that specifically attacked regions of the brain that regulate 
sleep and wakefulness (unknown at that time). Based on his work, he proposed that there 
was an ascending arousal system originating in the brainstem that kept the forebrain 
awake5. Since then, scientists have investigated further this hypothesis and currently the 
concept of the ‘ascending reticular activating system’, which begins in the rostral pons and 
runs through the midbrain reticular formation, is well accepted16,17,18. The ascending arousal 
system largely originates from a series of neuronal populations using different chemical 
neurotransmitters such as acetylcholine (Ach), noradrenaline (NA), dopamine (DA), serotonin 
(5-HT) and histamine (His). All of these neurons have widespread or diffuse projections to the 
cortex, thalamus and brainstem or spinal cord6. This network of fibers ensures cortical 
alertness and the ability to modulate reactions to surrounding stimuli. The input to the 
cerebral cortex is augmented by neurons in the lateral hypothalamus containing melanin-
concentrating hormone (MCH) or Orx, and by BF neurons containing Ach or GABA. Lesions 
along this pathway produce the most profound and long-lasting forms of sleepiness or even 
coma19. 
 
Ach-containing neurons of the brainstem: These neurons localized in pedunculopontine and 
laterodorsal tegmental nuclei (PPT/LDT), as well as in the pontine reticular formation (PFP) 
project to the thalamus which activates the thalamic relay neurons crucial for transmission of 
information to the cerebral cortex20,21. They discharge rapidly during stages accompanied by 
cortical activation: wakefulness and REMS21,22. These cells are much less active during NREMS, 
when cortical activity is low. Injection of carbachol, an Ach agonist into the 
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pontomesencephalic tegmentum causes cortical activation with muscle atonia, a state 
similar to REMS23. 
 
NA-containing neurons of the locus coeruleus (LC): These neurons project through the 
forebrain, brainstem and spinal cord and stimulate cortical activation. They are essentially 
active during wakefulness, slow down during NREMS and are totally silent during REMS. Two 
types of adrenoreceptors are involved: the α1 are associated to depolarization and α2 to 
hyperpolarization. Thus, NA can either stimulate other cell groups involved in wakefulness or 
inhibit sleep-promoting systems. Drugs acting through the stimulation of the release or the 
blocking of the reuptake of NA are used to treat sleepiness (amphetamine, modafinil)24,25,26. 
 
There is a balance between Ach-mediated and NA-mediated neurotransmission. The 
activation of both maintains a waking state accompanied by muscle tone and cortical 
activation. REMS can occur when Ach-containing neurons stay active and NA-containing 
neurons become inactive. For instance in the 1970s, it was shown that administration of 
acetylcholinesterase inhibitors induced wakefulness by increasing Ach activity. However, if 
these drugs are administrated following catecholamine (NA and DA) depletion the effect is 
totally different: REMS is stimulated23. Moreover, when administrated during wakefulness, 
the acetylcholinesterase inhibitors stimulate cortical activation, while their administration 
during sleep, when the arousal system such as NA system are inactive, provokes REMS27. 
 
DA-containing neurons in ventral periaqueductal grey matter (vPAG): These neurons play a 
major role in arousal, projecting to the striatum, BF and cortex. They seem to discharge in 
bursts of spikes in association with aroused and often positive rewarding states28,29. However, 
recently, controversial opinions about the function of DA on sleep–wake regulation 
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emerged. The debate resides on the demonstration that DA is a substance dramatically 
related to sleep processes, and not associated exclusively with wakefulness. It appears that 
REMS neural pathways are triggered when D2 dopaminergic receptors are activated30 and 
selective lesion of the substantia nigra pars compacta (SNpc) neurons elicits a remarkable 
disruption of REMS31. Additionally, the overall mean firing rate of the ventral tegmental area 
(VTA) neurons (which are largely dopaminergic), presents a large increase in the burst firing 
during REMS episodes. Such evidence prompts to speculate that DA neurons could be 
considered essential for sleep regulation, in particular for triggering and maintenance of 
REMS32. 
 
5-HT-containing of the dorsal raphé nucleus (DRN): These neurons discharge, like the NA-
containing neurons, maximally during wakefulness, decrease discharge during NREMS and 
cease firing during REMS33. However, unlike Ach-containing neurons, 5-HT-containing 
neurons appear to be active in association with less-aroused wakefulness states, such as 
grooming and rhythmic movement in animals. They also attenuate cortical activation 
through inhibitory influences on other neurons of the activating systems and particularly on 
Ach-containing neurons34. 
 
His-containing neurons of the tuberomammillary nuclei (TMN): These neurons which are 
located in the posterior hypothalamus stimulate cortical activation through diffuse 
projections35. They seem to discharge maximally during wakefulness, diminish during NREMS 
and cease firing during REMS. Through H1 (His type 1) and H2 receptors, His excites multiple 
neurons of the arousal systems as well as cortical neurons. Interestingly, it does not inhibit 
putative sleep-promoting neurons of the preoptic region36. Antihistamine drugs are widely 
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prescribed to alleviate allergies. However, these H1-antihistamines, particularly from the first 
generation, are also used as hypnotic agents due to their side-effects of somnolence37. 
 
Orx-containing hypothalamic neurons in the hypothalamus: Orx, also called hypocretin 
(Hrct), is a recently discovered peptide in the brain. Like its receptor, Orx is necessary for the 
maintenance of wakefulness as shown with transgenic mouse models lacking either Orx or 
Orx receptors38,39,40. These mice showed clear symptoms of narcolepsy. Narcolepsy is a sleep 
disorder characterized by excessive daytime sleepiness and attacks of cataplexy (sudden loss 
of muscle tone triggers by strong emotion)41. Moreover, these patients also show unnatural 
short REMS latency and high number of arousals during their sleep leading to a poor sleep 
quality42. The biological basis of this disease is Orx deficiency. The posterior and lateral 
hypothalamus, which has long been known to be important in maintaining wakefulness, is 
the location of the Orx-containing neurons. Orx stimulates cortical activation, behavioral 
arousal and autonomic changes by diffuse projections and excitatory influences on the 
cortex, BF Ach-containing neurons, His-containing TMN neurons, NA-containing LC neurons, 
and spinal cord motor and sympathetic neurons43. Orx-containing neurons have been found 
to tonically discharge during wakefulness, decrease firing during NREMS and cease firing 
during REMS44,45. Thus, they are assumed to stimulate arousal, and antagonize cortical 
deactivation and loss of muscle tonus, which occurs in their absence in cases of narcolepsy. 
By diminishing the discharge frequency of REM-on cholinergic neurons located in the 
PPT/LDT, they block the occurrence of REMS episodes during wakefulness46. They have a 
central role in stimulating and maintaining wakefulness, given their innervation and 
excitatory role on all the other arousal systems. However, Orx does not inhibit sleep-
promoting neurons in the preoptic region5.  
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Ach-containing neurons of the BF: These neurons have an important role in cortical 
activation47. Local delivery of agonists of the arousal systems, such as NA, evokes fast cortical 
activity, especially high-frequency EEG called gamma activity. Conversely, local 
administration of blockers, such as lidocaine produces a loss of fast cortical activity and 
predominance of low-frequency EEG called delta activity. These Ach-containing neurons are 
found to be active during continuous wakefulness enforced by sleep deprivation48 and also 
during REMS. Their discharge rate correlates positively with the EEG power of fast gamma 
(30-60 Hz) and theta (4–8 Hz) across sleep–wake states, and correlates negatively with delta 
activity (1–4 Hz). Thus, they stimulate high-frequency gamma and theta activity during both 
wakefulness and REMS, through an activation of cortical neurons mediated by nicotinic 
and/or muscarinic Ach receptors20. 
For instance, Nicotine, one of the most common stimulants, provokes cortical activation and 
blocking nicotinic Ach receptors diminishes this cortical activation. Muscarinic Ach receptor 
antagonists such as scopolamine or atropine block fast cortical activity and induce a 
predominance of EEG delta activity even while animals appear to be awake49. Thus, BF Ach-
containing neurons have a crucial role in stimulating and maintaining cortical activation 
during both wakefulness and REMS. 
 
5.1.2.2.  Sleep-generating system 
The action of the ascending arousal system is counter-balanced by several other neuronal 
populations which have been identified as being sleep-active and are involved in promoting 
and maintaining natural sleep. These neurons mainly releasing GABA, provide inhibitory 
control of many arousal nuclei50.  
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GABA-containing neurons in the BF and preoptic area: Since the 20th century, it has been 
known that neurons in the BF and preoptic area have an important role in promoting sleep, 
because lesions in these areas result in insomnia. Moreover, it was shown that neurons 
located in these regions discharge at higher rates during sleep than during wakefulness51,52. 
The first neuronal population to be identified was neurons in the VLPO53, which provides 
inhibitory control of many of the arousal nuclei. These cells mainly release GABA, but some 
also release the small inhibitory peptide galanin. VLPO neurons increase their firing just 
before the onset of EEG synchronization and progressively increase their activity with sleep 
depth, a pattern that is consistent with them being involved in both causing and stabilizing 
natural sleep52. A second population of GABA-releasing neurons in the median preoptic 
nucleus (MnPO) also displays enhanced firing during both REMS and NREMS54, with firing 
increasing in anticipation of sleep but then slowly declining during prolonged periods of 
NREM sleep, implying a role for these neurons in sleep initiation55. A last group of sleep-
active GABAergic neurons is interspersed among cholinergic cells in the magnocellular 
regions of the BF56. The firing of these neurons, like VLPO neurons, is associated with sleep 
depth, but in this case the firing rates are higher during NREM sleep than during REM sleep52. 
Thus, this suggests that sleep initiation and maintenance is an active process that exerts 
inhibitory control over the ascending arousal nuclei, predominantly through GABAergic 
inhibition from the hypothalamus and the BF. Importantly, arousal nuclei can also send 
reciprocal inhibitory feedback to the sleep‑promoting nuclei57,58,59. Thus, when the arousal 
nuclei are inhibited, this positive feedback disinhibits the sleep-promoting centers, further 
enhancing their firing. This results in a bi-stable system that can only flip-flop between 
sleeping and waking and cannot normally rest in some intermediate state59. 
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GABA-containing neurons in brainstem and thalamus: GABA-containing neurons in other 
areas also appear to be active selectively during sleep to inhibit wake-active neurons in 
many areas, including the brainstem reticular formation and LC60,61. GABA-containing 
neurons in the caudal medullary reticular formation, together with glycine (Gly)-containing 
neurons62 are active during REMS. Their projections to the spinal cord might inhibit spinal 
motor neurons directly during REMS producing atonia. 
In the thalamus, GABA-containing neurons inhibit thalamocortical relay neurons to dampen 
cortical activation by diminishing the sensorial influx going through the cortex63. Their burst 
pattern of discharge during NREMS triggers spindle activity (12–14 Hz). With increasing level 
of hyperpolarization of the thalamocortical relay neurons, spindles are progressively 
replaced by delta oscillations (1-4 Hz). This delta rhythm of the entire cerebral cortex is not 
only imposed by the thalamus but also intrinsically by pyramidal cells from the V cortical 
layer64,65. 
In summary, GABAergic transmission is therefore involved in the induction and maintenance 
of NREMS by inhibiting the ascending arousal nuclei and by sustaining the thalamocortical 
burst creating spindles and delta activity. 
 
Adenosine (AD): AD has long been thought to play a role in sleep since caffeine, the major 
stimulant used around the world, was found to act as an antagonist at AD receptors. AD 
antagonists increase wakefulness and decrease sleep along with EEG delta activity in 
humans and rodents66,67. Conversely, AD and its analogs increase sleep and enhance delta 
activity in a way suggesting that AD could serve as an endogenous sleep promoting 
substance. Moreover, mice with a loss of function of A2a receptors have reduced sleep and 
reduced response to sleep deprivation and caffeine68,69 and human polymorphism of the 
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catabolic enzyme, AD desaminase, directly affected homeostatic regulation of sleep70. This 
leads to the conclusion that adenosinergic modulation may play an important role in sleep.  
 
5.1.2.3.  REM-on and -off neurons 
During the past decade, evidence from both rat and cat studies has suggested that each of 
the events of REMS is executed by distinct cell groups located in the brainstem71. These cell 
groups are discrete components of a widely distributed network, rather than a single REMS 
‘‘center”. One of the most important experiment in the field was the discovery that many 
neurons of the perilocus coeruleus α (peri-LCα) show a tonic firing selective to REMS; i.e. 
REM-on neurons72,73. Two types of REM-on neurons were recognized: (1) the cholinergic ones 
projecting to rostral brain areas potentially involved in cortical activation during REMS, and 
(2) the non-cholinergic ones proposed to generate muscle atonia during REMS through 
descending excitatory projections to Gly pre-motoneurons. These non-cholinergic neurons 
were thought to be glutamatergic (Glu) 74. Another achievement in research for REMS 
regulatory mechanisms was the finding that 5-HT-containing DRN neurons, NA-containing 
LC neurons, His-containing TM neurons and Orx neurons from hypothalamus cease firing 
specifically during REMS, i.e, show a REM-off firing activity, reciprocal to that of REM-on 
neurons.  Nowadays, the hypothesis suggesting that REMS onset is gated by reciprocal 
inhibitory interactions between REM-on and REM-off neurons is well accepted. Recent 
findings have led to update models of the mechanisms controlling REMS onset and 
maintenance involving various neurotransmitters such as Glu, GABA, MCH and Gly 75. 
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5.2.  Regulation of sleep 
The discovery of specific pathways involved in governing sleep has improved our 
understanding of the differences in brain activity while we are asleep and awake. As seen 
previously, the mutual “inhibitory-excitatory loop” between the arousal system (active 
during wakefulness) and the sleep-generating system (active during sleep) is predisposed to 
a “flip-flop” switch mechanism, being in either one state or the other, with a very rapid 
transition5. This rapid transition state is highly conserved across species and is an important 
survival mechanism. 
Factors that influence this circuit have been the topic of considerable research, providing 
new insights and opportunity for treating sleep-related disorders. Two different factors have 
a major impact on sleep/wake distribution. First, homeostatic influences, such as the 
accumulation of sleep debt following prolonged period of wakefulness, and second, the 
endogenous circadian rhythm, which produces the 24h cycle and governs many biological 
processes. 
 
5.2.1. Circadian control of sleep regulation 
The regulation of sleep is strongly influenced by circadian rhythms.  Indeed, we are all 
conscious of bedtime and wake time, especially when the quality of our sleep is disrupted. 
This occurs, for example, in response to shift work and jet lag and leads to decrements in 
quality of life, performance, and health76.  
In mammals, a master circadian pacemaker critical for circadian organization of sleep/wake 
states has been localized to the suprachiasmatic nucleus (SCN), a cluster of neurons 
bilaterally distributed in the anterior hypothalamus77.  This pacemaker is interconnected with 
the cell groups specialized for the induction and maintenance of wakefulness, REMS and 
NREMS previously described in “sleep/wake neuronal pathways and neurochemistry”5,78. 
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Thus, SCN may control this system by actively promote arousal during the active phase and 
sleep during the rest phase79. 
Several studies in animals supported the hypothesis that SCN has intrinsic oscillatory 
properties and can affect sleep/wake organization. For instance, SCN transplantation of 
arrhythmic hamsters, whose own nucleus had been ablated, restored circadian rhythms, 
confirming the endogenous properties of the SCN80. Lesions of the SCN in rodents leads to 
total arrhythmicity in the sleep/wake distribution81,82. In addition to having a control over the 
sleep/wake distribution, SCN produces a rhythmic output that influences, activity, 
temperature, drug metabolism, heart rate, regulation of stress and hormones (melatonin, 
cortisol, growth hormones), immunity and even the timing of the cell-division cycle83. 
Most mammals have a circadian period very close to the 24h day and highly stable; longer 
than 24 h in human (24.18 h84) and shorter than 24 h in mice (22.88 h and 23.61 h in C57BL/6J 
and BALB/cJ inbred mouse strains respectively85. Kleitman performed the first experiment 
demonstrating that the endogenous circadian rhythm of body temperature continues to 
exhibit a near-24-hour circadian rhythm in a human subject living on a non-24h routine, 
deep within a cave shielded from all known periodic stimuli from the external environment86. 
Moreover, studies of naps, short and ultrashort sleep/wake schedules, short-term constant 
routines, long-term temporal isolation, and forced desynchrony have produced a coherent 
body of evidence consistent with the view that the circadian clock in humans plays a 
bidirectional role in sleep/wake regulation, alerting at some phases, and promoting sleep at 
other phases87,88. These studies also clearly demonstrate that the onset and duration of the 
main daily sleep episode and of REMS are strongly controlled by circadian phase.  
Importantly, environmental cues called Zeitgebers (German, literally "Time Givers") are 
necessary to reset the endogenous clock each day in order to keep a perfect 24h rhythm. 
One of the most important zeitgebers is light. The SCN receives information about 
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illumination through the eyes; the photopigment melanopsin sensitive to light (particularly 
blue light) and expressed in specific photosensitive ganglion cells of the retina detects and 
transmits light information through the retinohypothalamic tract to the SCN89.  
Overall, this supports the view that the distribution of sleep over the 24h day is strongly 
determined by the circadian system. 
 
5.2.2. Homeostatic aspects of sleep regulation  
The homeostatic process tracks sleep need. Sleep need and the propensity to initiate sleep 
increase during wakefulness and decrease during sleep. This homeostatic process of sleep 
also appears as a 24h oscillation with the important distinction that this oscillation is 
imposed or driven by the sleep/wake distribution whereas the circadian rhythm is self-
sustained. To emphasize this distinction, the oscillation generated by the homeostatic 
process is sometimes referred to as a “hour-glass” and the oscillation generated by the 
circadian process as a self-sustained oscillation. The homeostatic process is seen as a process 
which strives to maintain a preferred or required level of sleep. Thus, the quantification of 
sleep homeostasis might be assessed by the average level to which a specific sleep variable 
returns after a perturbation, such as sleep deprivation. Dependent variables may include 
total sleep time, REMS, NREMS and specific EEG variables such as EEG delta (1-4 Hz) power 
during NREMS or EEG theta (4-8 Hz) power during wakefulness. 
In this work, sleep homeostasis is indexed by delta power in NREMS. Delta power is the 
quantification of EEG delta activity through EEG spectral analysis. It is negatively correlated 
with the response to arousing stimuli90 and NREMS fragmentation91. Therefore, delta power 
seems to be the best electrophysiological indicator of sleep depth or sleep intensity in 
humans and in animals. Sleep loss evokes a proportional increase in delta power, while a 
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sleep excess induces a decrease92,93. Delta power during a night sleep decreases with the 
number of NREMS episodes. 
 
5.2.3. The two-process model of sleep regulation 
A dominant and well-validated model for sleep regulation today is the two-process 
model94,95. These two processes – the homeostatic process and the circadian process – 
sometimes work together and sometimes against each other, and the situation and wishes 
of the person can often override the process and keep us awake when we should be 
sleeping.  
Conceptually, the model considers the alternation of wakefulness and sleep to result from 
the interaction of two processes, S and C (Figure 5.3). The saturated exponential process S 
represents sleep need; the homeostatic process of sleep as seen previously. It increases 
during waking and decreases during sleep. Functionally, this implies that sleep would serve a 
recovery function. Process S is entirely determined by the temporal sequence of behavioral 
states. The sinusoidal process C (circadian process), in contrast, is totally controlled by the 
circadian pacemaker (SCN), irrespective of behavioral state, and is proposed to set limits to 
process S. Those limits vary with time of day. As soon as S reaches the lower limit during 
sleep, subjects will wake up. If S reaches the upper limit during waking, sleep will be initiated. 
Delta power behaves as predicted for a measure representing the decline of S during 
sleep96,97 and its increase during waking92. This relationship alone turned out to be sufficient 
to quantify the dynamic properties of both processes (Figure 5.3)94. 
 
 
 
 26 
Figure 5.3: The two-process model of sleep 
regulation. 
Process S represents sleep need. It increases 
during wakefulness and decreases during sleep. 
Its variation is restricted to a range of values 
determined by the circadian process C (dotted 
lines), which is not constant over time but varies 
with the time of day. In addition to the 24h 
variation of process C, there is an influence of 
conscious decisions, which can temporarily 
modify the positions of the process C 
thresholds. (Figure from ref. 98) 
 
The 2-process model reliably predicts increased delta power and sleep time in a sleep 
episode following a prolonged period of wakefulness, as seen after sleep deprivation (Figure 
5.4) 99,100. 
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Figure 5.4: Effect of sleep deprivation simulated by the two-process model. 
When subjects are sleep deprived (2nd 24h period), additional sleep pressure builds, leading to greater delta 
power and total sleep (TST) time on the subsequent night of recovery sleep. (Figure modified from ref. 101) 
 
 
Evidence showed that the homeostatic and circadian processes are controlled by distinct 
mechanisms. In arrhythmic SCN-lesioned rodents, increases in delta power and NREMS 
amount after sleep deprivation are not obliterated102, and animals exposed to different 
photoperiods show dramatic changes in the distribution of sleep and wakefulness, whereas 
S
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the homeostatic component of sleep (delta power) is unaffected103. In human, alertness and 
cognitive performance kept a clear circadian rhythm even during 88h sleep deprivation104. 
To summarize, the two processes are generated independently but their interaction 
determines the timing, duration and quality of both sleep and wakefulness105. 
 
5.3. Sleep-promoting drugs 
In the adult population, about one third is suffering from occasional sleep disturbances. 
About one in ten is suffering from a chronic sleep disorder, which is also affecting the 
person’s mood and daytime performance. This is a major social, medical and economic 
problem in modern society. This part reviews the pharmacology of sleep with special 
emphasis on sleep-promoting drugs. 
 
5.3.1. History 
While the effects of opium were known for thousands of years, it became a patent medicine 
product in the 1800s when it was combined with alcohol and sold as laudanum (tincture of 
opium). Although effective, this treatment had serious safety problems, including 
dependency and respiratory depression. Chloral hydrate, another abusable sedating 
medicine employed to induce sleep, became widely used in the mid-19th century. 
Barbiturates were developed in the early 20th century and remained the primary prescribed 
hypnotic medications until the 1960s. Other past hypnotics included glutethimide, 
ethchlorvynol, paraldehyde and bromide preparations. For all of these, there have been 
serious safety concerns106. 
In recent decades, pharmaceutical approaches to the treatment of sleep disturbance led 
primarily to major improvements in safety, however, none of the molecules currently used is 
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capable of producing “natural physiological” sleep.  
 
5.3.2. Benzodiazepines (BZD) 
BZD medications became available in the 1960s and were promoted first for the treatment of 
insomnia in the early 1970s with the introduction of flurazepam. Importantly, BZDs lacked 
the toxicity of barbiturates, as well as the risk of overdoses due to their pharmacokinetics107. 
They improve insomnia symptoms by binding to the GABAA receptors on postsynaptic 
neurons in the central nervous system, thus inhibiting neuronal excitation through increased 
neuronal chloride permeability.  Indeed, GABAA receptors are pentameric chloride channels 
(the five subunits form a rosette around a transmembrane ion channel) widely expressed in 
the central nervous system including in the thalamus and cortex, two key areas for sleep 
physiology108. The complex GABAA receptors heterogeneity, derived from the large variety of 
its subunits, influences the cellular and subcellular localization of these receptors as well as 
electrophysiological properties109,110,111. In addition to their sedative effect, BZDs produce 
anxiolytic, muscle relaxant, anticonvulsant effects and impair cognition112. The results of a 
meta-analysis published in 2000 revealed that BZDs increased total sleep time but did not 
significantly affect sleep latency113. However, BZDs reduce REMS and prolong REMS 
latency114. Daytime sleepiness or “hangover” effect, dizziness, and impaired memory are 
often reported as adverse effects. Anterograde amnesia has also been associated with BZDs, 
particularly BZDs with short half-life like midazolam (Dormicum®) and tiazolam (Halcion®) 
while agents with longer half-lifes like flurazepam (Dalmadorm®) and flunitrazepam 
(Rohypnol®), increase the risk of “hangover” effect, confusion, dizziness and falls115. Moreover, 
their long-term use could also lead to tolerance and dependence, as well as rebound 
symptoms at withdrawal116. These side-effects have stimulated research on novel, more 
selective compounds. 
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5.3.3. Z-drugs 
A new generation of sleep-promoting compounds, following the BZDs was launched in the 
1980s. This new class of drugs, called Z-drugs (Zolpidem (Stilnox®), (S)-Zopiclone (lunesta®), 
and Zaleplon (Sonata®)), is structurally different from BZDs although they act on the same 
GABAA-receptor binding site. Z-drugs, as well as BZDs, are positive modulators, i.e. they 
enhance the GABA-induced chloride current. They have little intrinsic activity in absence of 
GABA117. Overall, Z-drugs have similar effects on sleep as BZDs, including the shortening of 
sleep latency and reduction of REMS118. They are reported to cause less dependence and 
“hangover” effects compared with BZDs115, despite a lack of convincing evidence showing 
benefit of newer Z-drugs compared to BZDs119. Importantly, the prescription of both Z-drugs 
and BZDs should be restricted for short-term use to avoid side-effects such as amnesia, 
tolerance and dependence which showed increasing risk with long-term treatments120. 
Currently, two modes of GABAA-mediated transmission are distinguished: “phasic” and 
“tonic” transmission. Traditionally, GABAA-mediated transmission refers to phasic inhibitory 
postsynaptic currents following activation of synaptic receptors by high concentration of 
GABA released from presynaptic nerve terminals121. The persistent tonic inhibition, recently 
discovered, is thought to be mediated by extrasynaptic GABAA receptors, which are 
continuously activated by low concentration of GABA. Thus, phasic conductance rapidly and 
transiently inhibits neuronal excitability, while tonic conductance slowly reduces the 
capability of neurons to be excited. This property to establish a baseline excitability level of 
neuronal network raises the possibility that such a mechanism may be involved in sleep117. 
Molecules mediating this tonic inhibition, such as gaboxadol (THIP) and tiagabine, were 
investigated for the treatment of insomnia. It is important to mention that, conversely, BZDs 
and Z-drugs target GABAA receptors mediating phasic inhibition. 
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5.3.4. Drugs modulating tonic inhibition 
THIP is a selective GABAA agonist and its effects on sleep differ substantially from those 
induced by allosteric modulators such as BZDs and Z-drugs. THIP increases NREMS EEG slow 
oscillations (<10 Hz), decreases of NREMS EEG spindle frequency range, and does not affect 
REMS amount or cognition, diametrically opposing the effects of BZDs and Z-drugs117. 
However, THIP was discontinued in March 2007 while in a Phase III clinical trial, because of an 
overall unfavorable therapeutic profile, including lack of efficacy in a three-month study and 
a higher incidence of psychiatric side effects122. 
Tiagabine is a GABA uptake inhibitor (inhibition of GABA transporter GAT-1) launched 
initially as an anticonvulsant in the treatment of epilepsy. Recently, it has been investigated 
for its potential as a hypnotic123,124. Its effects on sleep was similar than those found for THIP. 
Currently, new compounds targeted specific subunits of GABAA receptors either located in 
sleep neuronal networks or involved in tonic conductance are under investigation as 
potential hypnotic agents125,126. 
 
5.3.5. Anti-histamines and antidepressants  
First-generation antihistamines, such as diphenylhydramine and doxylamine, are frequently 
used as nonprescription sleeping aids, although not much of the existing data support their 
use. They can give temporary relief for sleep problems, but long-term treatment are not 
recommended due to tolerance development127. 
The prescription of antidepressants as sleep-promoting drug is not uncommon, but typically 
more beneficial in patients with comorbid depression. Sedative effects of trazadone, 
amitriptyline and mirtazapine for example are well known128.  
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5.3.6. Serotonin antagonists 
The 5-HT2 receptors have been recently among the most promising targets in the search of 
effective and well-tolerated novel medications for the treatment of sleep disorders129. 
Ritanserin has been found to increase the amount of delta activity and deep NREMS (SWS) in 
healthy volunteers and young poor sleepers130,131, and in rats132. Ketanserin another 5-HT2A/5-
HT2C receptor antagonist, has also been demonstrated to promote SWS, although to a lesser 
extent than ritanserin133. Epilvanserin, considered as a selective 5-HT2A receptor antagonist134, 
is in late Phase III clinical development for chronic insomnia characterized by difficulties with 
sleep maintenance. This compound appears to increase EEG delta and theta power in NREMS 
but does not produce physiological EEG sleep135.  Antagonists and inverse agonists of 5-HT2 
receptors are promising sleep-promoting drugs, which in addition, appear to be well 
tolerated with a lack of abuse potential. 
 
5.3.7. Melatonin agonists 
The hormone melatonin has a strong circadian rhythm136 and serves as a sleep-anticipating 
cue in humans. The ability of melatonin to shift circadian rhythms is well known. As a result, 
melatonin has been used in the treatment of various circadian rhythm sleep disorders, such 
as advanced and delayed sleep phase disorders, jet lag and shiftwork disorder. However, the 
current evidence for melatonin being effective in the treatment of primary insomnia is less 
compelling137. Melatonin appears to have a clear beneficial effect on sleep in individuals with 
a low endogenous level of melatonin such as elderly or those suffering from circadian-
rhythm disorders. However, melatonin receptors agonists, which have a longer half-life than 
melatonin, represent a novel approach in the therapeutic management of insomnia. 
Ramelteon, the first melatonin-receptor 1 and 2 agonist on the market, appears to be well 
tolerated and efficient especially to induce sleep138. Evidence supports that ramelteon can 
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also increase total sleep time (TST)139, however subjective measures of sleep quality are not 
consistent140,141. Further comparative studies with others hypnotic agents are needed to 
assess the real impact of this treatment in insomnia. 
 
5.3.8. Orx antagonists 
Expectedly, in light of the wake-promoting effects of Orx, antagonists of Orx receptors are 
under investigation as a potential new class of sleep-promoting drugs. Almorexant (ACT-
078573), a selective, dual Orx1 and Orx2 receptor antagonist, showed to increase NREMS, 
delta power in NREMS and REMS without producing symptoms of narcolepsy such as 
cataplexy142,143, although several important points to further investigate has been raised144.   
 
5.3.9. GHB 
Several studies in humans and in animals suggest that GHB may promote “physiological” 
NREMS and particularly SWS145,146,147 which makes GHB highly interesting, because the other 
sleep-promoting drugs induced a “pharmacological” or “non-physiological” sleep (except 
perhaps Orx and melatonin receptor antagonists) and appear to have much more severe 
side-effects than GHB. As already mentioned, one of the aim of this thesis was to investigate 
whether GHB is able to induce physiological sleep and better understand its mechanisms. 
The following part introduces GHB and its potential mechanisms of action.  
 
5.4. GHB 
GHB is a short-chain fatty acid derivative of GABA, the major inhibitory neurotransmitter in 
the brain148(Figure 5.5). Early studies on GABA function were hampered by its inability to 
cross the blood-brain barrier. In an attempt to produce a GABA analogue that could more 
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easily enter the brain, H. Laborit introduced GHB in 1960149, which showed sedative 
properties. Since then, GHB has been used as an anaesthetic for minor surgical procedures in 
the laboratory150,151 and in the clinic152, and is marketed in Italy for treating alcoholism 
(Alcover®)153,154 and in Europe and USA for treating narcolepsy with cataplexy (Xyrem®)155,156. 
GHB is also currently under investigation for potential treatment of different disorders such 
as fibromyalgia157,158, depression and anxiety159,160. 
However, GHB is notoriously known as a recreational drug of abuse. Indeed, GHB and its 
precursors (γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD); Figure 5.5) are currently 
abused for their recreational and pleasurable properties (heightened sexual pleasure, stress 
reduction, sedative, anti-anxiety, and antidepressant effects) by club attendees (rave parties); 
anabolic effects by body builders; and disinhibitory and sedative effects by sexual predators. 
Of interest, GHB’s physiochemical properties (colorless, odorless, and slightly salty taste) 
have been exploited as an “ideal” date rape drug160.  
 
 
 
 
Figure 5.5: Structure of GABA, GHB and the two prodrugs of GHB: GBL and 1,4-BD. 
The chemical structure of these four molecules are very similar. The prodrugs of GHB, GBL and 1,4-BD, are rapidly 
converted into GHB in humans and rodents. GHB is a metabolite of GABA. Both are found naturally in the 
mammalian brain. (Figure modified from ref.161). 
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5.4.1. GBL, a prodrug of GHB 
Since the GHB banning and series of warnings from different health agencies, the interest of 
GHB users for its recreational properties has shifted to GHB prodrugs, in particular GBL, due 
to its readily availability as a common solvent in numerous industrial processes162. The in vivo 
pharmacological properties of GBL are thought to be secondary to its final conversion into 
GHB163. Evidence showed that GBL is biologically inactive164 and all its biologic and 
behavioral effects are due to its rapid conversion to GHB by peripheral lactonases or by 
nonenzymatic hydrolysis165,166. The half-life of conversion of GBL to GHB has been estimated 
to be less than 1 minute164. Moreover, GBL has a greater lipid solubility than GHB, allowing 
uniform and rapid absorption. This greater liposolubility might also explain why several 
studies show that GBL has a better bioavailability, and is slightly more potent than GHB 
itself167,168,169,170. 
 
5.4.2. GHB: Neurotransmitter and metabolism 
GHB is unequivocally a naturally substance occurring in the mammalian brain171, which is 
present in micromolar concentration (1-4 µM)172. Regional distribution studies revealed that 
the substantia nigra, thalamus, and hypothalamus contain the greatest amount of GHB, 
whereas the cerebellum and certain areas of cerebral cortex have the lowest 
concentrations173,172. The distribution of GHB is not limited to the nervous system. Indeed, it is 
normally present in other extraneural tissues like kidney, heart and skeletal muscle, 
containing markedly greater concentrations than the brain174.  
GHB is derived from the conversion of its parent neurotransmitter, GABA, to succinic 
semialdehyde through mitochondrial GABA transaminase. Succinic semialdehyde is then 
reduced to GHB by cytosolic succinic semialdehyde reductase175,176. GHB may be metabolized 
through the action of GHB dehydrogenase to succinic semialdehyde, which may be further 
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metabolized either to GABA, by GABA transaminase or to succinate through the action of 
mitochondrial succinic semialdehyde deshydrogenase to finally enter into the Krebs cycle 
(Figure 5.6).  
 
 
Figure 5.6: Metabolism of GHB and interrelationship with GBL and 1,4-BD.  
The most important synthetic pathway for GHB entails conversion of GABA to succinic semialdehyde by 
mitochondrial GABA transaminase, followed by reduction of succinic semialdehyde to GHB by cytosolic succinic 
semialdehyde reductase. Mitochondrial succinic semialdehyde dehydrogenase, converting succinic 
semialdehyde to succinate, couples neurotransmitter metabolism to mitochondrial energy production. This is the 
enzyme missing in clinical and experimental deficiency of succinic semialdehyde dehydrogenase. A minor 
pathway for GHB production involves partial oxidation of 1,4-butanediol. Systemically administered GBL is 
converted by a circulating lactonase to GHB. This lactonase is not present in the brain tissue. The most significant 
catabolic pathway for GHB degradation is the oxidation of GHB to succinic semialdehyde by NADP+-linked 
succinic semialdehyde reductase. The resultant succinic semialdehyde undergoes further metabolism to either 
GABA or succinate. A mitochondrial NADP+-independent transhydrogenase is capable of metabolizing GHB to 
succinic semialdehyde with the production of D-2-hydroxyglutaric acid from L-2-hydroxyglutarate and an end-
product of 4,5-dihydroxyhexanoate. There is disagreement as to whether there is significant metabolism of GHB 
through a β-oxidation scheme. (Figure from ref.177) 
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GHB is thought to be a neuromodulator or neurotransmitter because it shows many of the 
requisite properties, including a discrete, subcellular anatomical distribution in neuronal 
presynaptic terminals, along with its synthesizing enzyme178. Furthermore, a release of GHB 
after calcium-dependant neuronal depolarization, a sodium-dependent GHB-uptake system 
and an active vesicular uptake system have all been reported178,179,180.  
 
5.5. GHB receptors 
The existence of specific GHB receptor is suggested by specific, high-affinity GHB-binding 
sites that are observed in the brains of rats and humans181,182,183,184. The kinetics of GHB 
receptors are related to the 1-to-4 µM concentration of GHB that is typically found in 
mammalian brain tissue172,185. Maitre’s lab even cloned a GHB receptor in the rat and two 
other GHB receptors in humans186,187. Although there are contradictory data188 (the reported 
receptor may just represent cloning artifacts), some evidence suggests that the GHB receptor 
is presynaptic and G-protein-coupled189 and that it may inhibit the release of GABA190. 
 
5.6. GABAB receptors 
Despite data showing that GHB may be biologically active in its own right, compelling 
evidence suggests that most of the physiological and pharmacological effects of systemically 
administrated GHB are mediated by the GABAB receptors in humans and in animals. Data 
showed that the systemic administration of GHB induced different molecular changes 
including an increase of serotonin turnover191, acetylcholine level (as other anaesthetics)192 
and dopamine level193, but also a decrease of glucose use in the brain194 and binding to 
NMDA receptors195. Moreover, it was shown that GHB altered presynaptic release of GABA 
and glutamate190,196. At the physiological level, after ingestion of GHB, the different effects 
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appear as hypothermia197, hypertension, tachycardia, increase of the renal sympathetic 
nerves activity198, decrease of minute ventilation and intestinal motility, secretion of growth 
hormone145, impairment of spatial learning195, increase of protection against neurotoxicity199 
and changes in EEG and behaviour145,200. All of these GHB effects seem to be due to the direct 
activation of GABAB receptors or their indirect activation after GHB conversion into GABA. 
 
Thirty years ago, metabotropic GABAB receptors were first identified based on the receptor’s 
distinct pharmacological profile compared to ionotropic GABAA/C receptors201,202. A few years 
later, it was shown that GABAB receptors are G-protein coupled receptors (GPCR) that usually 
inhibit adenylyl cyclase (AC) activity via the Gαi/o subunits of the activated G-protein203,204. The 
physiological consequences of inhibiting AC activity via GABAB receptors are not well 
understood but include effects on transcription factors (CREB2 (cAMP responsive element 
binding protein-2) and kinases (extracellular signal-regulated kinase 1 and 2 
(ERK1/2))205,206,207. Electrophysiological experiments on GABAB receptors revealed that these 
receptors modulate potassium and calcium channels activity, thereby controlling 
presynaptic transmitter release and postsynaptic silencing of excitatory 
neurotransmission208. Presynaptic GABAB receptors are present on inhibitory and excitatory 
terminals where they function as auto- and heteroreceptors, respectively. Stimulation of 
presynaptic GABAB receptors suppresses neurotransmitter release by inhibition of voltage-
sensitive Ca2+-channels, but a direct modulation of vesicle priming was also proposed209. 
Postsynaptic GABAB receptors induce a slow inhibitory postsynaptic current by gating Kir3-
type K+-channels, which hyperpolarizes the membrane and shunts excitatory currents210.  
GABAB receptors are expressed throughout the mammalian tissues and appear to be quite 
widely distributed in brain with however some regional variations211,212. 
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Although biochemical and pharmacological studies have long suggested the presence of 
diverse GABAB receptor subtypes213, molecular cloning has only identified two genes 
encoding receptor subunits: GABAB1 and GABAB2208. It is now well accepted that most 
functional GABAB receptors in the brain are formed as GABAB1 and GABAB2 heterodimers214,208. 
In the heteromeric receptor, GABAB1 is responsible for binding of all known GABAB ligands, 
whereas GABAB2 is necessary for surface trafficking and G-protein coupling215,216. 
The only firmly establish molecular diversity in GABAB system thus far arises from the two 
isoforms of the GABAB1 subunit: GABAB1a and GABAB1b217. The transcripts of these two subunits 
are generated from a single GABAB gene by differential promoter usage 218,219 Structurally, the 
isoforms differ in their N-terminal ectodomain by pair of sushi domains (SDs) that are present 
in GABAB1a but not in GABAB1b. SDs, also known as complement control protein modules, or 
short consensus repeats, are found in other GPCR as well and mediate protein-protein 
interactions in a wide variety of adhesion proteins209. The SDs in GABAB1a bind to auxiliary 
proteins that can modify receptor subcellular location220,221.  
To improve understanding about the localization and the functions of each GABAB receptor 
subunit in vivo different knock-out and knock-in mice were generated: GABAB1–/–, GABAB2, 
GABAB1a–/– and GABAB1b–/– mice. GABAB1–/– mice do not exhibit detectable electrophysiological, 
biochemical or behavioral responses to GABAB agonists222, suggesting that GABAB1 subunit is 
absolutely necessary for the GABAB receptor operation. These mice and GABAB2–/– mice suffer 
from spontaneous seizures, hyperlocomotor activity, severe memory impairment, 
hyperalgesia, altered anxiety and depression-related behavior222,223. This clearly 
demonstrates that the lack of heteromeric GABAB1,2 receptors underlies these phenotypes. 
This finding also renders the existence of additional obligatory receptors subunits unlikely. 
However, GABAB1 exhibits a broader cellular expression pattern than GABAB2. Indeed, GABAB2 
mRNA was found only expressed in neurons, while GABAB1 mRNA is expressed both in 
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neurons and glia. This suggests that GABAB1 could be functional in the absence of GABAB2224. 
Atypical electrophysiological GABAB responses and GABAB1 protein relocation from distal 
neuronal sites to the soma and proximal dendrites GABAB2–/– mice support this view. These 
data on genetically modified mice suggest that association of GABAB2 with GABAB1 is 
essential for receptor localization in distal processes but is not absolutely necessary for 
signaling. It is therefore possible that functional GABAB receptors exist in neurons that 
naturally lack GABAB2 subunits. Apart from this atypical electrophysiological GABAB response 
and the subcellular relocalization of GABAB1 protein in GABAB2–/– mice, the two knock-out 
mice are relatively similar; they have similar phenotypes and pharmacological responses, and 
show a down-regulation of the GABAB subunit, which they are still able to produce. The 
requirement of one subunit for the stability of the expression of the other subunit supports 
again the view that in WT mice, virtually all GABAB2 protein is associated with GABAB1222,225,226. 
In conclusion, it remains unclear whether these atypical GABAB1 responses are of 
physiological relevance or represent an artifact of the knock-out condition which would be 
in accordance with numerous in vitro studies showing that GABAB2 subunit is necessary for 
activating the G-protein and for receptor trafficking to the cell surface. 
GABAB1a–/– and GABAB2–/– mice were generated a few years after GABAB1–/– and GABAB2–/– mice 
to determine whether the two isoforms of GABAB1 contribute to distinct native GABAB 
functions220. These mice allowed to show that GABAB1a and GABAB1b have distinct 
physiological properties and function due to their differential subcellular localizations but 
not due to their binding pharmacology, which is similar. GABAB1b was mostly localized to 
dentritic spines opposite to glutamatergic terminals and mediates the postsynaptic 
inhibition, whereas GABAB1a was largely found in distal axons and formed presynaptic 
heteroreceptors inhibiting glutamate release220,227,228. In agreement with the differential 
localization of the two isoforms of GABAB1, GABAB1a–/– and GABAB1b–/– mice display dissimilar 
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phenotypes. GABAB1a–/– mice have a deficit in long-term potentiation (LTP), which is 
correlated with an impairment of nonspatial hippocampal memory formation (object 
recognition task)220. This lack of LTP caused by the absence of presynaptic GABAB1a,2 receptor 
inhibition in amygdala give rise to a generalization of conditioned fear to nonconditioned 
stimuli229. In contrast to GABAB1a–/– mice, GABAB1b–/– mice display no LTP and object 
recognition impairment, but fear conditioning was totally impaired in these mice. Other 
reports assessing memory and anxiety also showed differences between GABAB1a–/– mice and 
GABAB1b–/– mice230,231,232. Furthermore, it was recently shown that baclofen (BAC), a high-
affinity agonist of GABAB receptors, and GHB decreased temperature and locomotion 
similarly in both genotypes, but to a lesser extent than WT mice. However, in baseline 
conditions, GABAB1b–/– mice exhibit higher locomotor activity in a novel environment 
compared to GABAB1a–/– and WT mice233.  
Thus, the differential distribution of GABAB1 isoforms may underlie some of the differences in 
GABAB physiological function and agonists’ potencies, but not all. Very interestingly, two 
recent studies open new exciting perspectives for the understanding of native GABAB 
response diversity. First, it was shown that regulators of G-protein signaling (RGS), and 
particularly RGS2 protein, are able to decrease the activation of GABAB agonists. This 
complex mechanism can modulate agonist activation differently according to the type of 
neuronal populations234. Second, a proteomic study showed that C-terminal domain of the 
GABAB2 subunit can bind tetrameric proteins, which present distinct but overlapping 
distribution pattern in the brain. These associated tetramers seem to determine both 
pharmacological properties and the kinetics of the receptor response. Specifically, they alter 
agonist potency, onset and desensitization of the GABAB response. Since most if not all 
GABAB receptors in the brain are associated with these tetramers, they qualify as auxiliary 
subunits of GABAB receptors235.  
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5.7. GHB and sleep 
A number of reports suggest that GHB may promote NREMS, particularly SWS, and decrease 
sleep latency both in patients with a history of impaired sleep236 and in healthy subjects145,237. 
Studies in animals also suggest that GHB may promote SWS and decrease wakefulness (e.g., 
in rats147,238 and cats146,239). 
On the other hand, several reports indicate that GHB has behavioral and EEG side effects that 
complicate the interpretation of these findings. GHB not only promotes delta oscillations 
during sleep, but can induce EEG hypersynchrony during wakefulness as well, both in 
humans145,236 and animals200,238,239,240. Thus, in studies that only rely on EEG recordings, it may 
be difficult to distinguish between overall EEG synchronization (including during 
wakefulness) and an increase in SWS. 
In addition, it appeared that the effects of GHB were GABAB receptor dependent. Indeed, for 
example GABAB1–/– mice, which did not express any functional GABAB receptors but kept 
normal binding to GHB receptors, showed neither the hypolocomotion, hypothermia, 
increase in striatal dopamine synthesis nor electroencephalogram delta-wave induction seen 
in wild-type mice241. 
Taken together, this suggests that GHB may have potential sleep-promoting effects by 
acting through GABAB receptors, but some of these effects may be difficult to distinguish 
and separate from its side effects (e.g. EEG synchronization). 
The currently most prescribed sleep-promoting drugs act through GABAA or H1 receptors 
and induce the so-called “non-physiological” sleep with less deep sleep and well-known side 
effects (e.g. dependence, tolerance). In this context, it is particularly interesting to investigate 
new substances such as GHB, which may induce “physiological sleep” and thus improve the 
treatment of different sleep disorders. 
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6. Research outline  
6.1. Animal study 
The aim of the present mouse study is to investigate the GHB effects and the role of each 
known subunits of GABAB receptors in vigilance states and EEG spectra by using different 
GABAB subunit knock-out mice: GABAB1–/–, GABAB2–/–, GABAB1a–/– and GABAB1b–/– mice. This will 
determine whether GHB (known to act as a low-affinity agonist of GABAB receptors) can 
induce “physiological” sleep and thus influences homeostatic regulation of sleep (and delta 
power) or not. Furthermore, GHB effects were compared with those of BAC, a high-affinity 
agonist of GABAB receptors. 
EEG and EMG of the different genotypes were recorded, three different experiments were 
performed. First, vigilance states and EEG spectra were analyzed during 24h baseline 
conditions. Second, 6h sleep deprivation followed by 18h recovery were performed. Finally, 
four and three different doses of GBL (precursor of GHB) and BAC respectively were 
administrated in the middle of the 12h light period when physiological delta power is low in 
order to see in what extent GHB and BAC can induce delta power by themselves and how 
that will influence physiological sleep. This work has been published in 2010 in Journal of 
Neuroscience. 
 
6.2. Human study 
The human study is a continuation of the mouse study. Its aim is to investigate whether GHB 
can induce physiological sleep and influence homeostatic process of sleep in humans. 
Furthermore, because two potential adverse effects of GHB are memory impairment and 
sedation and because sleep is known to consolidate memory, GHB effects on vigilance and 
memory are assessed by two vigilance tasks and three different memory tasks, respectively.  
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In order to determine the role of GABAB receptors in GHB response, BAC is administrated as 
well and its effects are compared to those of GHB.  
This study is a monocentric, placebo-controlled, double-blind and crossover study 
performed in young health volunteers. This human project has not yet been published. 
Please not that this part is not the final form and data analysis is still on going. 
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7. Animal study:  
Differential effects of GABAB receptor subtypes, GHB, and 
baclofen on EEG activity and sleep regulation 
7.1. Abstract 
The role of GABAB receptors in sleep is still poorly understood. GHB (γ-hydroxybutyric acid) 
targets these receptors and is the only drug approved to treat the sleep disorder narcolepsy. 
GABAB receptors are obligate dimers comprised of the GABAB2 subunit and either one of the 
two GABAB1 subunit isoforms GABAB1a and GABAB1b. To better understand the role of GABAB 
receptors in sleep regulation, we performed EEG recordings in mice devoid of functional 
GABAB receptors (1–/– and 2–/–) or lacking one of the subunit 1 isoforms (1a–/– and 1b–/–). The 
distribution of sleep over the day was profoundly altered in 1–/– and 2–/– mice suggesting a 
role for GABAB receptors in the circadian organization of sleep. Several other sleep and EEG 
phenotypes pointed to a more prominent role for GABAB1a as compared to the GABAB1b 
isoform. Moreover, we found that GABAB1a protects against the spontaneous seizure activity 
observed in 1–/– and 2–/– mice. We also evaluated the effects of the GHB-prodrug GBL (γ-
butyrolactone) and baclofen (BAC), a high-affinity GABAB receptor agonist. Both drugs 
induced a state distinct from physiological sleep that was not observed in 1–/– and 2–/– mice. 
Subsequent sleep was not affected by GBL while BAC was followed by a delayed 
hypersomnia even in 1–/– and 2–/– mice. The differential effects of GBL and BAC might be 
attributed to differences in GABAB-receptor affinity. These results also indicate that all GBL 
effects are mediated through GABAB receptors while these receptors seem not to be 
involved in mediating the BAC-induced hypersomnia. 
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7.2. Introduction 
GABAB receptors are involved in epilepsy222,242, anxiety and depression230,243, nociception244, 
memory232,245, addiction246,247,248, and potentially sleep249,250. While a prominent role of GABAA 
receptors in sleep is firmly established and is central in the pharmacological management of 
disturbed sleep117, little is known about the importance of GABAB receptors in regulating 
sleep and the electroencephalogram (EEG). Although the effects of specific GABAB agonists, 
like BAC, on rapid eye movement sleep (REMS) remain unclear249,251, available data indicate 
that BAC increases non-REMS (NREMS) and promotes EEG slow (delta) waves (0.75-4.5 Hz) 
during NREMS251,252,253. 
GHB is a GABA metabolite found in low concentrations throughout the mammalian 
brain171,176,254. Since its synthesis in the 1960s149, GHB has been used as an anesthetic, 
sedative, and hypnotic agent150,151. Because of its abuse potential GHB is banned in many 
countries. GHB is approved as a treatment for narcolepsy with cataplexy155,255. Although the 
mechanism of action is still unclear, GHB decreases excessive daytime sleepiness and attacks 
of cataplexy in narcolepsy patients256,257. Despite conflicting results suggesting that GHB acts 
through specific GHB receptors172,258, compelling evidence suggests that most of the 
physiological and pharmacological effects of exogenous GHB are mediated through GABAB 
receptors197,241,259,260,261. 
Both in patients and in healthy subjects, GHB decreases sleep latency and promotes deep 
NREMS evidenced by the marked increase in the prevalence and amplitude of EEG delta 
waves145,236,237. Animal studies also suggest that GHB promotes NREMS147,238,239. However, it 
was also reported that GHB and its GBL can induce paradoxical EEG slow/delta waves in 
awake humans145,236 and animals200,238. This finding challenges the claimed physiological 
sleep-promoting effects of GHB. A first aim of the present study was to investigate the role of 
each of the known GABAB receptor subunits in sleep-wake regulation and in mediating the 
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effects of GHB. A second aim was to perform a detailed sleep and EEG analysis to investigate 
whether the delta waves induced by GHB contribute to normal physiological sleep. 
7.3. Materials and Methods 
Animals and housing conditions 
All experiments were performed in accordance with the protocols approved by the Ethical 
Committee of the State of Vaud Veterinary Office, Switzerland. 
GABAB1–/– (1–/–), GABAB2–/– (2–/–), GABAB1a–/– (1a–/–), GABAB1b–/– (1b–/–) mice were generated on a 
BALB/c background as described previously220,222,225. Adult male mice of the four genotypes 
along with their wild-type controls (WT) were used in baseline conditions, 6h sleep 
deprivation, and in experiments with GBL and saline injections (n=8-9/genotype, age: 10-15 
weeks, weight: 24-31g). For the BAC experiments, BALB/cJ (WT) mice were purchased from 
Jackson Laboratory (Maine, USA). All mice were kept individually in polycarbonate cages (31 
x 18 x 18 cm) under a 12h light/dark cycle (lights-on at 9:00 a.m.) at an ambient temperature 
of 24.5–25.5 °C. Food and water were available ad libitum. 
Surgery and sleep recordings 
EEG and electromyogram (EMG) electrodes were implanted under deep anesthesia as 
previously described262. Four to six days of recovery from surgery were allowed before 
connecting animals to the recording leads. A minimum of 6 adaptation days (or 10 including 
recovery from surgery) were scheduled before data collection. The analog signals were 
digitized at 2 kHz and subsequently stored at 200 Hz on hard disc. The EEG was subjected to 
a discrete–Fourier transformation yielding power spectra (range: 0.75–90 Hz, frequency 
resolution: 0.25 Hz, time resolution: consecutive 4s epochs, window function: hamming). 
Hardware (EMBLA®) and software (Somnologica–3®) were purchased from Medcare/Flaga 
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(Iceland). Activity in the 50 Hz band was discarded from further analysis because of power 
line artifacts in the EEG of some of the animals. 
Based on the EEG and EMG signals, the animal’s behavior was classified as REMS, NREMS, or 
wakefulness 263. In addition to these three behavioral states, seizures, and drug (i.e., GBL or 
BAC)-induced states were also assessed (for description see below “GBL and BAC 
administration”). All states were scored by visual inspection of the EEG and EMG signals 
displayed on a PC monitor. 4s epochs containing EEG artifacts were marked, and excluded 
from EEG spectral analyses. 
Five to twelve animals were recorded together in one experimental session (1b-/- mice: n=9; 
1a–/– mice: n=8; WT mice: n=8; 1–/– mice: n=8; 2–/– mice: n=8). At least two genotypes were 
included per session in an attempt to equally distribute the environmental variation over 
genotypes. Overall, eight sessions were necessary to complete the study.  
Baseline and sleep-deprivation experiments 
EEG and EMG signals were recorded continuously for at least 48 hours with the first 24 hours 
serving as baseline followed by 6h sleep deprivation (SD) starting at light onset and 18 hours 
of recovery sleep. SD was achieved by ‘gentle-handling’ consisting of introducing novel 
objects into the cage, approaching a pipette next to the mouse, or gentle cage-tapping, as 
soon as a sleeping behavior was observed. Note that due to health deterioration, particularly 
when disturbed, 1–/– and 2–/– mice were not included in the sleep deprivation protocol. One 
subset of mice was used for the baseline conditions protocol (n=8/genotype), and one other 
subset of mice was included in the drug protocol (see below).  
Mean EEG spectra were calculated over 4s epochs scored as artifact-free NREMS, REM, or 
wakefulness to construct behavioral state-specific spectral EEG profiles for baseline. EEG 
delta power (a measure of homeostatic sleep need) was calculated by averaging EEG power 
density in the 1-4 Hz range for 4s epochs scored as NREMS. Time-course analysis of EEG delta 
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power during baseline and after SD was described in detail elsewhere264. In short, the 
recording was divided into sections to which an equal number of 4s epochs scored as NREMS 
contributed (i.e., percentiles). The first 6 hours of the baseline light period was divided into 6 
such sections; the second 6 hours into 4. The second 6 hours of the recovery light period was 
divided into 6 sections, the dark periods of both the baseline and recovery dark periods into 
8 sections. The choice of the number of sections per recording period depended on NREMS 
prevalence. Delta power values were normalized by expressing them as a percentage of the 
individual mean value reached over the last 4 hours of the main rest period when delta 
power is minimal during baseline.  
The main rest period was calculated as described previously265 with modifications. Mean 
sleep duration was calculated over a 2h moving average at 15min increments within 
individual mice. Fifteen-minute intervals in which mice slept more than their individual 24h 
baseline mean were termed as ‘rest’. Fourteen or more 15min ‘rest’ intervals interrupted by < 
6 non-‘rest’ intervals constituted a rest period. Applying this algorithm to mice, generally one 
main rest period is obtained associated with the light period. 
Sleep quality was assessed by analyzing its consolidation by counting the number of brief 
awakenings and the number of short and long NREMS episodes as previously described265. 
GBL and BAC administration 
Five days after the sleep deprivation experiment, EEG and EMG signals were recorded 
continuously for 6 consecutive 24h periods, starting at lights-on. 24h baseline was followed 
by a “saline” day and 4 days with administration of four different doses of GBL (50, 100, 150, 
and 300 mg/kg) or 3 days with administration of three different doses of BAC (5, 7.5, and 10 
mg/kg). WT mice taking part in the BAC experiment and 1–/– and 2–/– mice were not 
previously used in the sleep deprivation experiment. Out of concern of health condition in 1–
/– and 2–/– mice the drug protocol was slightly simplified, i.e., only saline and the highest drug 
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dose were tested (n=3/genotype/drug). To exclude any carry-over or tachyphylaxis due to 
our increasing dosing protocol, eighteen wild-type BALB/cJ mice (n=9/drug) were studied in 
a randomized cross-over experiment with GBL and BAC at the lowest and highest doses and 
saline. Mice were included in one of 3 conditions: (A) administration of the highest dose 
followed 24 hours later by the lowest dose and 24 hours later by saline, (B) administration of 
the highest dose followed by 48h washout, then the lowest dose and 24 hours later saline 
and, (C) administration of saline followed 24 hours later by the lowest and 24 hours later by 
the highest dose. The results indicated that the order of dose or duration of washout did not 
significantly affect the results for three main and tested sleep phenotypes: amount of drug-
induced state, time course of delta power in NREMS following the drug-induced state, and 
amount of NREMS after drug administration (rANOVA factor ‘condition’; data not shown). 
Drug doses were chosen according to the literature to cover a large range of 
sedative/hypnotic effects that could be compared between drugs200,222,266,267. Saline, GBL, and 
BAC were i.p. administrated 6 hours after lights onset at Zeitgeber Time (ZT) 6 (light onset 
being ZT0). At least 18 hours were recorded after the last injection. BAC- and GBL-induced 
states were characterized by an increase of hypersynchronous slow waves and/or spiky EEG 
pattern following drug injection. The drug-induced state can be readily distinguished from 
the three classical behavioral states, and were therefore analyzed separately. The drug-
induced state was determined as follows: at the onset of the drugs effects animals were 
awake while large amplitude short lasting (2-4s) burst of hypersynchronous slow waves 
appeared and progressively dominated the EEG until ‘normal’ EEG activity could no longer 
be discerned. The first waking 4s epoch in which abnormal EEG activity was observed was 
taken as drug-induced state onset. Towards the end of the drug-induced state this 
alternation between ‘normal’ waking and drug-induced state reappeared. The last 4s epoch 
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with abnormal EEG was taken as the end of the drug-induced state. Please note that the 
amount of drug-induced state was the sum of 4s epochs scored as drug-induced state. 
Four-second epochs of NREMS, BAC-, and GBL-induced states were subjected to spectral 
analysis to calculate the EEG power density in the delta frequency range (1-4 Hz). Time-
course analysis of the delta power on the saline day and the three or four days with 
injections of BAC or GBL, respectively, were performed similarly to the baseline condition. 
Delta power during the BAC- and GBL-induced state is presented as a single time-point as its 
duration was too short to reliably estimate a time course. 
Spectral content of the EEG during NREMS, BAC-, and GBL-induced state was quantified as 
described above. EEG spectra were normalized to be directly comparable as follows: EEG 
power in each frequency bin for each mean NREMS or drug-induced state spectrum was 
expressed as a percentage of the mean NREMS EEG power determined over all artifact-free 
4s epochs during 4 hours of the rest period in baseline within individual mice. 
Analysis tools 
TMT Pascal Multi-Target®5 (Software, TMT Development Corp, Brighton (MA), U.S.A) was used 
to manage the data, SigmaPlot® 10.0 (Systat Software Inc., London, UK) for graphics, and SAS 
Institute (Cary, NC) software, Ver. 9.1 for statistical analyses. 
Drugs 
Placebo was a saline solution (NaCl 0.9%, B. Braun Medical AG, Emmenbrücke, Switzerland). 
GBL and racemic BAC (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) were freshly diluted 
in saline solution to obtain different solutions of GBL (50, 100, 150, and 300 mg/kg) and BAC 
(5, 7.5, and 10 mg/kg) with an injection volume of 5ml/kg of body weight. 
GBL has a greater lipid solubility than GHB, allowing uniform and rapid absorption268. The in 
vivo pharmacological properties of GBL are secondary to its final conversion into GHB163. GBL 
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is biologically inactive164 and all its physiologic and behavioral effects are due to its rapid 
conversion (< 1 min) to GHB by peripheral lactonases or by non-enzymatic hydrolysis 165,166. 
 
7.4. Results 
Spontaneous epileptiform activity in 1–/–, 2–/–, and 1a–/– mice 
Both 1–/– and 2–/– mice lack functional GABAB receptors while 1a-/- mice still have functional 
GABAB1b,2 receptors and 1b–/– mice GABAB1a,2 receptors. As previously observed 222,225, all 1–/– 
and 2–/– mice displayed spontaneous seizures. Over the 24h baseline recording period, 5 out 
of 8 mice of both 1–/– and 2–/– genotypes showed at least one seizure. Health status of 1–/– and 
2–/– mice gradually deteriorated manifested as weight loss, ruffled fur, and hunched posture 
accompanying the increasing number of seizures (up to 20 seizures per day). Only data from 
healthy animals were included in the analyses. 
Interestingly, 4 out of 8 1a–/– mice also exhibited similar spontaneous epileptiform activity 
(Figure 7.1A), a phenotype never described before for this genotype. This epileptiform trait 
was, however, less severe with the number of seizure never exceeding 4 per day and without 
affecting their overt health status. Almost all seizures observed in the three genotypes were 
of the clonic type lasting between 12 seconds and 1.5 minutes. On occasion, tonic-clonic 
seizures were observed after audiogenic stimuli, handling, or cage change. In addition, 
epileptic mice displayed high-voltage EEG spikes generally in the hours prior and/or 
following a seizure (Figure 7.1B,C). Seizures could occur in all behavioral states and during 
both light and dark periods. No epileptiform activity was observed in any of the 1b–/– or WT 
mice. 
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Loss of GABAB receptors delays the rest period, reduces delta and theta activity in the 
NREMS EEG, and increases theta activity in the waking EEG. 
Although genotype did not affect behavioral state duration under baseline conditions (Table 
7.1) a lack of functional GABAB receptors greatly altered the sleep-wake distribution (Figure 
7.1D). While the main rest period in 1a–/–, 1b–/–, and WT mice was initiated several hours 
before light onset (-4.6 ± 0.7, -6.9 ± 0.4, and -6.2 ± 0.8 h, respectively; mean ± SEM throughout 
the text) which is typical for male BALB/c mice 85,265, in 1–/– and 2–/– mice the onset of the rest 
period was delayed by 6 h compared to WT and became closely associated with light-onset. 
The end of the rest period was similarly delayed in 1–/– and 2–/– mice compared to 1a–/–, WT, 
and 1b–/– mice (11.7 ± 0.2, 11.8 ± 0.1, 10.0 ± 0.3, 9.0 ± 0.4, and 8.9 ± 0.3 h after light onset, 
respectively; one-way ANOVA for rest-onset and rest-end: p<0.0001, Paired t-test: p<0.05). 
1a–/– mice displayed an onset and end of their rest period intermediate between 1–/– and 2–/– 
mice on the one hand, and WT and 1b–/– mice on the other. The delay of the end of the rest 
period was also reflected in the increased time-spent-asleep in the second half of the light 
period with highest values reached in 1–/– and 2–/– mice, intermediate in 1a–/– mice, and 
lowest in WT and 1b–/– mice (Figure 7.1D, Figure 7.2A,C). 
Genotype difference in the duration of the rest period, calculated as the time-span between 
the onset and end of the rest period, also distinguished 1–/– and 2–/– mice, from 1a–/–, WT, and 
1b–/– mice, the former two genotypes showing a significantly shorter rest period (one-way 
ANOVA for total rest duration: p<0.0001, 1–/– = 2–/– < 1a–/– = WT = 1b–/–; Tukey’s test: p<0.05; 
Figure 7.1D). Also for this phenotype, 1a–/– mice appeared intermediate between mice 
completely lacking GABAB receptors and WT and 1b–/– mice. While all other genotypes 
displayed only one rest period per 24 h, 1b–/– mice showed a consistent 3.0 ± 0.2 h ‘gap’ 
interrupting the rest period (Figure 7.1D). Apart from this marked re-distribution of sleep and 
waking over the day, we also noticed genotype differences in sleep architecture at the level 
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of individual sleep episodes. Judged by the increased number of brief awakenings (< 16 s), 
sleep in 1a–/– mice was more fragmented compared to all other genotypes (Figure 7.1E) 
consistent with the fragmented sleep recently reported in mice lacking functional GABAB 
receptors in orexin neurons specifically269. In contrast, we found that an overall lack of 
functional GABAB receptors (i.e., in 1–/– and 2–/– mice) lead to a greater number of longer 
periods of sleep (> 1 min) compared to the other genotypes (Figure 7.1E). Thus, brain site-
specific effects of GABAB receptors and subcellular localization of GABAB receptors 
subunits220,270 can have a profound impact on the consolidation of sleep. 
GABAB receptor genotype also affected EEG activity and the main spectral changes were 
found in frequencies below 20 Hz. During NREMS, 1b–/– mice exhibited a reduced EEG activity 
in theta frequency range compared to WT (3.75-7.5 Hz, Figure 7.3). This decrease became 
more pronounced both in terms of amplitude and frequency range in 1–/– and 2–/–mice, which 
showed a strong decrease over a broad frequency range (1.75-10 Hz), including both delta 
and theta frequencies, compared to WT mice. This decrease is reminiscent of the reduction in 
EEG synchronization observed after the thalamic administration of a GABAB receptor 
antagonist250 underscoring the crucial role of GABAB receptors in thalamocortical oscillations 
characteristic of NREMS271,272. 
The waking EEG spectra of the latter two genotypes also markedly differed from 1a-/-, 1b–/–, 
and WT mice in that theta activity, especially at around 7 Hz, was more pronounced (Figure 
7.3; statistics not shown for 1a–/– and 1b–/– mice). The increase in theta power during 
wakefulness might suggest an increase in active and exploratory behavior which is 
associated with hippocampal theta oscillations273. Alternatively, GABAB receptors seem to be 
directly involved in theta rhythm generation274 although the REMS spectral signature, with its 
characteristic theta peak around 7 Hz, remained unaffected by genotype. 
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The homeostatic regulation of sleep is not affected in mice lacking GABAB receptor 
subunits 
A 6h sleep deprivation (SD) was performed to assess whether GABAB receptor subunits 
contribute to sleep homeostasis. Due to the health deterioration of 1–/– and 2–/– mice during 
SD these two genotypes were excluded from this experiment. Recovery of sleep loss in the 
three remaining genotypes was evident by increases in both NREMS duration and in EEG 
delta power in the first 6 hours after SD (i.e., recovery light period). This response did not 
differ among 1a–/–, 1b–/–, and WT mice (Figure 7.2). EEG delta power steeply declined over the 
course of recovery and fell below baseline in the subsequent recovery dark period. During 
this period levels of delta power in 1a-/- mice were higher than those observed in 1b–/– and 
WT mice. This genotype difference was observed also in the dark period of baseline after a 
spontaneous period of wakefulness (Figure 7.2B). Although the effect of SD could not be 
evaluated in 1–/– and 2–/– mice (see Materials and Methods section), EEG delta power during 
baseline also decreased during the rest period and increased over the course of the active 
period. Like for 1a–/– mice, delta power levels reached in the baseline dark period in 1–/– and 
2–/– mice seemed higher than WT and 1b–/– mice (Figure 7.2B). These results together with the 
effects observed after SD in the other three genotypes suggest that GABAB receptors do not 
play a major role in sleep homeostasis as indexed by EEG delta power. 
GBL, through GABAB receptors, induces an anesthetic-like state distinct from 
physiological sleep 
We tested the effects of GBL and BAC on sleep and the EEG at various doses. Order of dose 
did not affect the main drug effects presented here (see Materials and Methods). 
Administration of GBL or BAC did not affect behavior or the EEG in 1–/– and 2–/– mice. In 
contrast, GBL and BAC dose-dependently affected the EEG and behavior in WT, 1a–/–, and 1b–
/– mice without noticeable behavioral or EEG differences among these three genotypes. At 
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low doses of GBL (50 and 100 mg/kg), EEG slow waves appeared (Figure 7.4A) and locomotor 
activity decreased, while animals remained behaviorally awake with eyes open and 
responded normally when stimulated. At higher GBL doses (150 and 300 mg/kg), mice 
became immobile with an unnatural flat body posture with hind limbs stretched sideways 
while eyes remained open. Their EEG displayed hypersynchronous slow waves and a spike-
like pattern, which was more abundant after the highest dose (Figure 7.4B). Importantly, at 
the highest GBL dose, animals became completely unresponsive to stimulation resembling a 
state of deep anesthesia. BAC, administered in WT mice, also induced hypersynchronous 
slow waves and decreased locomotor activity. However, even at the highest dose (10 
mg/kg), BAC did not induce the spike-like EEG pattern observed after 300 mg/kg of GBL 
(Figure 7.4C,D). Moreover, although at 10 mg/kg animals were also immobile with abnormal 
flat posture and open eyes, they still responded to tactile stimuli. The EEG patterns combined 
with behavioral observations indicated that the state induced by the drugs could not be 
interpreted as either normal sleep or wakefulness. We therefore scored periods with 
abnormal EEG following drug administration as “drug-induced state” (see Materials and 
Methods). While the GBL-induced state appeared 4 to 9 min after injection in 1a-/-, 1b-/-, and 
WT, the BAC-induced state appeared significantly later (13 to 17 min, one-way ANOVA: 
p<0.001) in WT mice. The amount of both drug-induced states varied according to dose and 
both 1a–/– and 1b–/– mice displayed an overall shorter GBL-induced state amount than WT 
mice (Figure 7.5E,F). 
Because of the induction of slow waves, especially at lower drug doses, reminiscent of those 
present during NREMS, we contrasted delta power during drug-induced state to the levels 
usually obtained during NREMS. Delta power during GBL-induced state increased from 50 to 
100 mg/kg but did not further increase at higher doses (Figure 7.6A). In 1a–/– and 1b–/– mice 
delta power reached at the highest three doses was significantly higher compared to after 50 
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mg/kg of GBL (Figure 7.6A). Furthermore, in 1a–/– mice, levels reached at the three highest 
doses were around 2-fold higher compared to 1b–/– and WT mice and 3-fold higher than the 
baseline reference reached in NREMS. During the BAC-induced state, delta power levels 
remained within the baseline range determined for NREMS and did not differ among doses 
(Figure 7.6B). 
Similar to the analysis of delta power, we contrasted the full EEG spectra during the drug-
induced state to the EEG spectra obtained during NREMS over the last four hours of the 
baseline rest period. In addition, because like GBL and BAC also SD increased delta power 
(Figure 7.2B), we compared the drug-induced state EEG spectra to the EEG spectra obtained 
during NREMS after 6h SD. Results for the highest GBL and BAC doses are illustrated in Figure 
7.6A,B (for all doses see Suppl 7.1). Spectral analyses revealed that the abnormal EEG activity 
following the injection of the highest GBL dose (300 mg/kg; Figure 7.4B) was due to a large 
increase of EEG activity in the low delta frequencies (0.75-1.5 Hz) reaching 3 to 4-fold higher 
levels than those reached after BAC and saline injections and ~1.5-fold higher compared to 
the effects of SD (Figure 7.6A). An equally large suppression of EEG activity was observed at 
frequencies over 3 Hz with the largest reduction reached at around 13 Hz (Figure 7.6A). The 
GBL effects on the EEG spectra were dose-dependent (two-way ANOVA in WT mice: factor 
‘dose’: p<0.0001, factor ‘bin’ p<0.0001, interaction p<0.0001) with a progressive increase with 
dose in the low delta frequencies (0.75-1.75 Hz) and a decrease with dose for frequencies 
above 3 Hz (Suppl 7.1). 
EEG spectra during the BAC-induced state revealed that only fast delta activity (4-5.25 Hz) 
contributed to the slow waves induced by this drug (Figure 7.6A). Although the increase in 
this frequency range was similar to the increase observed in the NREMS EEG after SD, the 
effect of SD also included slower delta oscillations (Figure 7.6A). EEG activity in higher 
frequencies (10.75-37.5 Hz) encompassing the sigma and beta ranges, was clearly reduced 
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by BAC compared to the NREMS spectrum after saline injection (Figure 7.6A, statistics not 
shown). Dose-dependent spectral differences for BAC were restricted to 3.25-4.5 Hz range, 
where 5 mg/kg has a significantly smaller effect than 10 mg/kg (Suppl 7.1D). Decreases in 
power density at higher EEG frequencies in the NREMS EEG were not observed after SD. 
Together these results suggest that neither the GBL- nor the BAC-induced state reflect 
physiological sleep found after 6h SD or saline injection. 
Genotype affected the drug-induced changes in EEG spectra. The most salient of these 
genotype differences are illustrated for the highest dose of GBL (300 mg/kg) in Figure 7.6B. In 
1a-/- mice, the increase in low frequencies during the GBL-induced state was more 
pronounced compared to WT and 1b–/– mice and significant increases in EEG power density 
extended to 2.75 Hz (high doses vs. the lowest dose; Suppl 7.1A,B,C ). Moreover, the decrease 
in EEG power density for frequencies >3 Hz, equally observed in 1b–/– and WT mice, was less 
pronounced in 1a–/– mice. In general, 1b–/– mice displayed a GBL EEG signature very similar to 
that observed in WT mice (Figure 7.6B and Suppl 7.1A,B). The same held true for the EEG 
spectra during subsequent NREMS (Figure 7.6D and Suppl 7.2A,B). 
BAC induces hypersomnia similar to that observed after sleep deprivation 
After the acute effects of the drugs on behavior and the EEG waned, normal behavioral 
states could again be assigned. We quantified the longer-term effects of both drugs on sleep 
and the EEG in WT as well as in 1–/– and 2–/– mice. Compared to individually-matched 
recording periods after saline injections, both BAC and GBL initially suppressed REMS. This 
loss in REMS time was fully compensated over the course of the final 12 h of the recording 
period (Figure 7.7A and Suppl 7.3). The effect on NREMS amount importantly differed 
between the two drugs, illustrated for the highest doses of BAC and GBL in Figure 7.7B (For 
other doses see Suppl 7.3). Over the entire recovery period after BAC injection mice spent 40 
min more in NREMS than calculated over the same period after saline injection (Figure 7.7B). 
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Especially during the dark period, extra NREMS was accumulated. In stark contrast, GBL was 
followed by an immediate decrease of NREMS in the recovery light period (Figure 7.7B and 
Ref200). During the subsequent dark period no differences in NREMS time were observed. As a 
result of these opposing drug effects, at the end of the recording period, WT mice treated 
with BAC gained 1.0 h of NREMS compared to WT mice treated with GBL, indicating that BAC 
induced a long-term hypersomnia (Figure 7.7A,B; ANOVA: p=0.0005). Interestingly, 
hypersomnia was also observed after BAC administration in 1–/– and 2–/– mice now 
concerning both NREMS and REMS (Figure 7.7C,D). This indicates that, in contrast to the 
acute effects of BAC, BAC-induced hypersomnia might not be mediated through GABAB 
receptors.  
GBL affected REMS in 1a–/– mice in a similar fashion as observed for WT mice with an initial 
decrease that was compensated during the recovery dark-period (Suppl 7.3). In 1b–/– mice 
the extra REMS occurring during the dark period was somewhat more pronounced resulting 
in an overcompensation of REMS at the end of the recording period for the lowest two GBL 
doses (Suppl 7.3). In contrast to WT and 1a–/– mice, 1b–/– mice spent significantly more time in 
NREMS during the dark period relative to the saline condition. 
Besides sleep amounts we also quantified the distribution and consolidation of sleep but did 
not observe significant changes in sleep fragmentation after any dose of GBL or BAC 
compared to saline conditions (Suppl 7.4). However, similar to baseline conditions, sleep in 
1a–/– mice was more fragmented compared to 1b–/– and WT mice. Moreover, as pointed out 
above for baseline (Figure 7.2C), 1a–/– mice spent more time asleep during the last 6h of the 
light period than 1b–/– and WT mice throughout the 5-day drug experiment (one-way ANOVA 
for each day: p<0.05, Tukey’s test: 1a–/–>1b–/–=WT, data not shown). 
Recovery from drug effects was also assessed at the level of delta power in NREMS. Despite 
the pronounced increase in EEG delta power during the GBL-induced state (Figure 7.5A, 
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Figure 7.6A), the time course of delta activity during subsequent recovery sleep remained 
unaffected in the genotypes tested (i.e., 1a–/–, 1b–/–, and WT; Figure 7.5A). As expected, GBL 
also failed to alter the time course of EEG delta power during NREMS in 1–/– and 2–/– mice 
(Suppl 7.5). In stark contrast to the lack of an effect of GBL, the BAC-induced state was 
followed by an immediate increase in NREMS delta power, independent of dose (Figure 
7.5B). Delta power quickly decreased in the presence of NREMS and, in the dark period, 
values below those obtained during the same period after saline injection were reached. This 
decrease became more pronounced with increasing dose (one-way ANOVA factor ‘dose’ 
p<0.0001, Tukey’s test: saline > 5 = 7.5 > 7.5 = 10 mg/kg) consistent with the dose-
dependent BAC-induced increase in NREMS time during the dark period (Suppl 7.3).  In 
contrast to the BAC-induced hypersomnia (see above), the BAC-induced increase in delta 
power during NREMS was not observed in 1–/– and 2–/– mice (Suppl 7.5), suggesting that only 
the latter effect involves the GABAB receptor. The effects of BAC in WT mice on NREMS time 
and especially on the dynamics of delta power are very similar to the effects of SD (Figure 
7.2). 
We analyzed these drug effects on the NREMS EEG in further detail by comparing NREMS 
spectra obtained immediately after the end of the drug-induced states with the NREMS 
spectra obtained immediately after a 6h SD and after a saline injection in WT mice. EEG 
spectra were calculated over the first 20 minutes of NREMS following each of these 
conditions and expressed as a percentage of the individual mean NREMS spectra over the 4 
last hours of the rest period (same reference was used for evaluating the EEG during the 
drug-induced state; see Figure 7.6). The similarity between the EEG effects of BAC and SD 
were not restricted to the delta frequencies. EEG spectra calculated over the first 20 minutes 
of NREMS following the BAC-induced state and SD were similar over a broad frequency 
range and differed only in the low delta frequencies (1-2 Hz; Figure 7.6C) independently of 
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dose (Suppl 7.2D). EEG power density during NREMS after GBL was significantly lower in the 
delta and low theta frequency range (1-5.75 Hz) and higher in gamma and higher frequency 
ranges (30-90 Hz) compared to the NREMS spectra obtained after both BAC and SD (Figure 
7.6C). Compared to the saline conditions GBL increased EEG activity in the theta (7.25-9.75 
Hz) and in the higher beta, gamma, and higher frequency ranges (18.5-90 Hz; Figure 7.6, 
statistics not shown). Note that in WT mice, relative NREMS spectra after any dose of GBL and 
BAC were significantly different from those after saline (Suppl 7.2A,D). In WT and 1b–/– mice 
relative NREMS spectra after GBL exhibited a significant dose-dependent increase in theta, 
beta and gamma activity (7-10 Hz and 18-90 Hz; Suppl 7.2A,B). In 1a–/– mice, although a 
similar tendency was observed no significant difference among doses were obtained (Suppl 
7.2C). This decreased EEG response in 1a–/– mice was illustrated for the highest GBL dose (300 
mg/kg); the relative increase in NREMS EEG activity in the 8-10 Hz range was lower in 1a–/– 
mice compared to that observed for the two other genotypes (Figure 7.6D). 
 
7.5. Discussion 
We studied the role of GABAB receptors in sleep in mice lacking functional GABAB receptors 
or one of the two GABAB1 receptor subtypes. We identified a number of sleep and EEG 
phenotypes under baseline conditions and after the administration of GABAB-receptor 
agonists that not only separated 1–/– and 2–/– mice from 1a–/–, 1b–/–, and WT mice but also 1a–/– 
from 1b–/– and WT mice. Among the most salient phenotypes we observed in 1–/– and 2–/– 
mice are the presence of clonic seizures, the marked delay in the distribution of sleep over 
the 24h day, the altered spectral composition of the NREMS and waking EEG, and the 
complete lack of the acute response to GBL and BAC. 1a–/– mice differed from 1b–/– and WT 
mice in that they showed seizures, their sleep was more fragmented and more prevalent in 
the second half of the light period, and after GBL administration responded with a larger 
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increase in EEG delta power. For several sleep and EEG phenotypes 1a–/– thus seemed 
intermediate between 1b–/– and WT mice, on one hand, and 1–/– and 2–/– mice on the other, 
suggesting functional differences between the two GABAB1 receptor isoforms. These 
differences are likely to be due to differential subcellular localizations of the two isoforms 
because binding pharmacology showed similar properties220,221. 
The GABAB1a receptor subunit protect against seizures 
Spontaneous epileptiform activity has been reported in mice lacking functional GABAB 
receptors222,225. We discovered that mice lacking subunit GABAB1a also display spontaneous 
seizures indicating a specific role for GABAB1a subunit in preventing seizures. GABAB1a and 
GABAB1b subunits localize to distinct synaptic sites thereby conveying separate functions. Of 
relevance for the epileptiform trait is the fact that at hippocampal synapses, GABAB1a,2 
receptors inhibit glutamate release, while GABAB1b,2 receptors predominantly mediate 
postsynaptic inhibition220. The lack of presynaptic inhibition of glutaminergic neurons in 1a–/–
mice might have contributed to the presence of seizures. Functional differences between 
these two subunits might also have contributed to the sleep and EEG genotype differences 
we report here.  
GABAB receptors determine the diurnal organization of sleep 
The distribution of sleep and wakefulness over the 24h day markedly differed among 
genotypes. BALB/c and BALB/cByJ mice initiated their main rest period in the middle of the 
dark period (Figure 7.1; Ref 85,265) while the rest period in 1–/– and 2–/– mice coincided largely 
with the light period, which is common for most other inbred strains. We and others 
attributed the earlier rest onset and resulting compression of the active period to the shorter 
endogenous circadian period length observed in BALB/c mice85,265,275. Several studies 
implicate GABAB receptors in circadian timing. Activation of GABAB receptors in the 
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suprachiasmatic nucleus (SCN), the master circadian clock, phase-shifts circadian rhythms 
both in vitro and in vivo276,277, and the effects of light on circadian phase are blocked by 
BAC278,279. It remains to be established whether the large delay in the timing of the rest period 
we report here is due to a role of GABAB receptors at the level of the (light) input to the SCN 
or at the level of rhythm generation itself. 
GABAB receptor agonists do not promote physiological sleep 
The lack of any behavioral and EEG effects of GBL in 1–/– and 2–/– mice, clearly indicates that 
exogenous GHB acts through GABAB receptors only. A similar lack of effect in 1–/– mice has 
been reported for other variables such as the GHB-induced decrease in locomotor activity 
and hypothermia197,241. Our behavioral and EEG observations show that GBL does not induce 
physiological sleep, but a sub-anesthetic state with EEG hypersynchrony consistent with 
reports by others200,238. Also BAC did not initially induce physiological sleep and its acute 
effects in WT mice had some similarities with the acute effects of GBL. However, BAC even at 
the highest dose failed to induce the spiky EEG pattern characteristic of the GBL-induced 
state while the amount of the drug-induced state was comparable between the two drugs. 
First evidence of spiky EEG patterns appeared at an extreme high BAC dose (50 mg/kg) but at 
this dose the drug-induced state lasted around 5 h (data not shown) demonstrating that the 
drug dynamics for EEG and behavioral aspects greatly differ. 
Delta power during NREMS is in a quantitative and predictive relationship with prior 
wakefulness and is therefore thought to reflect a need or pressure for NREMS and its 
underlying homeostatically regulated recovery process264. Delta power during NREMS is also 
considered a measure of the efficiency with which sleep need decreases during NREMS97,280. 
The profound increase in EEG delta activity during the GBL-induced state did not affect the 
dynamics of delta power in subsequent NREMS indicating that functionally, GBL-induced 
delta oscillations differ from those expressed during physiological NREMS. 
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The changes evoked by BAC on subsequent NREMS were even more remarkable than the 
lack of response observed after GBL; delta power importantly increased and the subsequent 
recovery dynamics were highly similar to those observed after SD. This similarity was true for 
the entire NREMS EEG spectrum supporting the puzzling conclusion that the BAC-induced 
state is functionally similar to intense wakefulness. Nevertheless, we cannot rule out that the 
increase in delta power is a residual direct effect of BAC on EEG synchronization rather than 
reflecting increased homeostatic drive. Also the pattern of NREMS recovery with its largest 
increase in the dark period is reminiscent of the effect of SD265. This delayed hypersomnia 
was observed also in 1–/– and 2–/– mice suggesting that this aspect of the sleep response is 
most probably not mediated through GABAB receptors. Studies in human subjects reported a 
BAC-induced increase in NREMS251,281 and somnolence as a side effect252,282. In contrast and 
similar to our findings in mice, GHB given at night did not increase total sleep time in healthy 
men and narcolepsy patients145,283 and did not induce daytime somnolence and, importantly, 
reduces excessive daytime sleepiness in narcolepsy patients257. 
Although GABAB receptors mediate the acute effects of both GBL/GHB and BAC and the two 
drugs have several effects in common (e.g. hypothermia, catalepsy, sedation284), the 
underlying mechanisms may not be identical267,285 For instance, in mice, NMDA receptor 
antagonists enhanced the cataleptic effects of GHB but not those of BAC286 suggesting a 
differential role of glutamate in GABAB receptor-mediated effects of GHB and BAC. Moreover, 
BAC inhibited both dopaminergic and GABAergic neurons in the ventral tegmental area, 
while GHB inhibited only GABAergic246. This discrepancy may be explained by the fact that 
GHB is a full, low-affinity agonist and BAC a full, high affinity agonist of GABAB receptors287. 
Thus, low-affinity compounds can have very different or even opposite effects compared to 
high-affinity agonists. These differences in drug kinetics could be further modulated by 
potassium channel tetramerization domain-containing proteins that function as auxiliary 
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subunits of GABAB receptors235. 
Conclusions 
It is believed that GHB, by consolidating sleep and promoting EEG delta oscillations, reduces 
excessive daytime sleepiness and cataplexy associated with narcolepsy. Although it has been 
reported that GHB consolidates sleep in narcolepsy patients288 and that BAC promotes sleep 
efficiency in healthy subjects251, we found no evidence for increased sleep consolidation after 
GBL or BAC in mice. Given the contradictory effects of both drugs on EEG and sleep among 
the various studies, species differences and potentially the dose used might play a role. Our 
in depth quantitative EEG analyses show that, at least in the mouse, GBL and BAC do not 
promote physiological sleep at the doses used and that delta oscillations during the drug-
induced state functionally differ from those during NREMS. We further identified several 
functional differences between the two GABAB1 isoforms, the most salient of which concerns 
the role of the GABAB1a subunit in epileptogenesis and sleep consolidation. Finally, BAC, but 
not GHB, seems to mobilize a sleep homeostatic mechanism comprised of hypersomnia and 
increased EEG delta power. Identifying the cellular mechanism contributing to this 
differential response might gain insight into the elusive sleep homeostatic process. 
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7.6. Tables and Figures 
Table 7.1: Behavioral states in baseline; 12 and 24h values. 
 Waking (min) NREMS (min) REMS (min) TS (min) 
24h period     
WT 753.9 ± 5.6 608.6 ± 8.9 77.5 ± 5.2 686.1 ± 8.9 
1a–/– 752.1 ± 18.4 607.9 ± 19.3 79.9 ± 4.6 687.8 ± 19.3 
1b–/– 796.7 ± 14.5 561.6 ± 16.7 81.7 ± 3.5 643.3 ± 16.7 
1–/–  781.5 ± 29.6 570.6 ± 32.5 81.3 ± 6.0 651.8 ± 32.6 
2–/– 812.4 ± 27.1 543.0 ± 30.1 82.7 ± 4.7 625.7 ± 29.6 
p 0.28 0.12 0.95 0.25 
12h light period    
WT 328.5 ± 13.3   bc 352.0 ±  15.9  ab 39.5 ± 3.7   a 391.5 ± 15.9   ab 
1a–/– 283.3 ± 7.8   ab 386.8 ±  8.6   bc 49.7 ± 4.5   ab 436.5 ± 8.6   bc 
1b–/– 350.9 ± 10.6   c 325.1 ± 12.1   a 44.0 ± 2.7   a 369.1 ± 12.1   a 
1–/–  244.5 ± 18.9   a 413.4 ± 20.5   c 58.8 ± 4.3   b 472.2 ± 19.9   c 
2–/– 244.7 ± 16.6   a 429.2 ± 16.4   c 64.4 ± 2.9   b 493.6 ± 16.5    c 
p <0.0001 <0.0001 0.0001 <0.0001 
12h dark period    
WT 425.4 ± 14.4   a 256.5 ± 17.5   b 38.0 ± 4.0   b 294.6 ±17.5   b 
1a–/– 468.8 ± 16.9   ab 221.0  ±19.4   bc 30.2 ± 2.7   ab 251.2 ± 19.4   bc 
1b–/– 445.8 ± 11.5   ab 236.5 ± 14.9   b 37.7 ± 4.1   b 274.2 ± 14.9    b 
1–/–  537.0 ± 24.7   bc 157.2 ± 29.7   ac 22.4 ± 5.1   ab 179.7 ± 29.5   ac 
2–/–  587.7 ± 28.3   c 113.8 ± 18.2   a 18.2 ± 4.7   a 132.1 ± 33.0   a 
p <0.0001 <0.0001 0.0048 <0.0001 
 
Mean (±SEM; n=8-9) artifact free recording time in 24h baseline, 12h light, and 12h dark period for the time spent 
in waking, NREMS, REMS, and total sleep time (TS; NREMS+REMS). Behavioral states varied among genotypes ( p 
values of one-way ANOVA indicated). a–c, Tukey’s test, p<0.05; genotypes for which mean values significantly 
differed do not share the same character. 
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Figure 7.1: Sleep and EEG phenotypes for 1a–/–, 1b–/–, 1–/–, 2–/–, and WT mice.  
A, EEG and EMG signals illustrating a spontaneous clonic seizure in 1a–/– mouse during undisturbed baseline 
conditions. This seizure occurred during NREMS (2 s before seizure onset). Both EEG amplitude and frequency 
were increased as well as muscle tone (EMG). Animal showed rearing and bilateral clonus of the forelimbs during 
the seizure. B, Twenty seconds of typical NREMS in a WT mouse characterized by high amplitude of low-
frequency EEG oscillations (delta waves) and reduced muscle tone. C, Example of abnormal EEG during well 
identified NREMS in a 1–/– mouse. Arrow points to an abrupt EEG sharp wave. This epileptiform activity during 
NREMS was seen only in 1–/– and 2–/– mice, and was present during >20% of their NREMS. Waking and REMS were 
also affected to a lesser extent. These abnormal EEG events were excluded from the spectral analysis depicted in 
Fig.8. D, Time course of hourly mean values of total sleep amount (NREMS+REMS; ±SEM, n=8-9) during baseline. 
Values of the dark period (gray areas) were depicted twice to illustrate the changes at the dark-to-light transition. 
Horizontal dashed lines mark the mean baseline (0-24h) value for total sleep. Genotype did not affect sleep 
amount but its distribution changed (two-way ANOVA for factors ‘genotype’ p=0.11, ‘hour’ p<0.0001 and their 
interaction p<0.0001). Triangles below each curve indicate hourly intervals for which values differed from WT 
mice (Dunnett’s two-tailed t test, p<0.05). For each genotype, the main rest period is indicated by a horizontal bar 
connecting rest onset and end (mean±SEM, n=8-9). Rest periods were determined individually by selecting 
intervals in which NREMS and REMS were above the individual baseline mean (see Materials and Methods). In all 
1b–/– mice, the main rest period was interrupted by a 3h gap. E, Sleep fragmentation was quantified by counting 
the number of brief awakenings (<16 s; 1, 2, 3, or 4s epochs of waking; top) interrupting sleep and the number of 
short (<1min; <15 consecutive 4s epoch of NREMS; center) and long (>1min; bottom) NREMS episodes according 
to previously published criteria 289. Variables were expressed per hour of NREMS to correct for differences in total 
NREMS amount. Calculated over the 24h of baseline, 1a–/– mice had more short NREMS episodes than 2–/– mice 
and more brief awakenings compared with 1b–/– and 2–/– mice (one-way ANOVA for factor ‘genotype’ p=0.017 and 
p=0.0089, respectively). The number of long NREMS episodes was generally higher in 1–/– and 2–/– mice compared 
with 1a–/–, 1b–/–, and WT mice (one-way ANOVA for factor ‘genotype’ p<0.0001). Horizontal lines connect 
genotypes for which significant differences were observed (Tukey’s test, p<0.05). 
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Figure 7.2: Time course of the amount of NREMS and EEG delta power (1– 4 Hz) in NREMS.  
A, B, Mean 1h values for NREMS (A) and mean values for delta power (±SEM; B) during 24h baseline (BLN; 0-24h), 
6h sleep deprivation (SD; 24 –30h) and 18h recovery (REC; 30–48h) in WT, 1a–/–, and 1b–/– mice (n=8, n=8, and n=9, 
respectively). For comparison, baseline results were also shown for 1–/– and 2–/– mice (n=8 per genotype; these 
mice were not sleep deprived; see Materials and Methods). Delta power was expressed as a percentage of 
individual mean NREMS delta power over the last 4 h of the rest period. Gray areas mark the dark periods, white 
areas the light periods, and the black bar on the top indicates the 6h SD. Stars above the curves of 1a–/– and 1b–/– 
mice indicate significant differences from WT (one-way ANOVA; Dunnett’s two-tailed t test, p<0.05). In recovery, 
triangles below the curves indicate hours at which values differed from baseline (t tests, p<0.05, up-pointing 
triangles>baseline, down-pointing triangles<baseline). C, Mean values for NREMS amount during the last 6 h of 
the light periods of baseline and recovery in 1b–/– (n=9), 1a–/– (n=8), and WT (n=8) mice. These two values were 
compared among the three genotypes. Black stars indicate significant recovery-baseline differences (one-way 
ANOVA; Tukey’s test, p<0.05). Horizontal connecting lines indicate significant differences among genotypes (one-
way ANOVA; Tukey’s test, p<0.05). Amount of NREMS during the last 6 h of the baseline light period was shown 
also for 1–/– and 2–/– mice (n=8 per genotype), but values were not included in the statistics. 
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Figure 7.3: Average EEG power spectra (±SEM) for NREMS, REMS, and waking during baseline. 
For clarity, only the frequency range for which major genotype differences were observed is shown (0.75-20 Hz at 
0.25Hz bins). Genotype affected the EEG spectra of the three behavioral states (two-way ANOVA for each state for 
factors ‘genotype’, bin, and their interaction, p<0.0001). Colored triangles above each set of spectra indicate 
frequency bins for which power density differed from WT mice (Dunnett’s two-tailed t test, p<0.05; black, NREMS; 
blue, REMS; red, waking; color coding of lines and triangles match). 
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Figure 7.4: EEG and EMG effects. 
A–D, Representative traces illustrating the effects of GBL and BAC on the EEG and EMG in WT animals after 50 (A) 
and 300 (B) mg/kg of GBL and after 5 (C) and 10 (D) mg/kg of BAC. Similar EEG and EMG patterns after GBL were 
found in 1a–/– and 1b–/– mice. GBL did not affect behavior or EEG in 1–/– or 2–/– mice (data not shown). E, Length of 
GBL-induced state in 1a–/–, 1b–/–, and WT mice. The length of GBL-induced state increased linearly and dose-
dependently (linear regression; WT, n=8, R2=0.99; 1a–/–, n=8, R2=0.99; 1b–/–, n=9, R2=0.96). The length of GBL-
induced state varied with dose and genotype and was, in general, longer in WT mice (two-way ANOVA for factor 
‘genotype’ p<0.0011, ‘dose’ p<0.0001, and their interaction p=0.42; genotype, 1a–/–=1b–/–<WT; Tukey’s test, 
p<0.05; dose:,50<100<150<300 mg/kg; Tukey’s test, p <0.05). F, Length of BAC-induced state after each dose of 
BAC in WT mice. The length of BAC-induced state increased linearly and dose-dependently within this dosage 
range (linear regression, WT, n=8, R2=0.96; one-way ANOVA for factor ‘dose’, p=0.033; 5=7.5<7.5=10 mg/kg; 
Tukey’s test, p<0.05). 
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Figure 7.5: EEG delta power (1-4 Hz) during the GBL- and BAC-induced state and its time course during 
subsequent NREMS (mean±SEM).  
A, Delta power during GBL-induced state (triangles) increased from 50 to 100 mg/kg, where it reached a plateau 
(50 mg/kg, <3 highest doses in 1a–/– and 1b–/– mice; one-way ANOVA, Tukey’s test, p<0.05). Plateau levels reached 
were around twofold higher in 1a–/– mice than in 1b–/– and WT mice (one-way ANOVAs, p<0.0001; Tukey’s tests, 
p<0.05, stars). For NREMS delta power (circles), a comparison among genotype (1a–/–, 1b–/–, WT), day (1-5), and 
time (18 intervals per day) was performed (three-way ANOVA for factors ‘genotype’ p<0.0001, ‘time’ p<0.0001, 
‘day’ p=0.0003 and their interactions: ‘genotype’ x ‘day’ p=0.0020, ‘genotype’ x ‘time’ p=0.040, ‘time’ x ‘day’ 
p=0.10, ‘genotype’ x ‘day’ x ‘time’ p=0.10). Although the time course of NREMS delta power did not differ among 
the three genotypes, the overall dynamic range was smaller in 1b–/– and larger in 1a–/– mice compared with WT 
mice (Tukey’s tests, p<0.05). For NREMS delta power, differences among drug days were observed, but not in a 
dose-dependent manner (Tukey’s test, p<0.05: 150=saline=50=100>50=100=300 mg/kg). B, Delta power during 
BAC-induced state (black triangles) did not increase with dose in WT mice (one-way ANOVA, p=0.64). BAC 
affected the time course of delta power in NREMS (circles; two-way ANOVA for factor ‘day’ (1-4) p= 0.079, ‘time’ 
(18 intervals per day) p<0.0001 and their interaction p<0.0001). A large increase in NREMS delta power occurred 
after the BAC-induced state, followed by a decrease below saline levels during the subsequent dark period (white 
triangles mark significant differences from saline; Dunnett’s two-tailed t test, p<0.05). Note the dose-dependent 
decrease in delta power during the dark period (one-way ANOVA for factor ‘day’ p<0.0001: saline>5=7.5>7.5=10 
mg/kg; Tukey’s test, p<0.05).  
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Figure 7.6: EEG spectra during and after the drug-induced state for the highest doses of BAC (10 mg/kg) and GBL 
(300 mg/kg). 
All spectra (0.75-90 Hz; at 0.25Hz bins) were expressed as a percentage of the NREMS EEG spectrum averaged 
over the last 4 h of the baseline rest period, thereby allowing direct comparison among genotypes, drugs, and 
conditions. A, BAC- and GBL-induced state EEG spectra in WT mice (blue and red lines, respectively). For 
comparison, EEG spectra during the first 20 min of NREMS after 6 h sleep deprivation (SD; black) and after saline 
administration (gray line) were included. Spectra significantly differed among conditions (two-way ANOVA for 
factors ‘condition’, ‘bin’, and their interaction p<0.0001). Horizontal colored lines indicate frequency bins in which 
EEG power significantly differed (GBL vs SD, red; BAC vs SD, blue; GBL vs BAC, black; Tukey’s test, p<0.05). The 
GBL-induced state EEG spectrum differed strongly from that of the BAC-induced state, especially in the low delta 
(0.75–1.75 Hz) frequencies and for frequencies>3 Hz. B, GBL-induced state spectra in 1a–/–, 1b–/–, and WT mice 
(light gray, dark gray, and black lines, respectively; WT same as in A). Spectra significantly differed among 
genotypes (two-way ANOVA for factors ‘genotype’, ‘bin’, and their interaction, p<0.0001). Horizontal colored lines 
mark frequency bins in which genotypes differed (1a–/– vs 1b–/–, black; 1b–/– vs WT, dark gray; 1a–/– vs WT, light gray; 
Tukey’s test, p<0.05). EEG changes in 1b–/– mice closely resembled those of WT. C, EEG spectra during the first 20 
min of NREMS after GBL- (red) and BAC- (blue) induced state and after SD (black) and saline (gray line) in WT mice. 
SD and saline spectra same as in A. Spectra were affected by condition (two-way ANOVA for factors ‘condition’, 
‘bin’, and their interaction, p<0.0001; Tukey’s test for genotype, p<0.05), largely due to the low spectral values 
reached after GBL in frequencies<7 Hz. Statistics and color coding as in A. D, EEG spectra during the first 20 min of 
NREMS after GBL-induced state in 1a–/–, 1b–/–, and WT mice (color coding as in B). Spectra significantly differed 
among genotypes (two-way ANOVA for factors ‘genotype’, ‘bin’, and their interaction, p<0.0001; statistics and 
color coding as in B). 
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Figure 7.7: Effects of GHB and BAC on the amount of NREMS and REMS. 
A–D, Drug–saline differences in NREMS and REMS length (mean±SEM), counted from the end of drug-induced 
state in WT mice (A, B) or from the time of injection in 1–/– and 2–/– mice (C, D), to the end of the following dark 
period. Drug effects are shown only for the highest dose of GBL (300 mg/kg) and BAC (10 mg/kg). A, Both drugs 
decreased REMS during the remainder of the light period (Light) in WT mice (n=8), a decrease that was 
compensated for during the subsequent dark period (Dark; gray area), resulting in no overall difference (Total). B, 
During the light period, NREMS amount significantly decreased only after GBL. In the subsequent dark period 
NREMS, BAC increased NREMS compared with saline, resulting in a large overall increase (hypersomnia). C, D, 
Although neither drug affected REMS (C) or NREMS (D) during the light period in 1–/– and 2–/– mice, in the 
subsequent dark period, BAC surprisingly increased both sleep states whereas GBL tended to decrease sleep. 
Over the 18 h following drug injection (Total), BAC strongly increased REMS and NREMS. Note that results from 1–
/– and 2–/– mice were pooled (n=3 per genotype per group), as no genotype differences were observed. Stars mark 
statistical differences from saline (one-way ANOVA, p<0.05; paired t test, p<0.05). Significant differences between 
drugs are shown by connecting lines (one-way ANOVA, p<0.05; Tukey’s test, p<0.05).  
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Suppl 7.1: Drug-induced state EEG spectra for each dose of GBL in 1a–/–, 1b–/–, and WT mice and BAC-induced state 
in WT mice. 
Average EEG spectra (from 0.75-90 Hz at 0.25Hz resolution) were expressed as a percentage of the mean EEG 
spectrum during NREMS averaged over the last 4 hours of the baseline rest period (see Methods and Results). 
Logarithmic scales were used for both relative power density and frequency. GBL-induced state EEG spectra 
varied according to genotype (WT, 1b–/– and 1a–/– mice), dose (saline and the 4 GBL doses) and frequency (0.25Hz 
bins) (three-way ANOVA for factors ‘genotype’ , ‘dose’ , ‘bin’, p<0.0001, and their interactions: ‘genotype’ x ‘dose’ , 
‘genotype’ x ‘bin’, and ‘dose x bin’ p<0.0001; ‘genotype’ x ‘dose’ x ‘bin’ p=1.0). A, WT mice showed a dose-
dependant increase in low delta (0.75-1.75 Hz) and a progressive decrease from 3 to 90 Hz (one-way ANOVA for 
factor ‘dose’ p<0.0001, Dunnett’s two-tailed t test; contrasted to 300 mg/kg for each frequency bin; p<0.05, color 
of horizontal lines match dose; e.g., blue = 50 vs 300 mg/kg). B, GBL-induced state EEG spectra in 1b–/– mice 
displayed a similar pattern as WT mice with an even more accentuated decrease in sigma activity (10-15 Hz) for 
each dose (one-way ANOVA for factor ‘dose’ p<0.0001, Dunnett’s two-tailed t test (control = 300 mg/kg) every 
0.25 Hz, p<0.05). C, In 1a–/– mice, although GBL-induced state EEG spectra changed with dose similarly as in WT 
and 1b–/– mice (one-way ANOVA, p<0.0001), this effect was strongly attenuated in the 4-90Hz range (Dunnett’s 
two-tailed t test; contrasted to 300 mg/kg, p<0.05). D, BAC-induced state EEG spectra after each dose of BAC 
showed an increase in power density at around 4 Hz and a decrease in sigma activity (10-15 Hz) in WT mice. 
Although spectral changes in the EEG of the BAC-induced state significantly varied with dose (two-way ANOVA 
for factors 'dose’ p<0.0001, ‘bin’ p<0.0001, and their interaction p=1.0000), the dose-dependent changes were 
exclusively localized at 4 Hz (Dunnett’s two-tailed t test, contrasted to 10 mg/kg, p<0.05). 
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Suppl 7.2: EEG spectra during the first 20 min of NREMS following drug-induced state for each dose of GBL in 1a–/–, 
1b–/–, and WT mice and for each dose of BAC in WT mice.  
Average EEG spectra (0.75 – 90 Hz; 0.25Hz resolution) were expressed as a percentage of the mean EEG spectrum 
during NREMS averaged over the last 4 hours of the baseline rest period (see Methods and Results) allowing 
direct comparison with EEG spectra during drug-induced state (see Suppl 7.1 for details). EEG spectra following 
GBL injections were affected by genotype (WT, 1b–/–, and 1a–/– mice), dose (saline and the 4 GBL doses) and 
frequency bin (0.25Hz: bin; three-way ANOVA for factors ‘genotype’, ‘dose’, ‘bin’ p<0.0001, and their interactions: 
‘genotype’ x ‘dose’, ‘genotype’ x ‘bin’, and ‘dose’ x ‘bin’ p<0.0001; ‘genotype’ x ‘dose’ x ‘bin’ p=1.0). A, WT mice 
showed a dose-dependant increase in theta (around 8 Hz) and gamma (>20 Hz) activity (one-way ANOVA for 
factor dose p<0.0001, Dunnett’s two-tailed t test; contrasted to saline, p<0.05). Horizontal lines indicate 
differences from saline color-coded according to dose. B, EEG spectra in 1b–/– mice displayed a similar pattern of 
change as WT mice with an even more accentuated difference between saline and GBL doses (one-way ANOVA 
for factor ‘dose’ p<0.0001, Dunnett’s two-tailed t test; contrasted to saline, p<0.05). C, In 1a–/– mice, although the 
pattern of the dose-dependent changes in EEG spectra was similar to WT and 1b–/– mice (one-way ANOVA for 
factor ‘dose’ p<0.0001), differences from saline did not reach significance levels (Dunnett’s two-tailed t test; 
contrasted to saline, p<0.05). D, EEG spectra during NREMS after each dose of BAC showed a strong increase in 
power density in the delta and theta frequency ranges compared to saline, and in the high sigma range (13-15 
Hz) for the two higher doses (one-way ANOVA for factor ‘day’ p<0.0001, Dunnett’s two-tailed t test; contrasted to 
saline, p<0.05). Horizontal lines indicate differences from saline with gray-scales matching dose. EEG spectra after 
all doses of BAC were different from saline and the lowest dose was different to those of the two other (one-way 
ANOVA for factor ‘dose’ p<0.0001, Tukey’s test, p<0.05, saline < 5 < 7.5 = 10 mg/kg). 
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Suppl 7.3: GBL-saline and BAC-saline differences in NREMS and REMS amounts from the end of drug-induced 
state to the end of the following dark period in the various genotypes.  
Mean differences (±SEM) were shown after each dose of GBL (50, 100, 150, and 300 mg/kg) in 1a–/– and 1b–/– and 
WT mice and each dose of BAC (5, 7.5, and 10 mg/kg) in WT mice. GBL and BAC were administrated the middle of 
the light period. “Light” and “dark” areas represent drug - saline differences in REMS and NREMS amounts from 
the end of drug-induced state to the end of the light period and for the 12h dark period, respectively. Overall 
drug - saline differences for REMS or NREMS (from the end of the drug induced-state to the end of the following 
dark period) were summarized in “Total” areas. Stars indicate significant changes in REMS (left) and NREMS (right 
panels) after drug administration compared to saline conditions (one-way ANOVA, p<0.05; paired t test, p<0.05). 
Horizontal lines connect doses for which a significant difference was obtained (one-way ANOVA, p<0.05; Tukey’s 
test, p<0.05).  
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Suppl 7.4: Effects of GBL (left) and BAC (right panels) on sleep fragmentation.   
Brief awakenings (upper) and the number of short (middle) and long (lower panel) NREMS episodes were 
calculated as in Figure 7.1. Averaged over the 24h of each day, the number of brief awakenings and the number 
of short and long NREMS episodes did not vary with drug dose (one-way ANOVA for factor ‘dose’ p>0.1). Over the 
entire GBL experiment, 1a–/– mice had more brief awakening and shorter NREMS episodes and fewer long NREMS 
episodes than 1b–/– and WT mice (one-way ANOVA factor ‘genotype’ p <0.0001 for the 5 recording days) 
consistent with the observation under baseline conditions (Figure 7.1). Horizontal lines connect genotypes for 
which significant differences were observed within each day (Tukey’s test, p<0.05). In WT mice, all three markers 
of sleep consolidation were similar in GBL and BAC experiment (two-way ANOVA for factors ‘experiment’ and 
‘day’: p>0.4). 
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Suppl 7.5: EEG delta power (1-4 Hz) of NREMS 
after saline, GBL, BAC administration in mice 
deficient for functional GABAB receptors. 
Time course of the EEG delta power following 
the injection of saline and either the highest 
dose of BAC (10 mg/kg) (A) or GBL (300 mg/kg; 
n=6/treatment) (B) in 1-/- and 2-/- mice. No 
differences were found between the time 
course of delta power following saline 
injection and that following drug injections 
(Two-way rANOVA for factor ‘treatment’ 
p=0.7749 for BAC and p=0.9913 for GBL). 
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8. Human study: 
The effects of sodium oxybate and baclofen on EEG, sleep, 
vigilance and memory 
8.1. Abstract 
Sodium oxybate (SO), the sodium salt of γ-hydroxybutyric acid (GHB), has been shown to 
increase EEG slow-wave (delta) activity in non-rapid eye movement sleep (NREMS). Delta 
activity is an index of sleep pressure, which decreases during sleep and increases with 
increasing duration of wakefulness. To investigate whether SO affects the homeostatic 
process of sleep and thus induces physiological deep sleep, we administrated SO before an 
afternoon nap and before the subsequent nighttime sleep in healthy volunteers. Because it 
is known that SO acts as a low-affinity agonist of GABAB receptors, we also compared its 
effects with those of baclofen (BAC), a high-affinity agonist of GABAB receptors. In addition, 
memory and neurobehavioral performance were assessed. We found that both SO and BAC 
counteracted the nap effects on the subsequent sleep by decreasing sleep latency and 
increasing total sleep time, deep sleep during the first NREMS episode and EEG delta and 
theta power during NREMS. However, SO also increased EEG delta and theta power during 
REMS and a nap under SO, with high level of delta power, did not affect the following 
nighttime sleep. This suggests that even if SO induces EEG slow waves, these are not 
involved in the homeostatic regulation of sleep. Thus, GHB seems to not produce 
physiological sleep. BAC showed very similar effects on sleep and EEG, but with a delayed 
action. This different BAC dynamics did not allow us to determine if BAC affects or not the 
homeostatic process of sleep. Although we found differential effects of BAC and SO on REMS, 
the EEG similarities induced by these two drugs suggest that SO might primary act through 
 79 
GABAB receptors without completely excluding the involvement of other receptors. Finally, 
overall, a nap under SO and BAC did not affect psychomotor performance and subjective 
sleepiness as well as memory consolidation. 
 
8.2. Introduction 
Sodium oxybate (SO) is the sodium salt of γ-hydroxybutyric acid (GHB), an endogenous fatty 
acid synthesized in the brain, recently accepted as a treatment for the sleep disorder 
narcolepsy (Xyrem®). GHB has been demonstrated to increase slow-wave sleep (SWS) and/or 
slow-wave activity, also called EEG delta activity (0.75-4.5 Hz), in a dose-dependent fashion in 
healthy subjects145,237,283 and in patients with narcolepsy and fibromyalgia158,290283. The 
increase of slow-wave sleep (SWS) and EEG delta activity has been hypothesized to represent 
cortical recovery from prior wakefulness and a time of neurophysiologic restoration or 
recuperation66,291. Like other restorative behaviors, sleep is homeostatically regulated. On one 
hand, sleep loss produces proportional increases in the tendency to fall asleep (sleep drive)292 
and in EEG delta activity during the recovery NREMS95. On the other hand, an 
afternoon/evening nap reduces the amount of SWS and EEG delta activity during the 
subsequent nocturnal sleep293. Thus, EEG delta activity, as a marker of sleep need/pressure, 
increases proportionally with increasing duration of prior wakefulness and decreases over 
the course of a sleep period in humans as well as in all animals so far studied93,96,100.  
We recently reported that the increase of EEG delta activity produced by GBL, a precursor of 
GHB, did not affect physiological sleep regulation in mice294. This finding is also supported by 
other studies describing paradoxical EEG delta waves induced by GHB and its precursors in 
awake humans145,236 and animals200,238. Together, this challenges the claimed physiological 
sleep-promoting effects of GHB. The first aim of this study was to investigate whether 
pharmacological enhancement of EEG delta activity with GHB is involved in the homeostatic 
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regulation of sleep in humans, which would support the capacity of GHB/SO to induce 
normal physiological sleep. To this end, we used an afternoon nap protocol to decrease 
sleep pressure during the subsequent nighttime sleep and investigated how slow-wave 
activity, induced by GHB, could modulate the homeostatic regulation of sleep (sleep 
pressure) in healthy volunteers. 
Previous animal reports suggest that GHB acts through GABAB receptors to affect the EEG 
and sleep222,241,294. In order to determine the role of GABAB receptors in GHB response in 
humans, baclofen (BAC), a high-affinity agonist of GABAB receptors, was also administrated 
and its effects compared with those of GHB. 
One potential adverse effect of GHB is sedation295,296 and napping is known to increase 
alertness297. Thus, we assessed GHB effects on sustained vigilant attention by a psychomotor 
vigilance task (PVT) and subjective alertness by Karolinska sleepiness scale (KSS). 
Finally, growing evidence continues to demonstrate that, following learning, additional 
‘offline’ memory improvements develop during sleep298,299,300. Consolidation and encoding of 
both procedural and declarative memory have shown to be sleep-dependent301,302. 
Interestingly, a positive correlation between performance and SWS and/or delta power 
artificially induced (transcranial direct current stimulation (tDCS)) was found303,304,305. Thus, 
because GHB increases EEG delta power and because another potential adverse effect of 
GHB is memory impairment306,307,308,309, we investigated the effect of GHB on declarative 
memory with two tasks (a two-dimentional (2-D) object-recognition task and a unrelated 
word-pair associate learning task), and procedural memory with a finger sequence tapping 
task.  
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8.3. Materials and Methods 
Subjects and Procedures 
Participants were healthy, of European origin and right-handed males (n=13 ; mean age: 23.5 
± 1.6 years old; age range: 20-26 years old) with a body mass index between 18.5 and 24.8 
kg/m2 recruited by a public ad at the University of Lausanne (Switzerland) and Centre 
Hospitalier Universitaire Vaudois (CHUV, Lausanne, Switzerland). They were paid for 
participation in this study. They reported having no personal or family history of neurologic, 
psychiatric, or sleep disorders, being in good health, not having recent stressful life events or 
transmeridian flight and not taking any medication or having consumed illicit drugs at least 
2 months before the study. All were non-smokers or soft smokers (max 5 cigarettes per day), 
GHB-naive and reported no excessive consumption of alcoholic beverages and stimulant 
drinks (coffee, tea, cola, red-bull, etc; they had to be able to stop drinking any of these 
beverages during several days without any problem). Their sleep, anxiety and depression 
questionnaires revealed that they were good sleepers with regular bedtimes (11-12 p.m.), no 
subjective sleep disturbances, no anxiety and depression (normal score at: Epworth 
sleepiness scale, Horne and Ostberg questionnaire (neutral type), and Beck anxiety and 
depression inventories). Upon reception of their written informed consent, they were 
screened by brief anamnesis, physical examination, blood test and wrist actimetry during 
two weeks and also for chronic or acute cardiovascular, respiratory, hepatic or renal diseases. 
They performed an assessment session where they spent two nights and a day in the sleep 
laboratory for diagnostic polysomnography to exclude sleep disorders like sleep apnea 
and/or periodic limb movements in sleep (PLMS), but also to verify if they were able to sleep 
during an afternoon nap at 3 p.m. Subjects with a sleep apnea index and/or a PLMS index of 
5 or more per hour of sleep, sleep efficiency lower than 85%, disturbances in sleep stage 
architecture, or unable to sleep more than 30 min during the afternoon nap were excluded. 
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The local ethics committee for research on human subjects and the Swissmedic approved 
the study protocol, which was carried out in accordance with the declaration of Helsinki. The 
study included five sessions of three consecutive nights separated by one week. In each 
session, the first and the second night served as an adaptation and a baseline night, 
respectively. The day following the baseline night, subjects stayed in the lab and took a nap 
at 3 p.m. The third night was the last night of the session, called experimental night. For each 
night bedtime was scheduled from 11 p.m. to 7 a.m. The nap lasted maximum 2 h but was 
stopped after one NREMS episode at the first appearance of REMS. If REM sleep appeared 
before sleep stages 3 and 4, the nap was not interrupted. If the nap lasted less than 30 min 
and/or did show stage 3 and 4, the nap and the subsequent night were excluded. During 
each night and nap EEG, EMG, electrooculogram (EOG), electrocardiogram (ECG) and core 
body temperature were recorded. Subjects received a single drug (baclofen (BAC) or sodium 
oxybate (SO)) per session either before the nap or before the third night and their vigilance 
and memory were also assessed (Figure 8.1). 
Drugs 
During the entire study, a dose of 30 mg/kg of sodium oxybate (Xyrem®, oral solution, 
500mg/ml, USB-Pharma SA, Bulle, Switzerland) and a dose of 0.35 mg/kg of baclofen (oral 
suspension prepared from pills of Lioresal® 10 mg, Novartis-Pharma, Basel, Switzerland) were 
given once before the nap and once before the third night according to the randomized, 
placebo-controlled, double-blind, crossover design. Thus, subjects received per session 
either one drug and three placebos or four placebos. Subjects took a solution (placebo or 
sodium oxybate) and a suspension (placebo or baclofen) 2 min before the nap and 2 min 
before the third night of each session (Figure 8.1). 
In order to avoid side effects including drowsiness, sleepiness and nausea during 
wakefulness after the nap, we chose relatively low doses known to affect sleep according to 
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the literature237,251. In healthy adults, the half-life and the median Tmax of BAC are 3.8-4 h282 
and 1.8 h310, respectively, and for SO, 30-50 min and 30-60 min311, respectively. 
Vigilance assessment 
Psychomotor vigilance task (PVT) is a simple visual reaction time task with no learning and 
virtually independent of aptitude312. Ten-minute PVT (PVT-192 Psychomotor Vigilance Task 
Monitor, Ardsley, NY) were performed 15 min before baseline night, every 2 hours during the 
following day starting at 9 a.m. and around 1 h after the third night wake-up time. Before 
and after a PVT, subjects carried out a Karolinska sleepiness scale (KSS). The KSS is a 9-point 
rating scale which provides a subjective and momentary measurement of 
alertness/sleepiness (1 = very alert, 9 = very sleepy)313. Therefore, subjective alertness and 
objective vigilance of the subjects were tested. 
Memory assessment 
An unrelated word-pair associate learning task and a 2-D object-location memory task were 
used to assess declarative memory, while a finger sequence tapping task evaluated 
procedural memory. 
The unrelated word-pair associate learning task seems to benefit particularly from SWS 
314,315,316 and emotion would modulate memory consolidation302. Five sets of 36 different 
French word-pairs (12 positives, 12 negatives and 12 neutral word-pairs), one by session, 
were chosen randomly from a list of 866 words showing a medium concreteness and 
imagery 317. Words consist of 4–10 letters and pairs are of low semantic relatedness. They 
were presented on a 15 inches flat computer screen.  
At learning testing at 2 p.m., subjects were asked to learn 36 word-pairs by forming a mental 
association/image of both objects. Each pair was presented once for 4 s with an inter-
stimulus interval of 100 ms. Immediately after the first run, subjects performed a cued recall, 
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i.e. the first word of each pair was presented for 10 s and they were instructed to type the 
second word using the computer keyboard. During these 10 s, subjects could see the result 
of their typing. Visual feedback was given in each case by presenting the correct second 
word for 2 s independent of whether the response was correct or not, to enable re-encoding 
of the correct word-pair. The first word of the next pair was showed after an inter-stimulus 
interval of 3 s. At retrieval testing at 8 p.m., the same cued recall procedure was used as 
during the learning phase. To indicate memory consolidation, we used the difference in the 
number of correctly recalled words at retrieval and minus that at learning. 
The 2-D object-location memory task was based on a previous study 315. Performance on this 
type of task relies on temporal lobe structures including the hippocampus 318,319 and benefits 
from SWS315. It consists of 10 card-pairs showing different images which are part of the 
Karolinska Directed Emotional Faces System (KDEF; 320). These images are standardized facial 
expressions of emotions, presented by amateur actors. Five sets of 10 different card-pairs (3 
happy faces, 3 angry faces and 4 neutral faces) were chosen randomly from KDEF, one for 
each session. Throughout the task, all 20 possible spatial locations are shown as grey squares 
on a 15 inches flat screen (“the back of the cards”). The locations are geometrically ordered in 
a checkerboard-like fashion (4 x 5 matrix). The 5 sets of card-pairs use different locations.  
At learning testing at 2 p.m., subjects were instructed to memorize the two locations 
associated with each image. The first card of each card-pair was presented alone for 1 s 
followed by the presentation of both cards for 4 s. After an inter-stimulus interval of 1 s, the 
next card-pair was presented in the same way. The whole set of card-pairs was presented 
once. Immediately after the first run, recall of the spatial locations was tested using a cued 
recall procedure, i.e., the first card of each pair was presented and the subject had to indicate 
the location of the second card with a computer mouse. Visual feedback was given in each 
case by presenting the second card at the correct location for 2 s independent of whether 
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the response was correct or not, to enable re-encoding of the correct location of the card-
pair. After presenting a card-pair both cards were replaced by grey squares again, so that 
guessing probability remained the same throughout the run. Feedback was given about the 
number of correctly recalled card-pairs. At retrieval testing at 8 p.m., the same cued recall 
procedure was used as during the learning phase. To indicate memory consolidation, we 
used the difference in the number of correctly recalled card locations at retrieval minus that 
at learning. 
The finger sequence tapping task was adapted from previous studies indicating a robust 
sleep-dependent improvement in skill on this task, especially REMS and stage 2321,322,323. It 
requires the subject to press repeatedly one of five 5-element sequences (‘1-2-4-3-1’, ‘2-1-3-
4-2’, ‘3-4-2-1-3’, ‘4-1-3-2-4’ or ‘2-3-1-4-2’) on a keyboard with the fingers of the non-dominant 
hand as fast and as accurately as possible for 30-s epochs interrupted by 30-s breaks. The 
numeric sequence was displayed on the screen at all times to keep working memory 
demands at a minimum. Each 30-s trial was scored for speed (number of correctly completed 
sequences) and error rate (number of errors relative to total number of tapped sequences). 
At learning, subjects performed on twelve 30-s blocks. The average score for the last three of 
these blocks was used to indicate learning performance. At retrieval, subjects were tested on 
another three blocks. Performance and accuracy are given as the absolute difference in 
averaged numbers of correct sequences or errors on the three blocks at retrieval minus the 
average of the last three blocks at learning, respectively.  
The order of memory tasks at leaning and retrieval as well as the different sets of word-pairs, 
card-pairs and tapping sequences was balanced across subjects and sessions. E-Prime 
software (Psychology Software Tools, Pittsburgh, PA) was used to design and run word-pair 
memory task and object-location memory task, while the finger-tapping task was made 
using MATLAB® R2007a (The MathWorks Inc, Natick, MA). 
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Polysomnographic, temperature and actigraphic recordings 
Six EEG channels (F3, C3, O1 and F4, C4, O2 referenced against linked mastoids A2 and A1 
respectively), two electrooculograms (EOG; one to each outer cantus), two surface submental 
electromyogram (EMG) electrodes, and one electrocardiogram (ECG) signal were recorded 
throughout each night and nap of each session in individual bedrooms using Embla® N7000 
recording system (Embla Systems, Broomfield, CO). Only data from C3-A2 EEG derivation are 
reported here. Signals were filtered by a high-pass filter (EEG and EOG: −3 dB at 0.5 Hz; EMG:  
10 Hz; ECG: 1 Hz), a low-pass filter (EEG: −3 dB at 35 Hz, EMG: 70 Hz), and a notch filter at 50 
Hz. Data were sampled at a frequency of 100 Hz (EEG, EOG and ECG) and 200 Hz (EMG). 
Infrared video was also simultaneously recorded. The raw signals were stored on-line on a 
computer hard drive and off-line on DVDs and a hard disk. Sleep stages during nights and 
naps were visually scored by a registered PSG technologist on a 20-s epoch basis 
(Somnologica® Software, Embla systems, Broomfield, CO) according to standard criteria 324. 
The EEG power spectra of consecutive 20-s epochs (average of five 4-s epochs, fast Fourier 
transform routine, Hamming window, frequency resolution 0.25 Hz) were calculated using 
MATLAB R2007a (The MathWorks, Natick, MA) and matched with the sleep scores. 
Movement- and arousal-related artifacts were visually identified and excluded. If more than 
50% of a 20s epoch contained artifacts, the entire epoch was removed from the spectral 
analysis. 
The NREMS–REMS cycles were defined according to criteria of Feinberg and Floyd325. For the 
completion of the first and the last cycle, no minimal criterion for the REMS duration was 
applied. Sleep-onset REMS period (SOREMP) was defined as at least one 20-s epoch of REMS 
occurring in the first 18 min of sleep (NREMS stage 1, 2, 3, 4 and REMS). The SOREMP did not 
contribute to sleep cycle length, i.e., when a SOREMP was present, the first cycle started after 
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the SOREMP according to above-mentioned criteria (succession of a NREMS episode and a 
REMS episode). At least four NREMS–REMS cycles were completed in all recordings. 
Core body temperature data was sampled once per minute and stored via a portable device 
(Mini-Logger®, series 2000, Mini-Mitter, Bend, OR) connected to disposable rectal probe 
(Steri-probe, Cincinnati Sub-Zero Products, Inc., Cincinnati, OH). Temperature was recorded 
during each night and each laboratory day during the five sessions of the study. 
At least, ten days before the assessment session and seven days before each session of the 
study, an actiwatch was worn by subjects to their left wrist and a sleep agenda was filled out 
in order to control their sleep schedule (23:00-07:00), their sleep quality and their activity. 
Actiwatchs (Mini-Mitter, Bend, OR) sampled activity once per 30 s. 
Data Analyses and Statistics 
The effect of treatments and nap on sleep variables, the EEG in REMS and NREMS (stages 2 to 
4), sustained vigilant attention (PVT), subjective alertness (KSS) and memory were analyzed 
in 13 subjects. Of the 13 subjects included, one subject took anti-histamine medication for a 
rash provoked by a soap allergy. The two affected sessions of this subject were excluded 
(sessions: PL-SO and BAC-PL, for study design see Figure 8.1). Because of insufficient sleep 
during naps (<30min), two sessions of another subject were not taken into account for 
analysis except sleep and EEG data for the two baseline nights (sessions: PL-BAC and PL-PL). 
Finally, the last night of one subject was excluded due to adverse effects provoked by SO 
(dizziness and anxiety) in the beginning of the night (session: PL-SO). Note that after an 
unremarkable general clinical exam, the subject slept and reported a good night 
(monitored.) Thus, for the following analysis, we included n=13, 12, 11, 12 and 13 for SO-PL, 
BAC-PL, PL-SO, PL-BAC, and PL-PL, respectively, and for comparison before the experimental 
(EXP) night, n =13, 12 and 33 for SO, BAC and PL, respectively. In addition, for all variables 
tested below, the baseline (BLN) nights of the five treatments (PL-PL, BAC-PL, SO-PL, PL-BAC, 
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and PL-SO) did not significantly differ (p>0.05). The same was true for the three placebos 
administrated before the nap (PL-PL, PL-SO, and PL-BAC), which allowed us to regroup them 
under the term ‘PL’. Spectral analysis was performed on C3-A2 derivation. Due to large 
extent of artifact on A2 for one subject, his C3-A2 trace was not included in the following 
analysis reducing the number of subjects for spectral analysis to 12. 
To approximate a normal distribution, absolute power densities were log-transformed 
before statistical tests. The SAS 9.1 statistical software (SAS Institute, Cary, NC) was used. The 
effects of nap and treatments on sleep variables and the EEG were assessed by comparing 
EXP night with BLN night: two-way mixed-model analyses of variance (ANOVA) with the 
within-subject factors ‘treatment’ (PL-PL, BAC-PL, SO-PL, PL-BAC, and PL-SO) and ‘night’. 
Sleep cycle and treatment effects on SWS and REMS duration, and EEG frequency ranges 
were estimated by performing a two-way mixed-model ANOVA with the within-subject 
factors ‘treatment’ and ‘cycle’ (1st-3rd) on BLN and EXP night or on the ratio EXP/BLN (see 
results). One-way mixed-model ANOVA with the within-subject factor ‘treatment’ (PL, BAC, 
and SO) served to evaluate effects of treatment on sleep variables and the EEG during the 
nap and on memory tasks. To assess the emotional factor on the word-pair associate 
learning task performance, a two-way mixed-model ANOVA with the within-subject factors 
‘treatment’ and ‘emotion’ was carried out. Finally, to estimate treatment effects on sustained 
vigilant attention and subjective alertness, a two-way mixed-model ANOVA for the within-
subject factors ‘treatment’ (PL, BAC and SO) and ‘time’ (time points where tasks were 
performed) and a one-way mixed-model ANOVA with the within-subject factors ‘treatment’ 
at specific time points were used. The significance level was set at α < 0.05. To localize 
differences within subjects paired 2-tailed t-tests, Tukey-Kramer’s tests or Dunnett-Hsu’s 
tests (control= PL-PL or PL) were only performed if main effects or interactions of the ANOVA 
were significant. The majority of the statistics is indicated in the figure legends. EEG power 
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was computed for consecutive 0.25-Hz bins and for specific frequency bands. The frequency 
bins and bands are indicated by the encompassing frequency ranges (e.g., 0.75-4.5 Hz band 
denotes 0.625-4.625 Hz). 
8.4. Results 
Nap 
During the scheduled nap, subjects had a sleep episode between 42 and 116 min with at 
least 7 min of SWS. In PL conditions (PL-PL, PL-SO and PL-BAC; Figure 8.1), sleep efficiency 
was below BLN night (one-way mixed-model ANOVA for factor ‘condition’ (BLN or NAP) 
p<0.0001) as expected 293, but not sleep latency (p=0.3718) (Table 8.1, Table 8.2, and Figure 
8.2A). Compared to PL conditions, naps under SO showed an increase in total sleep time 
(TST), sleep efficiency and REMS, as well as a decrease in REMS latency, movement time (MT) 
and stage1. Although BAC, as PL, did show significantly lower TST and REMS compared to 
SO, for several sleep variables, BAC was intermediate between SO and PL (sleep efficiency, 
REMS latency, MT as well as combined arousal variables and light sleep, see Table 8.1 and 
Figure 8.2A,B). The duration of SWS was significantly increased after SO compared to PL, but 
not compared to BAC, which was again intermediate between the two (Figure 8.3C). 
However, when expressed as a percentage of TST, the significant difference between SWS in 
SO condition and SWS in PL condition was lost (Table 8.1). 
Except for four naps, subjects were awakened after having completed one NREMS episode. 
During these four naps, subjects under SO were awakened at the end of the 2-h-opportunity 
nap without completely terminated NREMS episode. These naps had a sleep latency 
between 7 and 8 min, a sleep onset REMS period (SOREMP; i.e. REMS latency shorter than 18 
min) lasting between 30 and 50 min, a SWS amount between 36 and 73 min, and a sleep 
efficiency above 92% suggesting that subjects slept sufficiently and SO affected the classical 
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duration and structure of sleep (90-min sleep cycle with NREMS episode followed by REMS 
episode). The fact that naps under SO was significantly longer than under BAC or PL, also 
supported SO-induced changes in sleep duration (see ‘time in bed’ (TIB) in Table 8.1). 
Interestingly, several other cases of SOREMP were shown under SO (8/13 naps (62%)), as well 
as under BAC (5/12 naps (42%)) and under PL (13/33 naps (39%)). The subjects exhibiting a 
SOREMP were allowed to sleep until the beginning of the following REMS episode or until 
the end of the 2-h sleep opportunity.  
Number and duration of SOREMPs were higher under SO compared to PL and BAC, although 
the difference between SO and BAC was only a tendency, probably due to high variability of 
SOREMP appearance under each treatment and the low number of subjects (Tukey-Kramer’s 
test for SOREMP number: SO vs PL p=0.0248, SO vs BAC p=0.1884, and BAC vs PL p=0.8463; 
Figure 8.2C,D and Table 8.1). Similarly, REMS latency was lower with SO than with PL, but 
with only a tendency for BAC (Tukey-Kramer’s test: SO vs BAC p=0.1259). REMS duration 
during these naps reflected the duration of SOREMPs because naps were stopped at the end 
of the first NREMS episode (Figure 8.3D). 
Experimental night vs Baseline night 
All subjects displayed a good sleep quality during BLN nights. Typically for young healthy 
subjects, they fell asleep within the normal time range (12 min), exhibited little intermittent 
wakefulness and considerable amount of SWS, particularly during the first half of the night. 
In placebo (PL-PL) conditions, an afternoon nap decreased TST, sleep efficiency, stage 4 and 
SWS, but increased sleep latency, wakefulness after sleep onset (WASO) and light sleep 
(stage 1) of the following nighttime sleep (EXP night; Table 8.2). However, drug treatments 
influenced several sleep variables. Although SO administrated before the EXP night and BAC 
before the nap increased sleep latency during the EXP night compare to the BLN night, this 
increase was significantly lower than that of the three other treatments (Tukey-Kramer’s test, 
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p<0.05; Figure 8.2A). TST during the EXP night in BAC-PL condition was unchanged 
compared to the BLN night and significantly higher to all other treatments during the EXP 
night except PL-SO (Tukey-Kramer’s test, p<0.05; Table 8.2). The decrease of SWS found in 
placebo condition was not present in PL-SO and BAC-PL. The same was also found for stage 
4 in PL-SO treatment. Moreover, BAC administrated before the nap (BAC-PL) and SO 
administrated before the EXP night (PL-SO) affected SWS exclusively during the first cycle of 
the EXP night (Figure 8.3A). Together, this suggests that the two conditions (BAC-PL and PL-
SO) not only counteract the effect of the nap on sleep latency but also on SWS and TST.  
Interestingly, BAC administrated before the nap and before the EXP night (BAC-PL and PL-
BAC) increased significantly REMS during the entire EXP night compared to BLN night, while 
PL-SO significantly decreased REMS specifically in the beginning of the EXP night (cycle 1 
and 2) compared to the BLN night, although the overall mean REMS amount in PL-SO 
condition during the EXP night did not differ (for statistics and illustration see Figure 8.3B, 
Table 8.2). BAC-PL and SO-PL significantly induced SOREMPs in the beginning of the EXP 
night compared to the BLN night (paired t-test: p<0.05). Moreover, in the EXP night, BAC-PL 
and PL-SO increased significantly the number and the duration of SOREMPs compared to PL-
PL, respectively (Figure 8.2C,D and Table 8.2). This increase of SOREMPs after PL-SO and BAC-
PL treatments was also reflected through the decrease of REMS latency (Table 8.2). Although 
the averaged number of SOREMPs for SO-PL, PL-BAC and PL-PL did not differ from zero 
(paired t-test: p>0.05), a total absence of SOREMPs was found only for SO-PL (number of 
SOREMPs by treatment: SO-PL, 0/13 (0%); PL-PL, 2/12 (17%); PL-BAC, 2/12 (17%); PL-SO, 6/11 
(55%); BAC-PL, 8/12 (67%); for statistics see Figure 8.2). Compared to EXP night, 3 out of 65 
BLN nights exhibited a short SOREMP (2 -11min; SO-PL (1/13 (8%)), PL-PL (1/12 (8%)), and 
BAC-PL (1/12 (8%)), but overall the number of SOREMPs did not differ from zero (paired t-
test: p>0.05). 
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BAC seems to consolidate sleep during the EXP night, because combined arousal variables 
and light sleep (stage1+WASO+MT) together were significantly lower in PL-BAC and BAC-PL 
compared to the other three treatments and compared to the BLN night (Tukey-Kramer’s 
test p<0.05; Figure 8.2B and Table 8.2.). Moreover, number of transitions from one state to 
another was significantly lower for PL-BAC and BAC-PL compared to the three other 
treatments (data not shown). 
Note that for all sleep variables tested SO-PL did not significantly differ from PL-PL, meaning 
that the strong effects on sleep induced by SO when administrated before the nap did not 
affect subsequent nocturnal sleep. 
NREMS EEG 
To characterize the effect of the nap and treatment on sleep quality and on the homeostatic 
regulation of sleep, the spectral composition of the EEG in NREMS (stage 2-4) was quantified. 
After placebo intake, a nap reduced EEG power in delta and theta frequency ranges (0.75-
7.25 Hz) and enhanced 12.5 Hz and overall beta frequency range (>16 Hz) during the 
subsequent night (Figure 8.4A,B). The largest differences were present in the first NREMS 
episode for delta, theta and sigma power (cycle1: Figure 8.6A,B.C). According to the 
homeostatic process of sleep293, delta but also theta power decreased within the course of 
sleep for both the BLN and EXP nights. Conversely, sigma slightly increased from the first and 
second NREMS episodes to the third NREMS episode during BLN night, but decreased from 
the first to the second NREMS episode, then re-increased in the third episode during the EXP 
night (two-way mixed model ANOVA see Figure 8.6; Tukey-Kramer’s test, p<0.05). 
To determinate the effect of SO and BAC on the EEG, all drug treatments were compared to 
placebo (PL-PL) treatment (ratio EXP/BLN of each drug treatment was expressed as a 
percentage of the ratio EXP/BLN of PL-PL treatment; Figure 8.4C). Neither relative NREMS 
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spectra of PL-PL and SO-PL nor those of PL-SO and PL-BAC differed between them (two-way 
mixed-model ANOVA see Figure 8.4C; Tukey-Kramer’s test, p<0.05). 
Compared to PL-PL treatment, PL-SO, BAC-PL, and PL-BAC in EXP night increased delta and 
theta frequency ranges (0.75-7.25, 0.75-9.25, and 1.5-8.25, respectively), and BAC-PL also 
decreased sigma frequency range (13.5-13.75 Hz). 
Delta, theta and sigma power were analyzed during the three first NREMS episodes. The 
largest effects of drugs were present in the first episode of NREMS. BAC-PL and PL-SO 
enhanced significantly delta and theta power, while they reduced sigma power during the 
first cycle (p<0.05; Figure 8.7A,B,C). Already in the second NREMS episode, none of the 
treatments differed from the PL-PL treatment. However, it is interesting to note that PL-BAC 
tended to increase delta power in the second cycle without reaching the significance due to 
a high variability, suggesting that BAC took longer time to affect the EEG than SO, which is 
consistent with the pharmacokinetics of both drugs (Figure 8.7A). During the nap, SO, but 
not BAC, differed from PL; SO enhanced delta and theta frequency ranges (0.75-10 Hz) and 
reduced sigma frequency range (13.75-14.75 Hz) (Dunnett-Hsu’s test p<0.05; Figure 8.4D). 
Interestingly, SO administrated before the nap affected the EEG during the nap, but no 
difference with PL-PL were found in the EXP night, which is consistent with results obtained 
with sleep variables. 
REMS EEG 
Similar to NREMS, a spectral analysis was performed for REMS. In PL-PL treatment, a nap did 
not affect REMS spectrum (Figure 8.5A,B). EEG delta power decreased across cycles, and the 
BLN and EXP nights tented to differ even if the significance level was not reached (two-way 
mixed-model ANOVA for factors ‘night’ p=0.0536, ‘cycle’ p=0.0026 and their interaction 
p=0.1097). However, by taking each cycle separately, delta power in the EXP night was 
significantly lower than in the BLN night during the first REMS episode only (one-way mixed-
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model ANOVA for factor ‘night’ by cycle, p<0.05; paired t-test, p<0.05; Figure 8.6D, statistics 
not shown on the figure), and difference among cycles was only found for the BLN night, 
which showed a lower delta power in the third cycle compared to the first and second cycles 
(one-way mixed-model ANOVA for factor ‘cycle’ by night, p<0.05; Tukey-Kramer’s test, 
p<0.05); Figure 8.6D). Theta power differed by cycle and night (two-way mixed-model 
ANOVA see Figure 8.6E). Like delta power, theta power was reduced, but significantly, during 
the EXP night compared to the BLN night exclusively during the first cycle and only the BLN 
night showed significant differences between cycles (cycle 1>3). Note that SOREMPs were 
not included in this analysis. 
As for NREMS, to determinate the effect of SO and BAC on the EEG, relative REMS spectra of 
all drug treatments were compared to placebo (PL-PL). PL-SO, BAC-PL, and PL-BAC in the EXP 
night increased delta and theta frequency ranges (2.5-6.75, 0.75, 1.25-8.25, and 1.25-8.25, 
respectively) compared to PL-PL (Dunnett-Hsu’s test p<0.05; Figure 8.5C). During the first 
cycle, delta power was enhanced in PL-SO, while during the second REMS episode delta 
power was reduced in PL-BAC compared to placebo (Dunnett-Hsu’s test p<0.05 and see 
Figure 8.7D). PL-SO and BAC-PL increased theta power, while PL-BAC and BAC-PL started or 
continued to increase it, respectively, indicating a delayed and longer duration effect (Figure 
8.7E). 
During the nap, six subjects showed a SOREMP in BAC, SO and PL conditions. Thus, in these 
six subjects, EEG spectral analysis of SOREMPs was performed to determinate whether a 
SOREMP under drug had a different EEG fingerprint compared to PL. Neither SO nor BAC 
differed from PL (two-way mixed-model ANOVA for factors ‘treatment’ and ‘bin’, see Figure 
8.5D). 
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Vigilant attention and subjective alertness 
Laboratory experiments have indicated that afternoon naps improve subjective alertness 
and cognitive performance in young adults326. Thus, to quantify the effects of the nap with or 
without drugs on vigilant attention and alertness, we compared the trial performed just 
before BLN night with that just before EXP night (Figure 8.8A,C and Figure 8.1). Mean and the 
10% fastest reaction times as well as the KSS scores were increased during the trial 
performed just before EXP night compared to the trial performed just before BLN night 
independent of the treatment (two-way ANOVA for factors ‘trial’ p≤0.023 and ‘treatment’ 
p≥0.6298 and their interaction p≥0.1659, see Figure 8.8A,C). By comparing each treatment 
separately, this increase of alertness and attention just before EXP night was significant for 
the 10% fastest reaction time in all treatments and for the KSS scores only for BAC treatment. 
Therefore, generally the nap increased vigilant attention and subjective alertness late in the 
evening independent of the treatment during the nap. 
To evaluate the effects of a nap under SO or BAC on vigilant attention and alertness 
compared to those of a nap under PL, we analyzed the time course of mean, the 10% slowest 
and the 10% fastest reaction times on PVT and KSS scores starting with the trial performed 
just before the nap and ending with the trail performed just before EXP night (Figure 8.8B,D 
and Figure 8.1). All variables quantifying attention and subjective alertness differed by trial 
but not by treatment (two-way ANOVA). Overall, data described a fast increase of attention 
and alertness just after the nap compared to just before the nap followed by a plateau and 
then a slow and slight decrease until the end of the evening. Interestingly, by comparing the 
three treatments administrated before the nap (PL, BAC and SO) at each trial separately, only 
one trial, just after the nap, differed significantly between the three treatments for the 
following variables: mean and the 10% slowest reaction times as well as the KSS scores (one-
way ANOVA for factor ‘trial’ by treatment: p<0.05 see Figure 8.8B,D). Unlike BAC and PL, SO 
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did not show the increase of vigilant attention and subjective alertness during this trial 
(Tukey-Kramer’s test p<0.05, but note that for KSS score only PL differed significantly from 
SO). Two hours later this difference has already disappeared suggesting that SO slightly and 
temporarily affected sustained vigilant attention and the evaluation of subjective alertness 
compared to PL and BAC. Because naps under SO were significantly longer than naps under 
BAC and PL (see Table 8.1), sleep inertia (transitional state of lowered arousal occurring 
immediately after awakening from sleep and producing a temporary decrement in 
subsequent performance) may be the reason why subjects under SO showed lower cognitive 
performance and subjective alertness than subjects under BAC or PL 327, even if the trial just 
after the nap was performed at least 15 min after awakening. This hypothesis was tested by 
doing a correlation between TST and the 10% slowest reaction times (the most affected 
variable) resulting in a non-significant correlation for the three treatments (SO: R2=0.0068, 
p=0.3206; BAC: R2=0.2752, p=0.0795; PL: R2= 0.0724, p=0.1238). 
Memory tasks 
Growing evidence demonstrates that sleep, and its varied stages, play an important role in 
the consolidation of both procedural and declarative memories 328,329. Not only nocturnal 
sleep but also daytime naps can improve memory performance 321,330,331. In this study, we 
used a finger sequence tapping task to assess procedural memory, while declarative memory 
was tested by a verbal and a non-verbal tasks (word-pair associate learning task and 2-D 
object-recognition memory task, respectively). On average, for each task, subjects reached 
~60% of correct responses at learning and there was no significant learning difference 
among treatments (BAC, SO, and PL; Table 8.3 with statistics). 
Performance on the unrelated word-pair associate task and the finger sequence tapping task 
was increased similarly for all treatments at retrieval compared to learning (p<0.05; Figure 
8.9A,B), while for the 2-D object-recognition task, subjects did not show any improvement at 
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retrieval (Figure 8.9C). Accuracy (error rate) of the finger-tapping task was similar at learning 
and retrieval (Figure 8.9A, right panel). Interestingly, a nap under SO or BAC did not 
differently affect any tested memory variables compared to a nap under PL. 
Numerous behavioral studies have demonstrated that sleep benefits the consolidation of 
emotional relative to neutral memories compared with wakefulness 302,332,333,334,335,336. Thus, we 
explored the consolidation of neutral, positive, and negative emotional memories using the 
word-pair associate learning task (Figure 8.9B, left panel). Subjects remembered similarly 
negative, positive as well as neutral words and performance was higher at retrieval for all 
three emotional categories compared to learning, except negative words in SO condition for 
which performance was similar at learning and at retrieval. However, note that performance 
for negative, positive and neutral words in SO condition did not differ. Together, these 
results suggest that neither the emotional burden of the words nor treatment during the 
nap affected memory. 
 
8.5. Discussion 
These findings provide a substantial evidence that SO and BAC decreased sleep latency in 
low sleep pressure condition, produced SOREMPs and strongly increased EEG delta and 
theta power in NREMS as well as in REMS. Both counteracted the homeostatic effect of an 
afternoon nap on subsequent nocturnal sleep. The increase in the EEG delta power during 
the nap induced by SO, did not affect the following sleep suggesting that the delta activity 
produced by SO does not interfere with the homeostatic regulation of sleep. Thus, SO-
induced slow waves seem different from those produced during physiological sleep. The 
differential dynamics of sleep and EEG effects of BAC did not allow us to conclude whether 
or not BAC affects the homeostatic process of sleep. 
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Overall, memory, neurobehavioral performance and subjective alertness were not affected 
by SO and BAC. However, SO induced a slight and temporary decline of vigilance after the 
nap (potentially independent of sleep inertia). 
BAC reduced WASO and NREMS stage 1 suggesting a more consolidated sleep than SO and 
placebo during EXP night. The lack of increased consolidated sleep by SO during a long sleep 
(EXP night) might be due to its short action, because during a short sleep (nap) SO did show 
a decrease in stage 1 and MT. Thus, although the effect of BAC and SO on EEG and sleep 
were similar for several variables, their differential dynamics of action and affinity for GABAB 
receptors may explain the differences observed between them.  
The effects of a nap on sleep and EEG 
All 13 subjects succeeded in falling asleep during the afternoon nap. Consistent with a 
previous study293, sleep latencies and sleep efficiencies during the nap were similar and 
lower compared to BLN nights, respectively. Moreover, in BLN conditions, mean values of 
sleep variables were coherent with results reported in healthy volunteers337. In placebo (PL-
PL) conditions, an afternoon nap decreased TST, sleep efficiency and increased sleep latency 
during the postnap (EXP) sleep compared to BLN sleep. SWS was reduced in the entire sleep 
episode with a marked decrease during the first cycle, while the enhancement of REMS in the 
first sleep cycle did not significantly affect the mean REMS duration of the night. 
It has been proposed that NREMS exerts a sleep-dependent progressive disinhibition of 
REMS in the course of sleep episode 338,339. The increase in the duration of the first REMS 
episode from 12.9 (BLN) to 24.3 min (EXP) and the occurrence of a SOREMP (2/12 in EXP 
night) is further evidence for a disinhibition of REMS by the reduced NREMS pressure. This 
effect was present, however, only in the first sleep cycle and did not result in a significant 
increase in REMS in the entire sleep episode. 
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At the level of EEG, REMS EEG spectra of the entire night did not significantly differ between 
BLN night and EXP night (postnap night). However, by looking at the three first sleep cycles 
of the night, we found that the EEG theta power slightly decreased over the cycles in BLN 
condition and theta power in the first REMS episode of EXP night was significantly reduced 
compared to BLN night. The same tendency was found for delta power in REMS. To our 
knowledge this is the first study showing that the time course of theta and potentially delta 
power are affected by low sleep pressure and are decreased across sleep episodes 
suggesting that the EEG theta power and eventually the EEG delta power might represent 
potential markers of the homeostatic regulation of REMS. However, previous experiments 
with a sleep desynchrony protocol and a REMS-deprivation protocol did not find theta (4.5-8 
Hz) but alpha (8.25-11 Hz) power as a potential marker of REMS propensity340. Further 
investigations on the dynamics of the EEG theta and delta power during REMS under low 
and high sleep pressure are needed to better understand their involvement in the 
homeostatic regulation of REMS. 
The effects of a nap on the NREMS EEG spectra were not limited to the delta frequency range 
but extended to the theta frequency range. It has been observed that activity in the delta 
and theta frequency ranges decreases in the course of a sleep episode and is enhanced after 
sleep deprivation and reduced after an afternoon/evening nap92,293,341,342. Thus, our results are 
in good agreement with the expected reduction of sleep pressure induced by an afternoon 
nap. Moreover, activity in the sigma frequency range (spindle band) typically shows a small 
increase in the course of sleep 342,343,344 and a reduction after sleep deprivation345. In the 
present study, sigma frequency range changed in the expected direction, which was 
opposite to that induced by sleep deprivation. The effects of the nap on these three 
frequency ranges were particularly obvious in the first sleep cycle. 
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Taken together, in placebo condition, the changes in the NREMS EEG spectrum and sleep 
variables, dependent on the duration of prior wakefulness and sleep history, illustrate 
perfectly the homeostatic component of sleep regulation and are perfectly consistent with 
previous studies293.  
The effects of BAC and SO on sleep and the EEG  
To evaluate the effects of a nap under SO or BAC and the effects of SO and BAC on EXP night 
(postnap night) on sleep and its homeostatic regulation, we compared sleep variables and 
the EEG in NREMS and REMS of the different drug conditions with placebo condition. 
Naps under SO were longer than naps under PL. The increase of sleep efficiency and the 
decrease of combined arousal variables with light sleep (stage1+WASO+MT) of naps under 
SO suggest that these naps showed more consolidated sleep than naps under PL. SO 
increased slightly SWS duration compared to PL, however the significance was lost when 
SWS was expressed as a percentage of TST. Together these findings are consistent with 
previous studies regarding the dose used, the study design and the subjects (healthy 
volunteers). For example, Lapierre and colleagues showed that, with a dose of GHB similar to 
ours, healthy volunteers during a morning nap showed a decrease in WASO compared to PL, 
but identical SWS duration and sleep latency237. A significant increase in SWS duration during 
nocturnal and daytime sleep were found in healthy volunteers and in patients with sleep 
disturbances, only at higher doses145,236,283,288,346.  
Administration of SO before EXP night counteracted the effects of the nap by strongly 
decreasing sleep latency and increasing TST, sleep efficiency and SWS in the first NREMS 
episode. These findings are very similar to the results obtained during the nap under SO 
except for sleep latency, which was not reduced during the nap compared to placebo and 
BAC treatment. This is probably due to a ceiling threshold of sleep latency that cannot be 
further shortened with drugs. During BLN night and nap in our healthy subjects, all 
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treatments including placebo would be around this ceiling level, whereas during postnap 
sleep, the long sleep latency in placebo condition (induced by napping) could be reduced by 
the drugs.  
At the EEG level, SO administrated before the nap or before EXP night had similar effects. It 
increased EEG delta and theta power in NREMS. This result on NREMS spectra is consistent 
with a recent report346 which showed that even under high sleep pressure a dose of 3.5g of 
SO increased delta and theta power compared to placebo. Importantly, these effects are not 
exclusive to NREMS because also present in REMS during EXP night. This suggests a 
pharmacological EEG effect of SO rather than an induction of physiological SWS with a high 
prevalence of delta and theta waves restricted to NREMS. Moreover, a nap under SO did not 
affect the postnap sleep. Thus, it seems that SO acutely modifies sleep but its effects are not 
involved in homeostatic regulation of sleep, i.e. changing physiological sleep need and 
pressure. This is also consistent with what we recently reported in mice294. However, our 
results both in mice and humans, contrast with a recent study testing the effects of SO on 
sleep loss, which found that administration of SO during sleep restriction affected the 
rebound of delta power during recovery night (lower rebound) leading to the conclusion 
that SO seems to be involved in the homeostatic process of sleep. 
 
A common effect shared by BAC and SO was the increased occurrence of SOREMPs. First, 
although intriguing for healthy volunteers to show SOREMPs even under placebo treatment, 
others have also reported similar phenomenon during naps and nocturnal sleep293,347,348,349,350. 
Incidence of SOREMPs is increased in sleep-deprived subjects and in patients suffering from 
narcolepsy, depression, obstructive sleep apnea syndrome and periodic leg movement 
disorder. It is highly unlikely that our subjects included were in any of these conditions due 
to the careful screening and monitoring performed (continuous activity assessment, 
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habituation night before each session, and see also Materials and Methods). It is also 
interesting to note that SOREMPs appeared in placebo conditions especially under low sleep 
pressure (5% for BLN night vs 17% for EXP night (PL-PL)) and mostly during the nap (39% 
(PL)). As already mentioned, it has been proposed that NREMS pressure may inhibit REMS 
which supports our findings. In addition, circadian REMS propensity may probably play a 
role349, as well as the young age of our subjects (23 years old). It would be, therefore, 
interesting to further investigate which factor influence manifestation of SOREMPs in healthy 
populations, a topic poorly studied348. 
During the nap, the duration of SOREMPs was much longer with SO treatment compared to 
BAC and PL treatments, and the number of SOREMPs significantly higher than that in PL 
treatment. During EXP night, overall, both BAC-PL and PL-SO treatments showed higher 
number of SOREMPs with a longer duration compared to other treatments and BLN nights. 
REMS latency was also reduced with SO treatment during the nap and for PL-SO and BAC-PL 
during EXP night, mainly due to SOREMPs. This again pinpoints a delayed effect of BAC and 
the similitude between PL-SO and BAC-PL conditions. In addition, BAC and SO seems to 
induce SOREMPs which have never been described to our knowledge for BAC. Although 
rarely, SOREMPs under GHB has been already reported 236,283. To investigate whether 
SOREMPs under SO and BAC were different at the EEG level to SOREMPs under placebo, we 
analyzed SOREMP spectra during naps where we found the highest number of SOREMPs in 
each conditions. Although, SOREMP duration was longer with SO than with BAC and PL, no 
significant difference was found between SOREMP spectrum in SO, BAC, and PL. This 
suggests that SOREMP induced pharmacologically did not differ from ‘physiological’ 
SOREMP at the EEG level, that was not the case for the REMS spectrum which showed a large 
increase in EEG theta and delta power under SO and BAC during EXP night. However, note 
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that SOREMP spectrum analysis was performed in only 6 subjects who showed a SOREMP in 
the three conditions. 
 
BAC shares many common sleep and EEG effects with SO, but with a delayed action. During 
the nap, BAC did not differ from PL, but for several sleep variables, it was intermediate 
between SO and PL. BAC tended to increase sleep efficiency and to decrease MT and 
combined arousal variables with light sleep. However, the effects of BAC administrated 
before the nap was much stronger and visible during the subsequent nighttime sleep, where 
it counteracted the effects of the nap by strongly decreasing sleep latency and increasing 
TST, sleep efficiency and SWS in the first NREMS episode, like SO administrated immediately 
before the nighttime sleep. The delayed effect of BAC was also confirmed at the EEG level. 
BAC administrated before the nap slightly affected NREMS spectrum during the nap (i.e. it is 
intermediate between PL and SO), but had strong and similar effects on subsequent sleep 
than those exerted by SO-PL treatment on nap and SO-PL treatment on EXP night. During 
the first part of EXP night, BAC-PL, like SO-PL, increased NREMS and REMS delta and theta 
power and decreased NREMS sigma power. In agreements with the delayed sleep effect of 
BAC, the EEG delta and theta powers were also increased in PL-BAC condition but tented to 
be more pronounced from the 2nd cycle of the sleep episode, and TST and sleep latency were 
less affected than BAC-PL. Although, BAC, like SO, counteracts sleep and EEG effects of the 
nap and increased delta and theta power in NREMS and REMS suggesting induction of a 
“pharmacological” sleep rather that physiological sleep, we cannot conclude whether or not 
BAC affects the homeostatic process of sleep due to its delayed action. Hence, further 
investigations are needed to better understand the involvement of BAC in homeostatic 
regulation in humans. One interesting experiment could be to administrate BAC at least 2 
hours before a night sleep (Tmax of BAC : 1.8 h, half-life: 4 h). A nap protocol is probably not 
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ideal because of the prolonged action of BAC on sleep and the EEG. Note that we chose to 
administrate the dose of BAC just before sleep, like SO, because in mice the EEG effects of 
BAC appeared after ~ 15 min294 and to avoid any interaction with learning during vigilance 
and memory tasks. 
 
Although we found a high level of similarity between BAC and SO, several sleep and EEG 
aspects are different including WASO, stage 1 and REMS duration, as well as SOREMPs. Both 
PL-BAC and BAC-PL treatments increased REMS duration during EXP night compared to 
placebo, while PL-SO did not increase REMS duration during the entire sleep episode and 
even showed a decrease in the first and in the second REMS episode compared to placebo 
and BLN night, respectively. This decrease of REMS with SO in healthy volunteers is 
consistent with previous reports145,346, but see also ref.237. Importantly, SOREMPs were not 
taken into account in the first REMS episode. Thus, the fact that both PL-SO and BAC-PL did 
show significant occurrence of relatively long SOREMPs explains probably at some extent 
why REMS duration for the whole night in PL-SO condition where similar to placebo and why 
in BAC-PL the overall duration of REMS was increased. However, this BAC-related increase in 
REMS seems to be SOREMP-independent, because PL-BAC, which did not produce 
significantly SOREMPs (2/12 like placebo), also showed a significant increase of REMS 
compared to placebo. We also found REMS EEG differences between BAC and SO during the 
EXP night. Theta power and, in a lesser extent, delta power was increased specifically during 
the first REMS episode for PL-SO compared to placebo, while for BAC-PL, this increase was 
still present during the second and the third cycle. PL-BAC increased also the theta power 
during REMS but from the second cycle, underscoring again the delayed effect of BAC on 
sleep and the EEG. Also, unlike SO, BAC decreased WASO and NREMS stage 1 during the EXP 
night, suggesting induction of a more consolidated sleep and longer action compared to SO.  
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Therefore, SO and BAC showed some similar effects on sleep and EEG in humans, although 
evident differences were observed suggesting distinct mechanisms of action. This is 
consistent with a previous study in narcoleptic teenagers, which showed that BAC and SO 
increased TST and EEG delta power, but only SO decrease excessive daytime sleepiness and 
attacks of cataplexy252. Previous animal reports also showed differential effects for BAC and 
GHB 246,286. It is known that SO and BAC are low- and high-affinity agonists of GABAB 
receptors287 and we recently showed that the acute effects on sleep and the EEG in mice are 
mediated exclusively through GABAB receptors294. Although involvement of other receptors 
could not be completely excluded186,208, the discrepancy between BAC- and SO-effects may 
probably be explained by their differential pharmacokinetics and affinity for GABAB 
receptors. Indeed, BAC has a longer half-life than SO (4h vs 30-50 min) and it was shown that 
low-affinity agonists can have very different or even opposite effects compared to high-
affinity agonists234,246. Furthermore, potassium channels tetramerization domain-containing 
proteins that function as auxiliary subunits of GABAB receptors are most likely involved in the 
modulation of these differences235. 
Concerning the involvement of other receptors, selective GABAA agonists, such as gaboxadol 
(THIP), and the GABA uptake inhibitor tiagabine, showed increased SWS duration, EEG delta 
and theta power during a night sleep compared to placebo123,351. Gaboxadol also decreased 
the EEG sigma frequency band in NREMS and increased EEG delta and theta frequency bands 
in REMS352. In addition, Mathias and al. showed that gaboxadol counteracts the disrupting 
effects of a nap on subsequent sleep by promoting SWS, EEG delta and theta power in 
NREMS and by decreasing sleep latency353. These effects closely match those evoked by both 
SO and BAC suggesting, that as SO and BAC, gaboxadol exhibits significant hypnotic actions 
under conditions in which sleep pressure is experimentally reduced and in part mimics sleep 
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and EEG modifications seen during recovery sleep after sleep deprivation (i.e. increase of 
SWS, EEG delta and theta activity and decrease in EEG sigma activity in NREMS). In contrast, 
benzodiazepines as well as zopidem and zolpiclone, agonistic GABAA modulators, decrease 
EEG slow (delta) waves and increase EEG spindle (sigma) frequency band in NREMS, even in 
high sleep pressure conditions354,355,356,357,358. Although it was shown that BAC and GHB did 
not bind to GABAA receptors202,359, they may share effects on neuronal processes underlying 
the generation/synchronization of slow waves. 
Vigilance 
A recent study showed that the enhancement of SWS by SO results in a reduced response to 
sleep loss on measures of alertness and attention346. In the present study, in low sleep 
pressure condition, SO and BAC did not affect the nap-dependent increase of subjective 
alertness in late evening compared to placebo, even if sleepiness was considered as a 
frequent side effect of BAC360 and SO showed increased EEG delta activity during the 
afternoon nap. Furthermore, temporary, just after the nap, SO suppressed the increase of 
vigilant attention and alertness seen in BAC and placebo conditions. This effect could be due 
to either the direct pharmacological effect of SO on vigilance or the effect of the long nap 
induced by SO. We did not find a correlation between TST and neurobehavioral 
performance, but it does not excluded the effect of sleep inertia. Subjects performed 
vigilance tasks at least 15 min after awakening. In a non-sleep deprived situation, sleep 
inertia should last only a few minutes especially at this time of day (high circadian influence) 
and if subjects were awakened in light sleep (stage 1,2 or REMS). In SO condition, two 
subjects were awakened in SWS at the end of the nap, however, their performance 15 min 
later was not worse than the other subjects. A recent study in healthy volunteers showed 
that GHB dose of 2.4 g/70 kg still showed sedative-like side effects 2 h after administration, 
but then disappeared quickly295. However, they did not find changes in psychomotor 
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performance assessed by Digit Symbol Substitution Task. Together, this suggests that SO 
and BAC do not affect the benefit of a nap on attention and subjective alertness in the late 
evening and are comparable to placebo across the afternoon except SO which showed a 
slight and temporary reduction of performance after the nap.  
Memory 
As expected330, we found an improvement of word-pairs correctly recalled after a nap but 
neither SO nor BAC affected this performance. Thus, the ‘extra’ delta power induced by SO 
during the nap did not increase performance of this declarative memory task compared to 
placebo. Moreover, it was shown that emotion facilitates memory encoding302,332,361. 
However, we did not find any superior or inferior retention levels for positive or negative 
word-pairs compared to neutral word-pairs, although there is a tendency after a nap under 
SO to remember more positive rather than negative word-pairs. 
For the 2-D object-recognition task, the other declarative memory task, learning and retrieval 
did not differ. Maybe a nap was not sufficient to increase performance as observed with a 
similar task after 8 h of nocturnal sleep315. Another plausible explanation would be the high 
inter-individual variability of performance found at learning for this task especially. Indeed, at 
learning, subjects were tested only once and, although the averaged mean performance was 
around 60%, the range of objects correctly localized was between 20-90%. A previous study 
showed that only subjects who had most strongly acquired a declarative memory task 
during the training session showed a sleep-dependent performance benefit after a nap362. 
Therefore, to potentially improve the sensitivity of the task, each subject should have fulfilled 
a criterion of 60% of performance at leaning and the number of card-pairs should have been 
increased to avoid a too high level of performance after the first test. The result obtained 
with this task may not be as relevant as that with word-pairs for which the inter-individual 
variability was lower at learning.  
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As for the word-pairs associate learning task, we found an increased performance for the 
finger sequence tapping task independent of the treatment administrated before the nap. 
This improvement of procedural memory is in agreement with previous reports321,331. 
Therefore, although SO- and BAC-induced memory impairment were reported in animals 
195,363,364,365,366 and/or in humans 306,367,368, and although SWS and delta power was associated 
with increased performance in declarative memory task, we did not find any difference in 
memory consolidation with either SO or BAC compared to placebo. 
Conclusion 
We found that both BAC and SO counteracts the effects of a nap on the subsequent sleep by 
decreasing sleep latency and increasing TST and particularly SWS during the first NREMS 
episode and EEG delta and theta powers during NREMS. However, SO also increased EEG 
delta and theta power during REMS and a nap under SO with high level of delta power did 
not affect the following night sleep. This suggests that SO is not involved in the homeostatic 
regulation of sleep and thus, do probably not induce a physiological sleep. BAC showed very 
similar effects on sleep and EEG compared to SO, but with a delayed action. This different 
BAC dynamics did not allow us to determine if BAC affects or not the homeostatic process of 
sleep. Both BAC and SO increased the occurrence of SOREMPs during the nap and during the 
subsequent sleep, but their effects on REMS differed with an overall increase for BAC and a 
tendency to decrease particularly in the beginning of the night for SO. The strong similarities 
of BAC and SO effects on the EEG suggest that SO act through GABAB receptors, but the 
difference of the dynamics of action and on REMS may suggest different GABAB receptor 
modulation. Involvement of other receptors is not excluded. Finally, overall, a nap under SO 
and BAC does not affect psychomotor performance and subjective sleepiness neither 
memory consolidation compared to placebo. 
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8.6. Tables and Figures 
Table 8.1: Visually scored variables during the nap after placebo (PL), baclofen (BAC), or sodium oxybate (SO) 
intake. 
Variables PL BAC SO 
TIB (min) 74.5 ± 2.5ab 71.7 ± 3.1ab 95.5 ± 7.0ba 
TST (min) 58.6 ± 2.1ab 60.4 ± 2.8ab 84.1 ± 7.7ba 
SE (%) 79.9 ± 2.1ab 84.6 ± 2.6ab 86.9 ± 3.0ba 
 SL (min) 10.6 ± 0.9ab 8.6 ± 1.2ab 9.1 ± 1.2ab 
REMSL (min) 32.7 ± 4.7ab 31.6 ± 8.2ab 18.9 ± 5.8ba 
WASO (%) 12.0 ± 6.1†‡ 4.7 ± 2.7‡ 4.7 ± 3.6†‡ 
S1 (%) 16.3 ± 1.2ab 13.7 ± 2.0ab 9.2 ± 2.3ba  
S2 (%) 36.4 ± 2.3†‡ 32.6 ± 3.2†‡ 30.0 ± 4.8†‡ 
S3 (%) 5.8 ± 0.4†‡ 5.1 ± 0.9†‡ 4.7 ± 0.6†‡ 
S4 (%) 40.4 ± 2.2†‡ 43.7 ± 3.7†‡ 38.5 ± 4.6†‡ 
SWS (%) 46.2 ± 2.2†‡ 48.9 ± 3.7†‡ 43.2 ± 4.5†‡ 
REMS (%) 9.5 ± 1.3ab 11.8 ± 2.4ab 22.3 ± 4.0ba 
MT (%)  0.6 ± 0.0ab 0.6 ± 0.0ab 0.4 ± 0.1ba 
WASO+MT+S1(%) 28.5 ± 6.8ab 18.6 ± 4.4ab 14.1 ± 5.6ba 
SOREMP (#) 0.4 ± 0.1ab 0.4 ± 0.1ab 0.6 ± 0.1ba 
SOREMP (min) 4.5 ± 1.1ab 5.1 ± 1.8ab 19.0 ± 5.5b‡ 
 
Mean values (±SEM) from lights off to lights on (time in bed (TIB)). The nap was stopped after one cycle from the 
first appearance of REMS, except if REMS appeared before stage 3 and 4 present in all naps analyzed. Total sleep 
time (TST), sleep latency (SL; first epoch of S2 or REMS from lights off), REMS latency (REMSL), and duration of 
sleep onset REMS period (SOREMP) were expressed in min. Wakefulness after sleep onset (WASO), Stage 1 to 4 
(S1-S4), slow-wave sleep (SWS; Stage 3+4), REMS, movement time (MT) and combined arousal variables and light 
sleep (WASO+MT+S1) were expressed as a percentage of TST. Sleep efficiency (SE) was calculated by dividing TST 
by TIB (%). a-b: variables for which mean values significantly differed do not share the same character (one-way 
mixed-model ANOVA for factor ‘treatment’; Tukey-Kramer’s test, p<0.05). 
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Table 8.2: Visually scored variables in baseline (BLN) and experimental (EXP) night for the 5 different treatments. 
 BLN night  EXP night 
Variables All  PL-PL BAC-PL SO-PL PL-BAC PL-SO 
TIB (min) 480.0†‡  480.0†‡ 480.0†‡ 480.0†‡ 480.0†‡ 480.0†‡ 
TST (min) 453.6 ± 2.1†  414.4 ± 7.2† 451.4 ± 3.4‡ 412.6 ± 7.5† 427.6 ± 5.9† 437.5 ± 5.0† 
SE (%) 94.5 ± 0.4†‡  86.3 ± 1.5†‡ 94.1 ± 0.7†‡ 86.0 ± 1.6†‡ 89.1 ± 1.2†‡ 91.2 ± 1.1†‡ 
 SL (min) 12.1 ± 1.0†‡  40.0 ± 5.4†‡ 19.8 ± 3.6†‡ 39.3 ± 5.2†‡ 40.6 ± 5.9†‡  17.8 ± 2.3†‡ 
REMSL (min) 58.8 ± 2.2†‡  49.4 ± 7.5†‡ 19.9 ± 8.4†‡ 64.7 ± 4.8†‡ 49.1 ± 6.3†‡ 25.4 ± 8.7†‡ 
WASO (%) 3.3 ± 0.5†‡  6.4 ± 1.5†‡ 1.9 ± 0.3†‡ 7.2 ± 2.2†‡ 2.8 ± 0.8†‡ 5.8 ± 1.3†‡ 
S1 (%) 7.8 ± 0.4†‡  10.0 ± 1.0†‡  5.1 ± 0.5†‡ 10.7 ± 1.3†‡ 6.1 ± 0.6†‡ 10.6 ± 1.5†‡ 
S2 (%) 43.9 ± 0.8†‡  44.7 ± 1.8†‡ 44.1 ± 1.3†‡ 48.1 ± 1.8†‡ 42.8 ± 2.2†‡ 42.4 ± 1.7†‡ 
S3 (%) 4.1 ± 0.2†‡  3.9 ± 0.4†‡ 4.0 ± 0.4†‡ 4.0 ± 0.5†‡ 4.7 ± 0.4†‡ 3.1 ± 0.3†‡ 
S4 (%) 17.7 ± 0.5†‡  13.6 ± 1.0†‡ 15.1 ± 1.2†‡ 12.3 ± 1.2†‡ 15.6 ± 1.4†‡ 17.0 ± 1.1†‡ 
SWS (%) 21.8 ± 0.6†‡  17.5 ± 1.3†‡ 19.1 ± 1.5†‡ 16.3 ± 1.4†‡ 20.4 ± 1.7†‡ 20.1 ± 1.1†‡ 
REMS (%) 27.0 ± 0.4†‡  28.9 ± 1.3†‡ 31.9 ± 1.1†‡ 25.8 ± 0.9†‡ 31.7 ± 1.5†‡ 27.5 ± 1.0†‡ 
MT (%)  0.5 ± 0.0†‡  0.4 ± 0.1†‡ 0.6 ± 0.1†‡ 0.5 ± 0.1†‡ 0.4 ± 0.1†‡ 0.4 ± 0.1†‡ 
WASO+MT+S1(%) 11.5 ± 0.9†‡  16.8 ± 2.0†‡  7.6 ± 0.6†‡ 18.2 ± 3.2†‡ 9.4 ± 1.1†‡ 16.7 ± 2.5†‡ 
SOREMP (#) 0.0 ± 0.0†‡  0.2 ± 0.1†‡ 0.7 ± 0.1†‡ 0.0 ± 0.0†‡ 0.2 ± 0.1†‡ 0.5 ± 0.2†‡ 
SOREMP (min) 0.3 ± 3.2†‡  0.1 ± 0.1†‡ 10.6 ± 4.1†‡ 0.0 ± 0.0†‡ 3.5 ± 3.3†‡  18.6 ± 5.8†‡ 
 
Mean values (±SEM) from lights off to lights on (time in bed (TIB)). BLN night: for clarity, BLN night of the 5 
sessions was averaged, although for statistical analysis each subject’s EXP night was compared to its 
corresponding BLN night. EXP night: treatment intake before the nap and before EXP night (5 possibilities: 
placebo (PL) then PL, baclofen (BAC) then PL, sodium oxybate (SO) then PL, PL then BAC, and PL then SO). For 
variable definition see Table 8.2. 
EXP night significantly different from BLN night : † (p<0.05). Treatment significantly different from PL-PL : ‡ 
(p<0.05) . 
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Table 8.3: Memory performance 
   PL Mean ± SEM 
SO 
Mean ± SEM 
BAC 
Mean ± SEM p 
Speed learning 20.81  ±  0.95 21.15  ±  1.57 20.47  ±  1.46 NA 
 change +2.70  ±  0.42 +2.26  ±  0.46 +3.33  ±  0.48 NA 
Error rate learning 0.51  ±  0.09 0.43  ±  0.09 0.49  ±  0.10 NA 
Finger 
sequence 
tapping task 
 change -0.06  ±  0.08 -0.05  ±  0.11 -0.12  ±  0.10 NA 
       
 learning 22.57  ±  1.19 20.69  ±  1.97 23.50  ±  1.60 NA 
Word-pair 
associated task 
 change +4.64  ±  0.80 +5.23  ±  1.06 +4.25  ±  0.99 NA 
       
 learning 5.66  ±  0.30 5.62  ±  0.67 5.67  ±  0.73 NA 
2D object-
location task 
 change -0.08  ±  0.35 -0.77  ±  0.68 -0.67  ±  0.54 NA 
       
 
Memory performance for the administration of PL, SO or BAC after training. For the procedural finger sequence 
tapping task, performance during learning is indicated as speed (number of correctly tapped sequences) and 
error rate (errors per sequence). For the declarative word-pair learning task and the declarative 2D object-location 
task, performance during learning is indicated as number of correctly recalled word-pairs and correctly located 
card-pairs, respectively. For both declarative tasks, performance changes are calculated as absolute difference 
between memory performance during learning and retrieval (retrieval minus learning). Data are mean values 
(±SEM), and p-values for one-way mixed-model ANOVA for factor “treatment” PL, BAC, and SO). P > 0.05 is NA. 
(see also Figure 8.9) 
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Figure 8.1: Schedule of a typical study session. 
Each subject performed 5 similar sessions, which differed only by the treatment that they received. One week 
separated each session. Subjects started a session with a first 8h habituation (Hab) night, spent the day outside 
the lab and came back to carry out a 8h baseline (BLN) night. The following day, they stayed in the lab and 
performed vigilance tasks (PVT and KSS) every 2 h and three memory tasks before and after a 2h opportunity nap 
starting at 3 p.m. Finally, they spent a last 8h experimental (EXP) night and left the lab in the morning after having 
performed last vigilance tasks. Grey bars indicate times of nighttime and daytime sleep periods, and black bars 
depict mealtimes. Test times for the 10min PVT, preceded and followed by the KSS, are illustrated by the dashed 
lines. Blue Bars represent the time when memory tasks were performed. Before the nap and before the EXP night, 
subjects received a placebo (PL) and either sodium oxybate (SO), baclofen (BAC) or placebo (PL) leading to the 5 
possibilities: PL-SO, SO-PL, PL-BAC, BAC-PL and PL-PL (red triangles and lines). 
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Figure 8.2: Condition and treatment effects on sleep parameters. 
A, The afternoon nap increased sleep latency (first 20s epoch of stage 2 or REMS) during the subsequent night 
(EXP night) compared to BLN night in all treatments (right panel: two-way mixed model ANOVA for factors ‘night’ 
p<0.0001, ‘treatment’ p<0.0001 and their interaction p<0.0001; connected lines: Tukey-Kramer’s test by 
treatment, p<0.05). However, this increase was strongly reduced when BAC was administrated before the nap or 
SO before EXP night (connected lines: Tukey-Kramer’s test by night, p<0.05). This difference amongst treatment 
was not seen during the nap (left panel: one-way mixed-model ANOVA for factor ‘treatment’ p=0.1156)). B, 
During nighttime sleep, combined arousal variables and light sleep (wakefulness after sleep onset/latency 
(WASO) + Movement time (MT) + Stage 1 (S1)) differed among treatments (right panel: two-way mixed model 
ANOVA for factors ‘night’ p=0.1070, ‘treatment’ p<0.0001 and their interaction p=0.0307). While PL and SO 
increased combined arousal variables and light sleep during EXP night compared to BLN night (not significant in 
SO-PL treatment due to the high variability during BLN night), BAC before the EXP night did not affect them and 
BAC before the nap even decreased them (Tukey-Kramer’s test by night for factor ‘treatment’, p<0.05). During the 
nap, SO decreased significantly the combined WASO+MT+S1 compared to PL (left panel: one-way mixed-model 
ANOVA for factor ‘treatment’: Tukey-Kramer’s test, p<0.05). C,D, During nights, number and duration of sleep 
onset REMS periods (SOREMPs) were affected by both treatments and nights (right panel: two-way mixed model 
ANOVA for factors ‘night’ p<0.0001, ‘treatment’ p<0.0006 and their interaction p<0.0003). Only BAC administrated 
before the nap and SO given before the EXP night showed significant appearance and increased duration of 
SOREMPs during the EXP night (paired t-tests p<0.05, star). Moreover, they showed respectively a significant 
increased number of SOREMPs and a longer duration of SOREMPs compared to PL-PL as well as PL-BAC and SO-PL 
treatments (Tukey-Kramer’s test, p<0.05). During the nap, number and duration of SOREMPs were increased in all 
treatments (left panel: one-way mixed-model ANOVA: factor ‘treatment’; Tukey-Kramer test, p<0.05)). SO 
significantly augmented SOREMP number and duration compared to PL and, PL and BAC, respectively. For all 
panels, bars depict the mean values of each variable (mean±SEM), connected lines result from Tukey-Kramer’s 
test, p<0.05 and BLN night of each treatment did not differ significantly for each variable.  
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Figure 8.3:  SWS (stage 3 and 4) and REMS during the three first sleep cycles of the nighttime sleep and during the 
afternoon nap. 
A, During the first cycle of EXP night, SWS was decreased in PL-PL, SO-PL and PL-BAC treatments, but did not 
differ from BLN night in BAC-PL and PL-SO treatments (left panel: two-way mixed model ANOVA for factors ‘night’ 
p=0.0001, ‘treatment’ p=0.0256 and their interaction p=0.0542; connected lines: Tukey-Kramer’s test by treatment 
for factor ‘night’ p<0.05). Moreover, SWS was significantly higher when SO was given before the EXP night 
compared to PL. Overall, during the second and the third cycle, SWS was significantly lower in EXP night 
compared to BLN night (two-way mixed model ANOVA for factors ‘night’ p<0.05, ‘treatment’ p>0.1 and their 
interaction p>0.6; paired t-test: factor ‘night’ p<0.05). B, REMS was significantly higher in EXP night compared to 
BLN night for the first cycle only (left panel (1st cycle): two-way mixed model ANOVA for factors ‘night’ p<0.0001, 
‘treatment’ p=0.4538 and their interaction p=0.3926). Interestingly, PL-SO treatment was the unique treatment 
which did not show an significant increase in REMS during EXP night compared to BLN night (Tukey-Kramer test 
by treatment for factor ‘night’ p<0.05). Moreover, in the second cycle, this same treatment exhibited a shorter 
duration of REMS compared to BLN night (one-way mixed-model ANOVA for PL-SO treatment: factor ‘night’ 
p=0.0024). C, During the nap, SO increased SWS compared to PL but not compared to BAC (one-way mixed-
model ANOVA for factor ‘treatment’ p=0.0268; Tukey-Kramer test p<0.05). D, Naps were stopped when REMS was 
visually identified except if it was a SOREMP (see Materials and Methods and Figure 8.2). The three treatments 
showed significant increased in REMS duration (paired t-tests p<0.05) due to SOREMPs. SO induced a longer 
duration of REMS than BAC and PL (one-way mixed-model ANOVA for factor ‘treatment’ p<0.0001, Tukey-
Kramer’s test p<0.05). For all panels, bars depict the mean values of each variable (mean±SEM; n=13). 
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Figure 8.4:  EEG power spectra of NREMS during nighttime sleep and during the nap. 
A, Absolute NREMS spectra of BLN night and EXP night for PL-PL treatment (0.75-25 Hz, at 0.25Hz bins; note the 
logarithmic scale of absolute EEG power density). B, The ratio between these two spectra (EXP/BLN) was 
performed leading to a relative NREMS spectrum where 100% represents absolute NREMS spectrum of BLN night. 
NREMS spectrum differed significantly between nights and frequency bins (two-way mixed model ANOVA for 
factors ‘night’ p=0.0214, ‘bins’ p<0.0001 and their interaction p=0.9982. Low frequency bins (0.75-7.25 Hz), were 
significantly lower and a bin from the sigma band (12.5Hz) as well as overall high frequency bins (16-25 Hz) were 
significantly higher during EXP night compared to BLN night (black triangles: one-way mixed model ANOVA by 
bin for factor ‘night’ p<0.05) C, Relative NREMS spectrum of each drug treatment (EXP/BLN) were expressed as a 
percentage of relative NREMS spectrum of PL-PL treatment depicted in B. Relative NREMS spectra during EXP 
night was affected by treatment and by bin (two-way mixed model ANOVA: factors ‘treatment’ p<0.0001, ‘bin’ 
p<0.0001 and their interaction p<0.0001). Overall, BAC-PL, PL-BAC and PL-SO treatments differed significantly 
from PL-PL, while SO-PL did not (Dunnett-Hsu’s test (control=PL-PL) p<0.05). Colored triangles depict bins for 
which power differed significantly from PL-PL (Dunnett-Hsu’s test p<0.05, blue: BAC-PL, yellow: PL-BAC and red: 
PL-SO). D, During the nap relative NREMS spectra after SO and BAC treatments were expressed as a percentage of 
PL treatment. Overall, relative NREMS spectrum after SO was different from that after PL, while that after BAC did 
not differed from the two others (two-way mixed model ANOVA for factors ‘treatment’ p<0.0001, ‘bin’ p<0.0001 
and their interaction p=0.1923; Dunnett-Hsu’s test p<0.05). Colored triangles illustrate bins for which power 
differed significantly from PL. (Dunnett-Hsu’s test p<0.05, green: SO, blue: BAC). For each panel, lines depict the 
mean values (±SEM; n=12). 
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Figure 8.5:  EEG power spectra of REMS during nighttime sleep and during the nap. 
A, Absolute REMS spectra of BLN night and EXP night for PL-PL treatment (0.75-25 Hz, at 0.25Hz bins; note the 
logarithmic scale of absolute EEG power density). B, The ratio between these two spectra (EXP/BLN) was 
calculated leading to a relative REMS spectrum where 100% represents absolute REMS spectrum of BLN night. 
REMS spectrum did not differ significantly between nights (two-way mixed model ANOVA for factors ‘night’ 
p=0.0999, ‘bins’ p<0.0001 and their interaction p=0.1). C, To illustrate the comparison of each treatment to the PL-
PL treatment, relative REMS spectrum of each drug treatment (EXP/BLN) was expressed as a percentage of 
relative REMS spectrum of PL-PL treatment depicted in B. Relative REMS spectra during EXP night were affected 
by treatment and by bin (two-way mixed model ANOVA for factors ‘treatment’ p<0.0001, ‘bin’ p<0.0001 and their 
interaction p<0.0001). Overall, BAC-PL, PL-BAC and PL-SO treatments differed significantly from PL-PL, while SO-
PL did not (Dunnett-Hsu’s test (control=PL-PL) p<0.05). Colored triangles depict bins for which power differed 
significantly from PL-PL (Dunnett-Hsu’s test for each bin: p<0.05, blue: BAC-PL, yellow: PL-BAC and red: PL-SO). D, 
During the nap, relative SOREMP spectra after SO and BAC treatments were expressed as a percentage of PL 
treatment. Relative SOREMP spectra did not differ among treatments (two-way mixed model ANOVA: factors 
‘treatment’ p=0.2732, ‘bin’ p<0.0001 and their interaction p=1.0; note that n=6). For all panels, lines depict the 
mean values (±SEM; For A, B, C: n=12). 
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Figure 8.6:  Absolute EEG delta, theta and sigma power of NREMS and EEG delta and theta power of REMS during 
the three first cycles of nighttime sleep in PL-PL treatment. 
Absolute power derived from the average of 0.25Hz bins included in the specific frequency range, i.e. delta (0.75-
4.5 Hz), theta (4.75-8 Hz) and sigma (12-15 Hz) (mean±SEM: n=12). A, Absolute delta power of NREMS during the 
three first cycles of BLN night and EXP night for PL-PL treatment differed significantly between nights and cycles 
(two-way mixed model ANOVA: factors ‘night’ p=0.0041, ‘cycle’ p<0.0001 and their interaction p<0.5899). 
Moreover, delta power showed an overall cycle-dependent decrease (cycle 1 > 2 > 3: Tukey-Kramer’s test p<0.05). 
B, As delta, absolute theta power of NREMS differed significantly between nights and cycles (two-way mixed 
model ANOVA for factors ‘night’ p=0.0069, ‘cycle’ p<0.0001 and their interaction p<0.4093) and showed an overall 
cycle-dependent decrease (statistics see B). C, Although absolute sigma power of NREMS during the three first 
cycles of BLN night and EXP night for PL-PL treatment differed significantly between nights and cycles as delta 
and theta power (two-way mixed model ANOVA for factors ‘night’ p=0.0001, ‘cycle’ p<0.0001 and their 
interaction p<0.1453), it exhibited a lower level in cycle 2 compared to cycle 1 and 3 (Tukey-Kramer’s test: p<0.05). 
D,E, In REMS, absolute delta power differed only between cycles (two-way mixed model ANOVA for factors ‘night’ 
p=0.0536, ‘cycle’ p=0.0026 and their interaction p=0.1097); cycle 1 = 2 > 3: Tukey-Kramer’s test: p<0.05), while 
absolute theta power differed between cycles and nights (two-way mixed model ANOVA for factors ‘night’ 
p=0.0081, ‘cycle’ p=0.0485 and their interaction p<0.0049; cycle 1 =2 > 2 = 3: Tukey-Kramer test: p<0.05). For each 
panel, connected lines depict night and cycle differences by cycle and by night, respectively (Tukey-Kramer’s test 
p<0.05). 
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Figure 8.7:  EEG delta, theta and sigma power of NREMS and EEG delta and theta power of REMS during the first 
three sleep cycles.  
Relative EEG delta (0.75-4.5 Hz), theta (4.75-8 Hz) and sigma (12-15 Hz) power (mean±SEM; n=12) correspond to 
the EXP/BLN night ratio of each drug treatment expressed as a percentage of the EXP/BLN night ratio of the PL-PL 
treatment in the three first cycles of nighttime sleep. This illustrates the difference between drug treatments and 
PL-PL treatment for specific frequency ranges. A,B,C, Only in the first cycle, BAC-PL and PL-SO treatments showed 
increased relative delta and theta power and decreased relative sigma power compared to PL-PL treatment (one-
way mixed model ANOVA by cycle for factor ‘treatment’ p<0.05; Dunnett-Hsu’s test (control=PL-PL) p<0.05: star). 
D, In REMS, compared to PL-PL treatment, relative delta power for PL-SO treatment increased during the first 
cycle, while it decreased for BAC-PL treatment during the second cycle (one-way mixed model ANOVA by cycle 
for factor ‘treatment’ p<0.05; Dunnett-Hsu’s test (control=PL-PL) p<0.05: star). E, Relative theta power in REMS 
increased for BAC-PL and PL-SO treatment during the first cycle and increased for BAC-PL and PL-BAC treatments 
during the second and third cycles (for statistical tests see D). 
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Figure 8.8: Effects of nap with or 
without drug on sustained vigilant 
attention and subjective alertness. 
Objective measurement of cognitive 
performance was assessed by 10min 
psychomotor vigilance task (PVT) and 
subjective alertness by Karolinska 
Sleepiness Scale (KSS). A. Mean, the 
10% slowest and the 10% fastest 
reaction times (RT) expressed as 
speed (1/RT) are plotted for the trial 
performed 15 min before bedtime for 
the BLN and EXP nights (upper, 
middle and lower panel, respectively). 
Overall, mean and the 10% fastest 
speed (upper and lower panel) were 
affected by the nap but not by 
treatment (two-way mixed model 
ANOVA for factors ‘time’ p≤0.0023, 
‘treatment’ p≤0.7599 and their 
interaction p≥0.1728). Black 
connected lines depict speed 
difference before BLN and EXP nights 
(one-way mixed-model ANOVA for 
factor ‘time’ by treatment; Paired t-
test p<0.05). B. Mean, the 10% slowest 
and the 10% fastest speed were 
plotted at 5 consecutive trials with the 
first trial performing just before the 
nap (hour 0) and the last trial just 
before EXP night (hour 8). Generally, 
sustained vigilant attention was not 
affected by treatment, but by the time 
when trial was carried out (for the 3 panels: two-way mixed model ANOVA for factors ‘time’ p≤0.0003, ‘treatment’ 
p≥0.2205 and their interaction p≥0.2197). However, by analyzing each trial separately, SO treatment differed 
significantly from the two other treatments only at the trial just after the nap (one-way mixed-model ANOVA for 
factor ‘treatment’ by trials; Tukey-Kramer test p<0.05: black star). Colored connected lines show speeds, which are 
significantly different within the same treatment (Tukey-Kramer test p<0.05): black: PL, Blue: BAC and red: SO). C, 
Although independently of the treatment, the KSS score was increased during the trial performed just before EXP 
night compared to the trial performed just before BLN night (two-way ANOVA for factors ‘trial’ p=0.0010, 
‘treatment’ p=0.6298 and their interaction p=0.1659), analysis done by treatment separately showed that only 
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BAC treatment exhibited a significant increase of subjective alertness (black connected lines: one-way mixed-
model ANOVA for factor ‘time’ by treatment; Paired t-test p<0.05). D, Similar to results obtained with PVT, 
subjective alertness obtained by KSS was not generally affected by treatment, but by trial time (two-way mixed 
model ANOVA for factors ‘time’ p<0.0001, ‘treatment’ p=0.1695 and their interaction p=0.9041). Moreover, 
alertness after the nap was also temporarily altered by SO compared to PL (red star: one-way mixed-model 
ANOVA for factor ‘treatment’ by trial; Tukey-Kramer’s test p<0.05). However, this was not significantly different 
between SO and BAC treatments p=0.1547. For all panels, bars depict the mean values of each variable 
(mean±SEM; n=13). 
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Figure 8.9: SO and BAC do not affect memory 
A, Performance to the finger sequence tapping task is illustrated by the difference of the number of correctly 
completed sequences between retrieval and learning (change in speed; left panel) and the accuracy by the 
difference of the number of errors relative to total number of tapped sequences between retrieval and learning 
(error rate; right panel). B, The gain of performance to the unrelated word-pair associate learning task is shown by 
the difference of the number of word-pairs correctly recalled at retrieval minus those at learning (left panel). Out 
of 36 word-pairs, 9 were emotionally negative, 9 emotionally neutral, and 9 emotionally positive (right panel). C, 
Performance to the 2-D object-recognition task is evaluated by comparing the number of card-pairs correctly 
located at retrieval compared to this at learning (difference: retrieval-learning). Similarly for all treatments, 
performance of fingertapping task and of the word-pair associate learning task was increased (star: paired t-test 
p<0.05); one-way mixed-model ANOVA for ‘treatment’ p>0.7683). The emotionality of the words and drugs did 
not influence the performance (two-way mixed model for factors ‘treatment’ p=0.8027, ‘emotion’ p=0.3886 and 
their interaction p=0.5765). At retrieval, error rate during the fingertapping task and performance to the object-
location task did not differ from learning, and treatment has no effect (paired t-test p>0.05); one-way mixed-
model ANOVA for ‘treatment’ p>0.5208). For all panels, bars depict the mean values of each variable (mean±SEM; 
n=13). 
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9. Conclusions and perspectives 
GHB does not induce physiological sleep 
We showed that GHB in mice and in healthy volunteers induced EEG delta activity, a marker 
of sleep propensity. However, this increase is not involved in the homeostatic regulation of 
sleep, suggesting that GHB does not produce physiological deep sleep. In mice, behavior 
and EEG pattern induced by GHB suggest rather an anesthetic-like state particularly at high 
doses. Alertness as well as neurobehavioral and memory performance were not further 
improved by a nap under GHB, rich in EEG delta activity, compared to a nap under placebo. 
With GHB treatment, we even found a temporary and slight suppression of the increase in 
subjective alertness and vigilant attention shown after a nap with placebo treatment. This is 
additional evidence suggesting no restorative effects of EEG delta activity induced by GHB. 
 
A very recent study by Walsh and colleagues346, however, challenges our findings. They 
found that under high sleep pressure, vigilant attention and subjective alertness benefit 
from a short sleep under SO/GHB compared to a short sleep under placebo. They also 
showed with their sleep restriction protocol that EEG delta power in NREMS during recovery 
night sleep was slightly lower in healthy volunteers having prior naps under GHB than those 
having prior naps under placebo. Thus, they concluded that pharmacological enhancement 
of SWS/EEG delta power with GHB resulted in a reduced response to sleep loss on measures 
of alertness and attention, and SWS and NREMS EEG delta power enhancement during sleep 
restriction appears to result in a reduced homeostatic response to sleep loss. Sleep under 
GHB could have restorative effects only in high sleep pressure conditions, which does not 
contradict our results. However, the reduction of homeostatic response after naps with GHB 
remains unexpected compared to our findings. This discrepancy might be due to spectral 
analysis (they did not normalize EEG power density, while we did) or to subjects (they 
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included males and females, Caucasians and African Americans, we included only male 
Caucasians). Apart from this study, several other observations support the fact that GHB does 
not induce physiological sleep. First, GHB was used as an anesthetic agent and as far as we 
know no anesthetic induces physiological sleep, although the vast majority produce EEG 
slow (delta) waves369. Second, EEG hypersynchrony was not specific to NREMS but found also 
after GHB administration in awake animals200,238,370 and humans145,236,371. Finally, according to 
our results in healthy volunteers and a study in narcoleptics283, the increase of EEG delta 
activity is not exclusive to NREMS, but also found in REMS. This support the view of an overall 
pharmacological increase of slow-wave activity independent of sleep states. In conclusion, as 
far as we know we are the first to show concretely that GHB does not induce physiological 
sleep. Nevertheless, further investigations to support this finding and to better understand 
the role of increased EEG slow-wave activity by GHB in behavior are needed. 
 
Our results also bring new questions about how GHB improves symptoms of narcolepsy. The 
hypothesis suggesting that GHB induction of a deep and restorative nighttime sleep would 
explain the decrease of excessive daytime sleepiness in narcoleptics is not supported by our 
results in healthy volunteers. Therefore, the mechanism by which GHB decreases both 
excessive daytime sleepiness and cataplexy attacks remains elusive and needs further 
investigation.  
 
GHB mechanisms of action 
By using functional GABAB receptor deficient mice, we showed that all acute effects of GHB 
on sleep and the EEG are due to the stimulation of GABAB receptors. Hence, these receptors 
seem to exclusively mediate the behavioral and EEG effects of GHB, at least in mice. By 
comparing the sleep and EEG effects of BAC, a specific and high-affinity agonist of GABAB 
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receptors, to those of GHB, a low-affinity agonist of GABAB receptors, we demonstrated that 
the two drugs do not have identical effects (even if closely related). In contrast to GHB, BAC 
induced a delayed hypersomnia and lower EEG delta power during BAC-induced state in 
mice and, in humans, BAC increased REMS and decreased WASO. We also clearly established 
that BAC and GHB have distinct dynamics of action with BAC having a delayed effect. This 
discrepancy could be due to their pharmacokinetics with a longer half-life for BAC and to 
their differential affinity for GABAB receptors. For example, Curz and colleagues246 showed bi-
directional effects of BAC and GHB on the mesolimbic dopaminergic system. They found that 
the coupling efficacy (EC50) of G protein-gated inwardly rectifying potassium (GIRK, Kir3) 
channels to GABAB receptor was much lower in dopamine neurons than in GABA neurons of 
the VTA, depending on the differential expression of GIRK subunits. Consequently, in rodent 
VTA slices, a low concentration of BAC caused increased activity, whereas higher doses 
inhibited dopamine neurons. At behaviorally relevant doses, BAC activated GIRK channels in 
both cell types, but GHB activated GIRK channels only in GABAergic neurons. This may 
explain the opposing effects on the reward pathway exerted by BAC and GHB and similar 
mechanisms might be found in regions of the brain involved in sleep. Another example is 
the differential role of glutamate in GABAB receptor-mediated effects of GHB and BAC in 
mice. Indeed, Koek and colleagues286 found that NMDA receptor antagonists enhance the 
cataleptic effects of GHB but not those of BAC. Thus, differential interactions of glutamate 
with the GABAB receptor mechanisms mediating the effects of GHB and BAC may explain 
sleep and EEG differences found between BAC and GHB. Moreover, a recent study brought a 
new promising explanation for the pharmacology and kinetics of the GABAB-receptor 
response. This study showed that GABAB receptors in the brain are high-molecular-mass 
complexes of GABAB1, GABAB2 and members of a subfamily of the KCTD proteins. KCTD 
proteins 8, 12, 12b and 16 show distinct expression profiles in the brain and associate with 
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GABAB2 as tetramers. This co-assembly changes the properties of the GABAB1,2 core receptor 
by modifying agonist potency and altering the G-protein signaling. As for the study of Cruz 
and colleagues previously described, the differential affinity of GHB and BAC of GABAB 
receptors may therefore lead to distinct effects in specific brain areas, which affect behavior. 
Taken together, this means that differential effects of BAC and GHB on sleep and the EEG do 
not exclude the fact that they both act exclusively on GABAB receptors. 
 
Interestingly, our mice study challenges the specificity of BAC for GABAB receptors due to the 
presence of BAC-induced delayed hypersomnia in GABAB-receptor-deficient mice. It was 
shown that BAC did not bind to GABAA receptors372, but to our knowledge no experiment 
was done to see potential action of BAC on other receptors. However, it is worth noting that 
in our experiment, a relatively low number of GABAB-receptor-deficient mice (n=6) were 
used and the presence of seizure could have affected sleep. Thus, it would be interesting to 
characterize further the mechanism by which BAC induces delayed hypersomnia. 
 
Others studies, in mice and in humans, showed that gaboxadol, a GABAA agonist, and 
tiagabine, a GABA uptake inhibitor, had similar sleep and EEG effects than GHB. Both drugs 
increase EEG delta and theta power in NREMS and REMS, and enhance SWS in humans and in 
rodents124,352,373,374,375,376. Although it was shown that GHB did not directly bind to GABAA 
receptors, it is possible that GHB after having metabolized into GABA may indirectly act 
through GABAA receptors. This transformation into GABA is not possible for BAC. A future 
interesting experiment would be to administer GHB to mice deficient in the delta subunit of 
GABAA receptor. Indeed, it was shown that these mice did not respond to gaboxadol377. 
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Concerning the contribution of other receptors, theoretically, GHB receptors could be 
involved in the GHB response. However, it seems unlikely because our mouse experiment 
showed no effect of GBL/GHB in mice lacking GABAB receptors and a mouse report showed 
that the sedative/hypnotic effect of GHB and BAC were not reproduced by analogues of GHB 
which are not able to bind GABAB receptors188.  
 
Altogether, this suggests that GHB and BAC act most probably and only through GABAB 
receptors to affect sleep and the EEG (except for the delayed hypersomnia induced by BAC). 
However, these two drugs could share mechanisms involving in slow wave generation with 
agonists of other receptors such as GABAA ones. Interconnection between GABAA and GABAB 
function was already described for other effects378. 
 
Role of GABAB receptors and their subunits in sleep and EEG 
In baseline conditions, a lack of one GABAB receptor subunit altered the sleep/wake 
distribution over the 24h day in mice, although the total amount of sleep and wakefulness 
were not modified. For example, mice deficient for the GABAB1 and GABAB2 subunits, which 
do not express functional GABAB receptors, started their major sleep period 6 hours after WT 
mice. Therefore, GABAB receptors seem to play a crucial role in circadian distribution of 
sleep/wake. We would like to better understand this phenomenon by performing a circadian 
experiment with these mice. Because GABAB is also known to be involved in light signaling 
and is expressed in SCN, we are planning to see how the circadian phase of these animals 
could be shifted by light279,379. Because of the spontaneous epileptiform activity of GABAB1–/– 
and GABAB2–/– mice, this experiment will also give us new insights of the effects of seizures in 
the endogenous circadian clock, a topic still poorly studied. 
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We also found that a lack of the GABAB1a subunit in mice is sufficient to develop spontaneous 
epileptiform activity. This underlines the differential role of the two isoforms of the GABAB1 
subunit on the EEG and brain excitability. Although the mechanism by which a lack of 
GABAB1a subunit leads to an epileptiform phenotype remains to be discovered, the 
differential neuronal subcellular localization of the two isoforms is probably the cause. 
Indeed, GABAB1a assembles heteroreceptors inhibiting glutamate release, while 
predominantly GABAB1b mediates postsynaptic inhibition220. Since glutamate is the major 
excitatory neurotransmitter in the brain, a loss of inhibition of its release may lead to a 
hyperexcitability neuronal, a characteristic of seizures. 
 
GABAB1 and GABAB2 mice and to a lesser extent GABAB1b mice, showed decreased theta and 
high delta activity in their EEG NREMS spectrum. Interestingly, we found that GHB and BAC, 
which are agonists of GABAB, increased delta and theta activity in humans and particularly at 
low dose in mice. This emphasizes the role of GABAB receptors in the generation of low 
frequency oscillations originating from thalamocortical networks250,380,381. 
 
Temperature, EEG topography and memory 
During each session of our human study, core body temperature was recorded. We are 
planning to analyze these data soon. Both BAC and GHB are known to induced hypothermia 
in rodents and in humans. Moreover, temperature decreases during NREMS and is negatively 
correlated with EEG delta power in NREMS382,383,384,385. Thus, temperature analysis would 
inform us on the potential correlation between EEG effects of the drugs and temperature. 
 
In this work, only results for the central scalp EEG derivation (C3-A2) were presented, 
although frontal and occipital EEG derivations were also recorded. We would like to analyze 
 128 
other derivations and especially the frontal one. Indeed, there are sleep state-related and 
frequency-specific regional changes of EEG frequency bands 386,387. For example, in young 
adults, it was reported that delta power was higher in frontal derivations than in more 
posterior derivations during the initial part of sleep. Moreover, frontal areas of the cortex 
seem to be important for cognitive skills and particularly responsive to changes in sleep 
propensity388. Thus, a putative restorative process of NREMS may be most intense over the 
frontal cortex and the effects of GHB and BAC even more pronounced. 
 
Sleep is implicated in memory consolidation. As expected, we found an improvement of 
declarative and procedural memory performance after a nap. However, neither GHB nor BAC 
affected memory consolidation despite their EEG modifications. It was shown that distinct 
sleep stages was involved in the consolidation of different types of memories389. For 
example, NREMS stage 2 and spindle density have been correlated with improvement of 
procedural memory321,390, whereas declarative memory would benefit from SWS314. Thus, a 
future interesting analysis on our data would be to confirm the correlation between sleep 
variables and memory performance and particularly to see how GHB and BAC affect these 
correlations. 
 
Final conclusion 
Although the mechanisms by which GHB improves narcolepsy symptoms remain to be 
developed further, this present work has provided strong evidence that GHB does not 
induce physiological sleep as well as the unique role of GABAB receptors in its response. It 
has underlined differences and similarities shared by BAC and GHB in humans and in mice. It 
has demonstrated that the ‘extra’ EEG delta power produced by GHB did not generally affect 
subjective alertness, neurophysiological and memory performance. It has described in 
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details the importance of the GABAB receptors and its subunits on sleep and the EEG. Finally, 
it has brought new perspectives on the role of GABAB1a subunit in spontaneous seizure 
generation and on the circadian contribution of GABAB receptors on sleep/wake distribution. 
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11. Abbreviations 
 
5-HT Serotonin 
1,4-BD 1,4-butanediol 
AC Adenylyl cyclase 
Ach Acetylcholine 
AD Adenosine 
BAC Baclofen 
BF Basal forebrain 
BLN Baseline night 
BZD Benzodiazepine 
cAMP Cyclic adenosine-3',5'-monophosphate 
CREB2 cAMP responsive element binding protein-2 
DA Dopamine 
DRN Dorsal Raphé nucleus 
EEG Electroencephalogram 
EMG Electromyogram 
EOG Electrooculogram 
ERK1/2 Extracellular signal-regulated kinase 1 
EXP Experimental (night)= postnap (night) 
FFT Fast fourier transformation 
GABA Gamma-aminobutyric acid 
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Gal Galanin 
GAT-1 GABA transporter 1 
GBL Gamma-butyrolactone 
GHB Gamma-hydroxybutyrate 
GIRK,Kir3 G-protein-gated inwardly rectifying potassium 
Glu Glutamate 
Gly Glycine 
GPCR G-protein coupled receptors 
H1,2 Histamine 1,2 receptors 
Hab Habituation night 
Hcrt Hypcretin = orexin 
His Histamine 
KCTD Potassium channel tetramerization domain-containing 
KDEF Karolinska Directed Emotional Faces System 
KSS Karolinska sleepiness scale 
LC Locus coeruleus 
LDT Laterodorsal tegmentum 
LTP Long term potentiation 
MCH Melanin-concentrating hormone 
MT Movement time 
NA Noradenaline  
NREMS Non-rapid eye movement sleep (stages 2-4 in humans) 
Orx Orexin =Hypocretin 
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peri-Lcα Peri-locus coeruleus α 
PFP pontine reticular formation 
PL Placebo 
PPT Pendonculopontine tegmentum 
PVT Psychomotor vigilance task 
REC Recovery 
REM Rapid eye movement 
REMS Rapid eye movement sleep 
REMSL REMS latency 
RGS G-protein signaling 
RT Reaction time 
S1 NREMS Stage 1 
S2 NREMS Stage 2 
S2 NREMS Stage 3 
S4 NREMS Stage 4 
SCN Suprachiasmatic nucleus 
SD Sleep deprivation 
SDs sushi domains 
SE Sleep efficiency (TST/TIB) 
SL sleep latency 
SO Sodium oxybate 
SOREM Sleep onset REMS 
SOREMP Sleep onset REMS periods 
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SWS Slow-wave sleep= NREMS stage 3+4 
THIP Gaboxadol 
TIB Time in bed 
TMN Tuberomammillary nucleus 
TST Total sleep time 
VLPO Ventrolateral preoptic nucleus 
vPAG Ventral periaqueductal gray matter 
VTA Ventral tegmental area 
WASO Wakefulness after sleep onset 
  
